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Table of molecules 
Listed are all molecules that are mentioned in this thesis, serially numbered according to 
appearance as structural formula. While all compounds are given numerical designations, 
many have been labeled additionally with their particular acronyms. In some cases these 
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  V 
The ligands are generally depicted in their uncharged form. In the corresponding metal 
complexes, these compounds can be completely or partially deprotonated. For optimized 
comprehensibility the numerical designations or acronyms of the molecules are used 
regardless of ligand protonation state. However, the protonation states can be derived 
from the oxidation states of the metal ions and the overall charge of the complexes. 
Instead of the complete notation [M(ligand)](X)n for metal-ligand complexes with 
counterions X, the abbreviation M-ligand is often used for clarity. In addition, the brackets 
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Abstract 
Defeating cancer is one of the major challenges that humankind is facing today. To this 
end, nuclear medicine offers promising approaches, especially in cases where 
conventional methods like chemotherapy or irradiation are not effective. Due to the 
versatility of metallic radionuclides and their facile insertion into suitable targeting 
compounds, the usage of radiometal-based pharmaceuticals has become increasingly 
popular. Such radiopharmaceuticals consist of two main parts: a radioactive metal ion and 
a vector moiety (e.g. a peptide, an antibody, or a nanoparticle). The radiometal ion 
determines the mode of action via its decay, whereas the vector moiety governs the 
delivery of the radiolabeled agent to the diseased target structure (see Figure I). 
Depending on the nuclear properties of the metal ion, radiopharmaceuticals can be used 
for either diagnostic or therapeutic purposes. The incorporation of the radionuclide into the 
targeting vector is commonly performed using a bifunctional chelator (BFC) that 
possesses a coordination site for stable complexation of the metal ion as well as a 
suitable linker for conjugation to the vector moiety. 
 
Figure I. Schematic representation of a metal-based radiopharmaceutical and the bispa 







































The work presented in this thesis focused on the development of new ligand systems for 
application as metal-chelating units in radiopharmaceuticals. The main requirements for 
BFCs are fast complex formation and stable metal ion coordination under physiological 
conditions. Previously, the rigid and highly preorganized bispidine scaffold has been 
shown to provide a suitable platform for the design of BFCs for nuclear imaging using 
copper(II)-64, a promising radionuclide for positron emission tomography (PET). In the 
present study, picolinic acid groups, known to be excellent metal-binding moieties, are 
incorporated into the bispidine backbone to further improve the thermodynamic stability of 
the copper(II) bispidine complexes. This new class of chelators is refered to as the “bispa” 
ligands. Moreover, through the modification it was intended to expand the spectrum of the 
bispdine ligands to the complexation of other metal ions relevant to radiopharmacy. By the 
introduction of one or two picolinic acid groups into the bispidine scaffold, hexa- and 
octadentate bispa ligands were prepared as shown in Figure I. These novel ligands were 
evaluated in various non-radioactive and radioactive metal complexation studies 
concerning their potential application in nuclear medicine. 
The coordination chemistry of the isomeric hexadentate bispa ligands Hbispa1a (B1a) and 
Hbispa1b (B1b), as well as of the para-methoxy substituted B1a derivative 
(p-MeO)Hbispa1a ((p-MeO)B1a) was investigated. To this end, complexation reactions of 
the N5O-type bispa ligands with the metal ions cobalt(II), nickel(II), copper(II), zinc(II), and 
gallium(III) were performed. The resulting metal complexes were characterized by means 
of standard structural and spectroscopic methods. In the next step, the bispa ligands were 
evaluated in radiochemical investigations with the PET nuclides copper(II)-64 and 
gallium(III)-68. The human serum challenge experiments and biodistribution studies with 
radiolabeled 68GaIII-B1a revealed an inadequate complex stability, indicating that the 
hexadentate bispa ligands are not suited for applications involving the hard gallium(III) 
ion. The 64CuII-bispa systems, in contrast, showed auspicious properties including fast 
complex formation under mild conditions with molar activities as high as 200 GBq/µmol. In 
addition, excellent in vivo stability and favorable clearance behavior of the complexes 
were observed. These results are consistent with the high preorganization of the bispa 
ligands for copper(II) complexation and the high formation constants of the complexes 
determined by potentiometric titrations.  
Using the bispa ligand H2bispa2 (B2), the very first octadentate bispidine system was 
synthesized and examined for nuclear medicine. In the present thesis, the coordination 
chemistry of the N6O2-type ligand was investigated with the metal ions indium(III), 
lutetium(III), and lanthanum(III). Furthermore, the ligand B2 was evaluated in combination 
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with the radioactive metal ions 111InIII (imaging), 177LuIII (therapy), and 225AcIII (therapy). The 
metal-B2 complexes showed stabilities vs. human serum comparable to or higher than 
those of the respective complexes based on the macrocyclic “gold standard” chelator 
DOTA. Moreover, radiolabeling of B2 with 111InIII and 225AcIII could be performed 
quantitatively at room temperature, which is a major advantage in comparison to DOTA. 
In conclusion, the new hexa- and octadentate bispa ligands were shown to display 
promising properties regarding the stable complexation of diagnostic as well as 
therapeutic radiometal ions. In future investigations, these results will promote the 
development of functionalized derivatives of the respective ligands towards the putative 
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Kurzfassung 
Der Kampf gegen Krebs stellt eine der großen Herausforderungen unserer heutigen Zeit 
dar. Diesbezüglich bietet die Nuklearmedizin vielversprechende Ansätze, vor allem dort, 
wo konventionelle Methoden wie Chemotherapie und Bestrahlung nicht hinreichend 
wirksam sind. Aufgrund der vielseitigen Einsetzbarkeit metallischer Radionuklide und ihrer 
leichten Insertion in zielsuchende Verbindungen haben Radiometall-basierte Wirkstoffe in 
den letzten Jahren zunehmend an Bedeutung gewonnen. Prinzipiell bestehen solche 
Radiopharmaka aus zwei grundlegenden Komponenten, einem Radiometallion und einer 
Vektoreinheit (z.B. Peptid, Antikörper, oder Nanopartikel). Das radioaktive Metallion 
bestimmt durch seinen Zerfall die Wirkungsweise des Medikaments, während der Vektor 
zur spezifischen Erkennung der krankhaften Zielstruktur dient (siehe Abbildung I). 
Abhängig von den nuklearen Eigenschaften des jeweiligen Metallions können diese 
Radiopharmaka entweder für diagnostische oder für therapeutische Zwecke genutzt 
werden. Die Einführung des Radionuklids in die Vektoreinheit erfolgt im Allgemeinen 
mithilfe bifunktioneller Chelatoren (BFCs), die sowohl in der Lage sind, das Metallion zu 
komplexieren, als auch über einen Linker zur Kopplung an den Vektor verfügen. 
 
Abbildung I. Schematische Darstellung eines Metall-basierten Radiopharmakons, sowie 







































Die hier vorgestellte Arbeit beschäftigt sich mit der Entwicklung neuer Ligandensysteme 
für die Anwendung in Radiopharmaka. Die Hauptanforderungen an BFCs sind dabei 
schnelle Komplexbildung und eine stabile Bindung des Metallions unter physiologischen 
Bedingungen. Es wurde bereits gezeigt, dass das starre und hoch präorganisierte 
Bispidingerüst eine geeignete Plattform für das Design von BFCs für die nukleare 
Diagnostik mittels Kupfer(II)-64 im Rahmen der Positronen-Emissions-Tomographie (PET) 
darstellt. Um die thermodynamische Stabilität der entsprechenden Kupfer(II)-Bispidin-
komplexe zu erhöhen, wurden hier nun Picolinsäure-Gruppen (picolinic acid, pa), bekannt 
als exzellente Metall-bindende Einheiten, in das Bispidinrückgrat eingeführt. Die auf 
diesem Wege erhaltenen Chelatoren werden als “bispa”-Liganden bezeichnet. Darüber 
hinaus sollte durch diese Modifizierung das Spektrum der Bispidine auf weitere 
radiomedizinisch relevante Metallionen ausgedehnt werden. Durch die Einführung von ein 
oder zwei Picolinsäuren am Bispidingerüst wurden hexa- und oktadentate bispa-Liganden 
dargestellt (siehe Abbildung I). Diese neuen Ligandensysteme wurden anschließend in 
verschiedenen Studien mit nicht-radioaktiven und radioaktiven Metallionen hinsichtlich 
ihrer potentiellen Anwendung in der Nuklearmedizin evaluiert. 
Die Koordinationschemie der isomeren hexadentaten bispa-Liganden Hbispa1a (B1a) und 
Hbispa1b (B1b), sowie des para-Methoxy substituierten Derivats (p-MeO)Hbispa1a 
((p-MeO)B1a) wurde untersucht. Dazu wurden Komplexierungsreaktionen der N5O-
Liganden mit den Metallionen Cobalt(II), Nickel(II), Kupfer(II), Zink(II), und Gallium(III) 
durchgeführt. Die strukturellen und spektroskopischen Eigenschaften der so erhaltenen 
Metall-Komplexe wurden anschließend mittels Standardmethoden analysiert. Im nächsten 
Schritt wurden die bispa-Liganden in radiochemischen Untersuchungen mit den PET-
Nukliden Kupfer(II)-64 und Gallium(III)-68 evaluiert. Konkurrenzexperimente mit humanem 
Serum und Bioverteilungsstudien zeigten, dass der radiomarkierte 68GaIII-B1a Komplex 
unter den beschriebenen Bedingungen nicht stabil ist. Demnach erwiesen sich die neuen 
bispa-Liganden als ungeeignet für Anwendungen mit dem harten Metallion Gallium(III). Im 
Gegensatz dazu zeigten die 64CuII-bispa Systeme vielversprechende Eigenschaften wie 
schnelle Komplexbildung unter milden Bedingungen mit hohen molaren Aktivitäten von 
bis zu 200 GBq/µmol. Zudem wurden eine hohe in vivo-Stabilität sowie eine schnelle 
Ausschleusung der Komplexe aus dem Körper beobachtet. Diese Ergebnisse sind in 
Übereinstimmung mit der hohen Präorganisation der bispa-Liganden für die 
Komplexierung von Kupfer(II) und den hohen Komplexbildungskonstanten, die mittels 
potentiometrischer Titration bestimmt wurden.  
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Mit dem bispa-Liganden H2bispa2 (B2) wurde das erste oktadentate Bispidin synthetisiert 
und im Hinblick auf nuklearmedizinische Anwendungen studiert. In der vorliegenden 
Arbeit wurde die Koordinationschemie des N6O2-Liganden mit den Metallionen Indium(III), 
Lutetium(III), und Lanthan(III) untersucht. Darüber hinaus wurde B2 mit den radioaktiven 
Metallionen 111InIII (Bildgebung), 177LuIII (Therapie), und 225AcIII (Therapie) evaluiert. Die 
Metall-B2 Komplexe zeigten in Gegenwart von humanem Serum vergleichbare oder 
bessere Stabilitäten als die entsprechenden Komplexe basierend auf dem makro-
zyklischen “Goldstandard” DOTA. Zudem konnte B2 bei Raumtemperatur quantitativ mit 
111InIII und 225AcIII radiomarkiert werden, was einen deutlichen Vorteil im Vergleich zu 
DOTA darstellt.  
Es wurde somit gezeigt, dass die neuen hexa- und oktadentaten bispa-Liganden stabile 
Komplexe mit diagnostisch sowie therapeutisch interessanten Radiometallionen bilden. 
Diese Ergebnisse werden die Entwicklung und Untersuchung von Derivaten der hier 
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1 State of the art 
1.1 Metal-based radiopharmaceuticals 
1.1.1 Introduction 
The fascination for metal complexes, especially for their diverse range of impressive 
colors, goes far back to ancient times, long before Alfred Werner (1866-1919) first defined 
the concept of coordination compounds in 1893.[1-4] Nowadays, metal complexes are used 
and investigated in a variety of different areas, e.g. as highly specific molecular catalysts 
(homogeneous catalysis),[5] as biomimetic enzyme models[6-8] and as diagnostic or 
therapeutic metal-based drugs.[9,10] Prominent examples for metallodrugs are platinum(II) 
anticancer therapeutics like cisplatin and derivatives thereof,[11] gold(I) complexes against 
arthritis (e.g. auranofin),[12,13] and bismuth(III) compounds for the treatment of 
gastrointestinal disorders (e.g. bismuth subsalicylate, BSS).[14,15] In addition, 
gadolinium(III)-based contrast agents for magnetic resonance imaging (MRI)[16] as well as
diagnostic radiopharmaceuticals like 99mTcI-sestamibi (Cardiolite) are known.[17,18] 
The focus of this work lies on the application of metal complexes in nuclear medicine. 
Over the past decades, radiometal-based pharmaceuticals have become increasingly 
popular.[17,19,20] Such radiopharmaceutical agents consist of four components: the 
radiometal ion itself, which is tightly bound by a bifunctional chelator (BFC), a vector or 
targeting moiety (e.g. peptides or antibodies), and a molecular linker connecting the BFC 
with the vector (see Figure 1).[21] 
 
Figure 1. Schematic representation of a metal-based radiopharmaceutical and its 
components. 
It is essential for the intended use that the vector moiety is able to recognize a biological 
target in vivo, allowing site-specific delivery and accumulation of the radiopharmaceutical. 
Once attached to the target structure, the decay of the radiometal can be used to localize 
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(diagnosis) or destroy (treatment) diseased tissues (see Chapter 1.1.2).[21] The periodic 
table (see Figure 2) provides a wide variety of elements with radioisotopes suitable for 
nuclear imaging and radiotherapy.[22] 
 
Figure 2. Periodic table highlighting elements suitable for nuclear imaging (γ or β+) or 
radiotherapy (T). Adapted from reference [22]. 
Radiometals offer advantages over non-metallic nuclides like radiohalogens in terms of 
flexibility, modularity, and simplicity. Depending on the intended application, one can 
choose from numerous radiometals with different decay schemes, energies, physical half-
lives, and production methods. Furthermore, radiometallation reactions are generally fast 
and can take place under ambient conditions. In contrast, the incorporation of 
radiohalogens into organic systems via covalent bond linkage often requires multiple 
synthetic steps including harsh conditions and difficult purification procedures.[19]  
In the following, nuclear medicine techniques will be presented (Chapter 1.1.2) 
complemented by a discussion of the factors relevant for the design of metalloradio-
pharmaceuticals (Chapters 1.1.3 to 1.1.7). 
State of the art 
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1.1.2 Nuclear medicine 
Nuclear decay processes used for medical applications 
Radioactivity is a property of unstable atomic nuclei leading to spontaneous emission of 
ionizing radiation. A substance containing such a labile nucleus is thus considered 
radioactive. The nucleus changes its state by emitting particles or photons and this 
transformation process is commonly termed nuclear disintegration or decay.[23] The 
objective of this subchapter is not to provide a thorough introduction to the basic physics 
of radioactivity, but to highlight nuclear decay processes resulting in radiation suitable for 
medical applications (see Figure 3). There are three major forms of nuclear disintegration, 
i.e. alpha (α) decay, beta (β) decay, and gamma (γ) decay. During α decay a doubly 
ionized helium-4 atom (α particle) is ejected from the parent radionuclide and this 
radiation can be used for targeted alpha therapy (TAT).[24,25] The term β decay is used to 
describe different processes involving nuclei with unbalanced proton to neutron ratios. 
Radionuclides with an excess of neutrons for example, decay via conversion of a neutron 
into a proton accompanied by the emission of an electron, the so-called beta minus (β–) 
particle (therapeutic applications). Proton rich nuclei, on the other hand, may attempt to 
reach stability by converting a proton into a neutron with the emission of a beta plus (β+) 
particle (positron), the antiparticle of the electron. After ejection, the positron recombines 
with a suitable electron resulting in the emission of two γ rays, and these can be detected 
for diagnostic purposes (see subsection ‘Imaging’ for more details). Another process 
related to β decay is electron capture (EC). Here an unstable nucleus captures an inner 
orbiting electron (often from the K- or L-shell of the atom) followed by conversion of this 
electron and a proton into a neutron and subsequent ejection of a neutrino.[24] Thus, EC 
itself does not produce ionizing radiation but it creates a vacancy in the electron cloud of 
the decaying atom. Such vacancies are quickly filled by electrons from higher energy 
levels. These electron transitions then result in the emission of characteristic X rays or low 
energy electrons, collectively called AUGER electrons (radiotherapy).[24,26] The effect on the 
nucleus of EC is the same as positron emission and both decays compete with each 
other. However, the latter process requires a certain energy for the ejected positron and is 
thus not possible for every radionuclide. Following these types of decays (α and β), the 
nucleus often remains in an excited state and the excess energy can be emitted as 
γ photons (imaging). Furthermore, all described disintegration processes lead to nuclear 
transmutation, i.e. the conversion of a chemical element or an isotope into another. In 
contrast, γ decay involves transitions between different states of the same atom.[24] 
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Excited or metastable radionuclides can release their excess energy in the form of 
electromagnetic radiation (isomeric transition, IT). A prominent example for this is 
technetium-99m.[18,24,27] Alternatively, the energy can be transferred to an electron, 
resulting in its emission from the atom (internal conversion, IC).[24] These conversion 
electrons can be used in radiotherapy and additionally IC (just as EC) also leaves a 
vacant site in the electron shell (see above).[24,28] Often, not only one but several decay 
modes are accessible for a specific radionuclide and occur with a certain probability. In 
addition, if the daughter nuclide of a nuclear disintegration is radioactive itself, a number 
of consecutive decays will take place until a stable end product is formed.[24] 
 
Figure 3. Nuclear decay processes leading to ionizing radiation used in nuclear medicine 
for either diagnostic or therapeutic purposes. 
Imaging 
Diagnostic imaging techniques like single photon emission computed tomography 
(SPECT) or positron emission tomography (PET) use either gamma (γ) or positron (β+) 
emitting radionuclides, respectively (see Figure 4). These non-invasive methods are well-
established imaging modalities and have already been extensively reviewed in the 
literature.[24,29-34] They are used for the early detection of tumors in oncology, as well as for 
brain and cardiac (heart) imaging.[29] By monitoring the spatial and temporal distribution of 
the administered radiotracer, nuclear imaging provides functional information regarding 
the physiological condition of the patient.[24] For example, thallium(I) is known to 
accumulate in healthy heart muscle (myocardium), but not in infarcted or poorly perfused 
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imaging agent.[22,24,35] Both, SPECT and PET, are based on the detection of γ rays and 
subsequent data conversion into three-dimensional images by appropriate computer 
programs.[30] The following main aspects have to be considered when choosing a suitable 
diagnostic radioisotope: the half-life of the nuclide should allow for the preparation of the 
radiopharmaceutical, its administration to the patient, and its detection before it is 
eliminated from the body. Furthermore, the energy of the γ ray has to be high enough to 
be detectable by the gamma cameras, but at the same time, the radiation exposure to the 
patient should be kept as low as possible. In case of SPECT, the ideal γ ray energy range 
given by the detector is between 100-200 keV and the radionuclide should be chosen 
accordingly.[36] For PET, on the other hand, a β+-emitting nuclide is required. When a 
positron is ejected, it travels through matter for a short distance (in the range of a few 
millimeters[37]) losing energy by interaction with surrounding material. After the positron 
loses most of its kinetic energy, it combines with a suitable electron, resulting in two 
511 keV γ rays at an angle of 180 ° (annihilation process). Those photons are recorded by 
coincidence detectors that are arranged in a circular array (see Figure 4).[21,34] The range 
of charged particles like positrons in matter depends on the energy of the particle and the 
density of the medium. Low energy β+ emission, i.e. a small range in matter, is 
consequently better suited for PET in order to obtain good resolution.[34] PET shows in 
comparison with SPECT higher resolution in the range of ~5 mm (as opposed to ~10 mm 
for SPECT) and higher sensitivity with tracer concentrations of ~10-8 to 10-10 M (compared 
to ~10-6 M for SPECT).[38,39] In terms of multimodal imaging, the functional information 
gained by either SPECT or PET are often combined with methods delivering detailed 
anatomical data like computed tomography (CT) and MRI.[24,32,36] 
 
Figure 4. Schematic representation of SPECT (left) and PET (right) imaging. Adapted 
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Therapy 
The application of radiopharmaceuticals for the treatment of diseases is termed 
radiotherapy. In case of radioimmunotherapy (RIT) antibodies are used as vector moieties 
and a detailed presentation of vectors and biological targets is given in Chapter 1.1.3. In 
contrast to nuclear imaging, radiotherapy aims to deliver a sufficiently large radioactive 
dose to the diseased target to destroy it without harming surrounding healthy tissue. 
Essential for an effective treatment is the use of radionuclides that can cause irreparable 
DNA damage in the respective cells. To this end, emitters of alpha (α) and beta minus (β–) 
particles, as well as conversion and AUGER electrons are used.[21,26,40] An important factor 
related to the interaction of radiation with matter is the so-called linear energy transfer 
(LET). This value is used to quantify the amount of energy deposited by ionizing radiation 
per unit length of the path in soft tissue and is typically given in kiloelectron volts per 
micrometer (keV/µm).[34] Each particle displays different nuclear properties in terms of 
decay energy, penetration depth and LET (see Table 1). Beta particles have a long path 
length of 0.5-10 mm[21] corresponding to a low LET in the range of 0.2 keV/µm[26] in 
biological tissue and are thus well-suited for the treatment of large, solid tumors. Alpha 
particles, on the other hand, with their short range of 40-100 µm[21] and high LET of 
80 keV/µm[26] show ideal properties for treating micrometastases and lymphomas.[41] In 
comparison to those particles, AUGER electrons have the lowest energy (ca. 1-10 keV) 
and the smallest range (1-20 µm).[21] When working with AUGER electrons, it is therefore 
important that the radiolabeled drug is localized in the cell nucleus close to the DNA, i.e. 
the radiosensitive target.[26,42] Besides showing therapeutically useful emissions, the 
radionuclide should ideally also release a small amount of γ radiation (about 10 % of the 
decay, ~150 keV), as this allows to monitor the distribution of the radiopharmaceutical.[43] 
Table 1. Nuclear properties of particles used for radiotherapy.[21,26] 
Particles Typical energy of decay Typical range in biological tissue
(a) LET 
[keV/µm] 
AUGER electrons ~1-10 keV 1-20 µm (< 1 cell diameter) 4-26 
β– particles 0.1-2.2 MeV 0.5-10 mm (50-1000 cell diameters) 0.2 
α particles 5-8 MeV 40-100 µm (< 10 cell diameter) 80 
(a) Based on an average cell diameter of 10 µm. 
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Theranostics 
The term “Theranostics“ in nuclear medicine refers to the use of a radiopharmaceutical for 
combined therapy and diagnosis.[44-46] This implies that a targeting vector is first labeled 
with a diagnostic radionuclide to perform low dose imaging and to deliver therapeutically 
relevant information, i.e. about the heterogeneity of the diseased tissue, the receptor 
expression on the cell surface, as well as the biodistribution and clearance of the 
radiopharmaceutical. Based on this information, personalized treatment using the same 
vector labeled with a suitable therapeutic nuclide can then be performed.[44,47] Ideally, 
radioisotopes of the same element are used for theranostic purposes. This way, one can 
benefit from the fact that isotopes of a given element display identical chemical properties. 
A vector moiety can thus be radiolabeled with different isotopes while the biological 
properties of the compound are not altered.[48] Examples for this application are the 
copper isotopes 64Cu (β+ emitter, PET) and 67Cu (β– emitter, therapy).[49-51] Some other so-
called „matched pairs“ are e.g. 44/47Sc,[52] 67/68Ga,[53,54] and 86/90Y[55,56]. Alternatively, 
radionuclides from different chemical elements can be used. In this case, it is important to 
perform in vivo studies to confirm the pharmacological similarity of the differently 
radiolabeled agents.[45] There are some versatile chelators available which can effectively 
radiolabel various metal ions.[48] Prominent examples are DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid), DTPA (diethylenetriaminepentaacetic 
acid), and H4octapa (N,N’-bis(6-carboxy-2-pyridylmethyl)-ethylenediamine-N,N’-diacetic 
acid), as well as derivatives thereof. All of them bind firmly to radiometal ions like 
indium(III)-111 (γ emitter, SPECT) and lutetium(III)-177 (β– emitter, therapy), which can 
thus be used with the same ligand systems.[48,57,58] Either way, this clearly demonstrates 
the aforementioned modularity of metallic radionuclides.[19] 
Whether radioisotopes are used for diagnostic, therapeutic or combined purposes, the 
crucial part for all those applications is the in vivo delivery strategy, which will be 
discussed in the next chapter. 
1.1.3 Biological targets and vector moieties 
A radiopharmaceutical consists of two main parts: a radionuclide that determines the 
mode of action via its decay, and a targeting vector, often a biomolecule, responsible for 
the localization of the radiolabeled drug. A central topic in nuclear medicine is the 
diagnosis and treatment of cancer in its various forms. During cancer pathogenesis the 
corresponding cells undergo certain molecular changes and thus provide suitable targets 
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for radiopharmaceuticals. Some typical traits of cancerous tissues are fast cell 
proliferation accompanied by enhanced formation of cardiovascular structures 
(neoangiogenesis), and upregulation of receptor gene expression.[59-61] The fast 
construction of new blood vessels leads to structural defects and thus eventually to 
increased porosity, known as enhanced permeability and retention (EPR) effect.[62] This 
phenomenon allows for the passive transport of functional nanoparticles into tumor cells. 
In general, nanoparticles are well-suited for the development of drugs as they allow the 
use of various materials like iron oxide, silica, or gold and offer a large surface for the 
adsorption of active compounds.[63-66] Small molecule tracers, like the ubiquitous 
fluorinated glucose derivative 18F-fluorodeoxyglucose (18F-FDG)[67,68] or the radiolabeled 
amino acid 11C-methionine,[69] on the other hand, mimic metabolic substrates and are 
hence accumulated in fast-growing tumor cells.[70] However, the focus here will be on 
receptor targeting with radiolabeled biomolecules like peptides[57,71,72] or antibodies[73-75]. 
This approach relies on the over-expression of cell surface receptors in various human 
tumors compared to healthy tissues as depicted in Figure 5. Selected examples of such 
molecular targets together with their associated vector moieties are given in Table 2. 
  
 Figure 5. Over-expression of cell surface receptors in cancerous tissue in comparison to 
healthy tissue. Adapted from reference [21]. 
Some receptors do not only bind, but also internalize the targeting molecules, capturing 
them in the cell.[72] For AUGER electron emitters this is especially favorable as they have to 
be close to the nucleus in order to cause a cytotoxic effect.[42] The specific recognition 
between receptor and respective biomolecule can be described according to the so-called 
„lock and key theory“,[76] which is a fundamental principle in biochemistry (see 
reference [77] for modifications of this concept). Most commonly, peptides or antibodies, 
particularly monoclonal antibodies (mAbs), are used as vector moieties for surface 
receptors. The biological half-life of these compounds usually depends on their molecular 
size, i.e. the larger the molecule, the longer it circulates in the blood.[21] A large antibody 
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such as Immunoglobulin G with a molecular weight of 150 kDa has a blood clearance time 
of 3-4 weeks, whereas a monovalent 25 kDa antibody fragment is excreted in less than 
10 hours.[75] For diagnostic purposes the properties of the biomolecule have to be 
matched to those of the respective radionuclide, especially with its physical half-life. This 
means that antibodies, with their relatively long blood circulation, need to be labeled with 
a radionuclide having a comparably long half-life like for example actinium-225 
(t1/2 = 10.0 d[27]).[21,75] In contrast, peptides usually display high uptake in target tissue and 
fast clearance from the body.[72] For RIT the prolonged circulation of antibodies is a major 
drawback, as it causes an undesired radiation burden in healthy tissues. An interesting 
approach to solving this problem is the so-called pretargeting strategy, which is based on 
non-covalent or covalent interactions between pretargeted mAbs and small radiolabeled 
effector molecules.[78] Often the receptor’s native vector molecule cannot be used as part 
of a radiopharmaceutical because of rapid degradation in vivo (peptides) or slow blood 
circulation (antibodies).[21] Therefore, much effort has been put into developing suitable 
analogs to overcome these shortcomings while preserving the binding ability to the target 
receptor.[71,75,79] 
Table 2. Selected peptide and antibody receptors over-expressed in human tumor 
cells.[21,57,71,75] 
Target receptor Biomolecule (peptide or antibody) Tumor type 
αvβ3 Integrin Arg-Gly-Asp (RGD) Brain, lung, prostate, ovary, 









HODGKIN’s lymphoma, carcinoids, 
paragangliomas, melanoma, 
breast, brain, renal, small cell lung 
cancer, medullary thyroid cancer 
Gastrin-releasing 




Prostate, breast, pancreas, 
gastric, colorectal, small cell lung 
cancer 
HER-2/neu receptor Trastuzumab 
(Herceptin) 
Breast cancer 
Epidermal growth factor 
receptor (EGFR) 
Epidermal growth factor 
(EGF) 
Breast, colorectal, head and neck 
cancer 
Vascular endothelial 
growth factor receptor 
(VEGFR) 
Bevacizumab (Avastin) Metastatic colorectal cancer 
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Numerous receptor / vector pairs as shown in Table 2 are available and the underlying 
principle shall now be illustrated using the somatostatin receptors (SSTRs) as an 
example. Somatostatin (SST) is a cyclopeptide hormone modulating multiple cellular 
signal transduction pathways via its corresponding transmembrane receptors.[80] Several 
human SST receptors were characterized[80,81] and found to be over-expressed in various 
tumor types (see Table 2) in comparison to healthy tissues.[82-84] Thus, SST receptor-
positive tumors can be targeted using the peptide hormone somatostatin. However, 
naturally occurring SST is problematic for this purpose because of its short plasma half-
life (< 3 minutes).[81,85] Intensive structure-activity studies have led to the synthesis of a 
variety of SST derivatives.[79,86-88] In this context, it is important to preserve the structural 
feature (pharmacophore) of the original compound that is necessary for its molecular 
recognition by the receptor. A prominent example of an SST analog is the short-chain 
cyclopeptide octreotide (OC) 1 (see Figure 6).[87] The replacement of the amino acid 
L-tryptophan (L-Trp) by its corresponding D-enantiomer significantly increased the potency 
of octreotide (and other analogs) compared to native SST. Furthermore, octreotide is 
protected against enzymatic degradation by the D-phenylalanine (D-Phe) at its N-terminus 
and the amino alcohol at its C-terminus.[79] Other derivatives based on the cyclic 
octapeptide are Tyr3-octreotide (TOC) 2 and octreotate (TATE) 3.[57,79,81,88] 
 
Figure 6. Chemical structure of somatostatin analogs with the pharmacophore (orange) 
and the functional group used in conjugation reactions (dashed circle) highlighted.[21,81,87,88] 
After the successful identification of suitable biological targets and vector moieties, the 
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radiometal-based applications, one possibility is direct labeling of the compound with the 
respective nuclide. Examples of peptides and antibodies directly labeled with 99mTc and 
188Re have been reported,[89-94] even though the binding is generally non-specific.[95] 
However, the commonly used strategy for metalloradiopharmaceuticals involves the 
introduction of a bifunctional chelator (BFC) into the targeting vector via a molecular linker 
(Chapter 1.1.4) and subsequent radiolabeling of the attached ligand (Chapter 1.1.5).[95,96] 
Numerous vector-ligand conjugates have been developed based on this so-called BFC 
method and selected examples will be presented in subsections of Chapter 1.2. 
1.1.4 Linker – bioconjugation strategies 
Usually, a linker moiety bearing a functional group suitable for bioconjugation is attached 
to a ligand. The resulting bifunctional chelator (BFC) is subsequently coupled to the 
respective targeting biomolecule. Important in this context is the placement of the BFC 
with respect to the biological vector, as neither the binding ability of the chelate to metal 
ion nor the target affinity of the biomolecule should be affected by the conjugation mode. 
Other aspects to be considered are the reaction conditions of the conjugation procedure, 
as targeting vectors are often sensitive biomolecules and, therefore, susceptible to 
decomposition when heated. The bioconjugation should consequently occur fast and at 
ambient temperatures.[21] 
Commonly used conjugation strategies connecting a BFC and a vector moiety proceed via 
peptide (A), thiourea (B), thioether (C) or triazole (D) bond formation (see 
Figure 7).[21,97,98] Typical reactive groups on the side of the biomolecule are amines (e.g. 
lysines) or thiols (cysteines) and the BFC must hence contain compatible functionalities. 
Primary amines for example can be coupled with carboxylic acids forming amide bonds 
(A), as well as with isothiocyanates resulting in thiourea derivatives (B).[97] In case of 
peptide bond formation, the carboxylic acid has to be activated using coupling agents like 
EDC (3-(ethyliminomethyleneamino)-N,N-dimethylpropan-1-amine) or HATU (1-[bis(dimethyl-
amino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate).[99] Thiols, 
on the other hand, can be reacted with maleimides (C) with the added advantage that 
sulfhydryl groups are reactive at neutral pH in contrast to most amine functions.[97] 
Another approach involves the introduction of terminal alkynes and azides into the chelate 
and the biomolecule, respectively. Both functional groups can then be combined to 1,2,3-
triazoles in a so-called “click reaction“ using copper(I) catalysts (D).[100] These 
bioorthogonal cycloadditions are characterized by high selectivity in the presence of 
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various functionalities and are widely used in the labeling of biomolecules like 
peptides.[98,101,102] The application of copper(I) catalysts in a reaction involving chelates, 
can lead to metal ion complexation. However, there are several procedures for the 
removal of copper ions described in the literature, including extraction with aqueous EDTA 
(ethylenediaminetetraacetic acid) solutions[103] and precipitation using sodium sulfide.[104] 
In addition, there has been tremendous progress in the development of click reactions 
that proceed in the absence of a metal catalyst.[105,106] 
 
Figure 7. Examples for bioconjugation of a bifunctional chelator to a vector moiety. 
Adapted from reference [21]. 
Depending on the length of the linker, it can be useful to insert an additional spacer 
between the BFC and the biomolecule in order to avoid interference between these two 
moieties. In addition, a spacer can influence the pharmacokinetics and biodistribution of 
the conjugate by modifying its hydrophilicity. Such spacers often consist of amino acids, 
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1.1.5 Bifunctional chelatorsi 
A bifunctional chelator (BFC), as implied by the name, provides two functionalities, i.e. a 
linker for covalent attachment to the biomolecule and a chelating moiety for stable 
complexation of the radiometal ion. The linker can either be connected to an existing 
functional group of the ligand or an additional reactive site needs to be introduced. The 
latter option is preferable, as the first approach potentially uses a coordinating function 
and can thus influence the donor properties or even reduce the number of possible donor 
atoms.[40] By far the most important requirement for BFCs is the formation of metal 
complexes with high thermodynamic stability (equilibrium on the side of the complex) and 
inertness (slow dissociation rate) under physiological conditions. For the intended use as 
part of a radiopharmaceutical, it is essential that the complex remains stable in the 
presence of competing metal ions and native chelators like enzymes or transport 
proteins.[48,110,111] Potential complex dissociation in vivo could lead to negative side effects 
including the accumulation of highly toxic radiometal ions in non-target tissues (see 
Chapter 1.1.7).[112,113] In the case of applications involving short-lived radioisotopes or heat 
sensitive biomolecules like antibodies as targeting vectors, fast radiolabeling of the BFC 
under ambient conditions is desirable. However, one has to consider that the rate 
constants of metal ion complexation and release (forward and reverse reaction) are 
connected via the complex stability constant K and hence a reasonable balance of the 
discussed properties is needed in order to obtain a suitable metal-BFC system.[48] The 
overall pharmacokinetics of radiolabeled drugs depend on the physicochemical properties 
of all components, and the hydrophilicity and charge of the metal complex thus influence 
biodistribution and clearance of the respective radiopharmaceutical.[110,114] 
BFCs are often built up on the basis of polyaza-systems with high denticity allowing full 
saturation of the coordination sphere of the respective metal ion. In general, there are two 
categories of BFCs, those with macrocyclic and those with acyclic ligand scaffolds. Based 
on the tri- and tetraazamacrocycles tacn (L1, 1,4,7-triazacyclononane), cyclen (L2, 
1,4,7,10-tetrazacyclododecane), and cyclam (L3, 1,4,8,11-tetraazacyclotetradecane), a 
broad variety of systems has been developed with the carboxylic acid-substituted 
frameworks NOTA (L4, 1,4,7-triazacyclononane-1,4,7-triacetic acid, N3O3-type ligand), 
DOTA (L5, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, N4O4). and TETA 
                                                
i Reproduced in part with permission from P. Comba, L. Grimm, C. Orvig, K. Rück, H. Wadepohl, 
Inorg. Chem. 2016, 55, 12531-12543, Copyright 2016 American Chemical Society.; Parts of this 
chapter will be published in P. Comba, U. Jermilova, C. Orvig, B. O. Patrick, C. F. Ramogida, 
K. Rück, C. Schneider, M. Starke, Chem. Eur. J., submitted manuscript. 
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(L6, 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid, N4O4) being the most 
popular ones.[115,116] With regard to bigger metal ions larger macrocycles like PEPA (L7, 
1,4,7,10,13-pentaazacyclopentadecane-N,N’,N′’,N′′′,N′′′′-pentaacetic acid, N5O5)[117] and 
HEHA (L8, 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N′′,N′′′,N′′′′,N′′′′′-hexaacetic acid, 
N6O6)[118] were investigated.[119-121] 
 
Figure 8. Selected polyaza macrocycles. 
The substitution pattern of the macrocycles is not limited to carboxylic acids but also 
includes other pendent donor groups like phosphonic or picolinic acids.[115,122-125] 
Furthermore, there are cross-bridged[122,123,126] and various functionalized derivatives 
available.[48] Metal ion complexes of macrocyclic systems usually show high 
thermodynamic stabilities, but often require high temperatures and extended reaction 
times for formation, which is a major drawback when working with heat sensitive 
antibodies as the targeting moiety.[40] DOTA (L5), for example, needs elevated 
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111InIII, 177LuIII, and 225AcIII, but it is nevertheless probably the most widely used chelator to 
date owing to the high in vivo stability of its metal complexes and to the commercial 
availability of many bifunctional derivatives.[48] 
Acyclic systems, on the other hand, are able to quantitatively label radiometal ions within 
minutes at mild temperatures.[48,110] DTPA (L10, diethylenetriaminepentaacetic acid, 
N3O5), a prominent acyclic chelator, is known for its fast radiolabeling kinetics with many 
metal ions (e.g. 44/47ScIII, 86/90YIII, 111InIII, and 177LuIII), but suffers from stability issues in vivo, 
especially in comparison with macrocycles like DOTA.[48] Despite its poor stability, DTPA 
is used in the first clinically approved peptide-based imaging agent 111InIII-DTPA-octreotide 
(OctreoScan®) for the diagnosis of somatostatin receptor positive neuroendrocrine 
tumors.[40,127-129] In order to improve the in vivo stability, several DTPA analogs with 
preorganizing groups at the carbon backbone have been synthesized,[40,48] including the 
C-functionalized derivative CHX-AII-DTPA.[130,131] For both, macrocyclic and acyclic 
chelates, the introduction of an additional linker into the ligand scaffold often requires 
extended synthetic routes and the use of protecting groups.[40] 
 
Figure 9. Selected acyclic polyaza systems functionalized with carboxylic acid groups. 
Overall, there is a large number of different bifunctional chelators that will be displayed in 
more detail in Chapter 1.2. Which of these ligand systems is finally chosen, depends on 
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1.1.6 Radiometal ions 
The choice of the radiometal ion is dependent on the medical objective (diagnosis, 
therapy; target structure), and hence on the respective decay mode and physical half-life 
t1/2 (see Table 3). Ideally, the radionuclide should be readily available at reasonable cost 
containing essentially no stable isotopes (carrier).[24] Such “carrier-free“ii nuclides possess 
high specific activitiesiii and are thus preferred in radiopharmaceutical preparations as they 
minimize the required amount of the respective drug and consequently the toxicity for the 
patient.[24] The production methods for clinically used radiometals commonly involve 
particle accelerators (e.g. cyclotrons: 64Cu, 67Ga, 111In), nuclear reactors (89Sr, 99Mo, 
153Sm), or radionuclide generators (e.g. 68Ge / 68Ga, 90Sr / 90Y, 99Mo / 99mTc).[24] When a 
metal ion is then considered for medical applications, its coordination chemistry has to be 
taken into account which is where inorganic chemistry plays a major role.[19,96,136] This 
comprises aqueous hydrolysis chemistry, redox behavior, and affinity to native biological 
chelators.[21,48,137] Crucial for matching chelators and metal ions is a high degree of 
compatibility between these two components. Important factors are the size of the 
respective metal ion, as it has to fit into the binding site of the ligand, and its preferences 
regarding type and number of donor atoms, as well as coordination geometry.[132,137] In 
this context, the hard-soft acid-base (HSAB) principle can be a useful tool, as it divides 
metal ions (acids) and donor atoms (bases) into one of three classes, i.e. hard, borderline 
or soft. According to this concept a good fit between ligands and metal ions can be 
achieved when combining representatives of the same type.[138,139] The bifunctional 
chelator (BFC) should be selected depending on the unique properties of the metal ion. 
Preferable are, thereby, polydentate ligands which can occupy all coordination sites of the 
metal ion, resulting in its efficient encapsulation and shielding from the environment.[40] 
The energetics of metal ion complexation involves desolvation / solvation, metal-ligand 
bond formation, entropy changes, and steric effects. The steric energy is minimal when 
the structures of the metal-free and the coordinated ligand are identical, i.e. when the 
ligand is fully preorganized for the respective metal ion.[140-143] 
                                                
ii The terms “carrier-free“ (c.f.), “no-carrier-added“ (n.c.a) and “carrier-added“ (c.a.) are used in 
order to indicate the level of specific activity. “Carrier-free“ means that the radionuclide is not 
contaminated with any isotope of the same element, whereas the description “no-carrier-added“ 
only implies that no carrier was added intentionally. The expression “carrier-free“ is difficult to 
quantitate and should hence be used with caution.[133-135] 
iii Specific (radio)activity is defined as the measured radioactivity per gram of compound (unit 
[Bq/g]). In radiochemistry, the activity is often referred to using the amount of substance in mole 
and thus expressed as molar (radio)activity (measured radioactivity per mole of compound, unit 
[Bq/mol]).[135] 
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Table 3. Properties of some selected radiometal ions. 









ScIII 75 44Sc 3.9 h β+ (94 %) 
EC (6 %) 
PET 
  47Sc 3.4 d β– (100 %) therapy 
CuII 73 64Cu 12.7 h β+ (17 %) 
EC (44 %) 
β– (39 %) 
PET, (therapy) 
  67Cu 2.6 d β– (100 %) therapy 
GaIII 62 67Ga 3.3 d EC (100 %) SPECT 
  68Ga 1.1 h β+ (89 %) 
EC (11 %) 
PET 
YIII 90 86Y 14.7 h β+ (32 %) 
EC (68 %) 
PET 
  90Y 64.0 h β– (100 %) therapy 
ZrIV 72 89Zr 78.4 h β+ (23 %) 
EC (77 %) 
PET 
InIII 80 111In 2.8 d EC (100 %) SPECT 
LuIII 98 177Lu 6.7 d β– (100 %) therapy 
BiIII 103 212Bi 1.0 h α (36 %) 
β– (64 %) 
 
  213Bi 45.6 min α (2 %) 
β– (98 %) 
therapy 
AcIII 112 225Ac 10.0 d α (100 %) therapy 
(a) For coordination number (CN) 6.[148] 
In contrast to the metal ions listed above, the group 7 elements technetium and rhenium 
can attain a wide range of oxidation states and coordination geometries.[17,44] The 
chemistry of technetium (99mTc)- and rhenium (186/188Re)-based radiopharmaceuticals[18,149-
155] is hence quite different to that of the radiometals listed in Table 3 and is not consid-
ered in the present thesis. 
1.1.7 Evaluation of metal-ligand complexes 
As mentioned before, the radiometal ion complex as core component of a metalloradio-
pharmaceutical must be inert and stable. To evaluate the integrity of the metal-ligand 
moiety, different experiments with non-radioactive (“cold“) as well as radioactive (“hot“) 
isotopes are conducted. Initial studies of the coordination chemistry can for example 
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provide structural information on the “cold” metal complex in both solid state (X-ray 
analysis) and solution (e.g. NMR, nuclear magnetic resonance, and ESR, electron spin 
resonance, spectroscopy). Furthermore, the natural metal complex can be used as a 
standard for product identification in the studies with radioactive isotopes. In the following, 
various experiments evaluating the potential of the respective metal-ligand complex are 
described. 
Thermodynamic stability 
Complex formation constants as a measure of thermodynamic stability can be accessed 
by potentiometric titrations.[156-159] As a first step, the acid-base properties of the ligand 
need to be investigated in order to determine its protonation behavior. Therefore, a 
defined volume of an acidified ligand solution with known concentration is titrated with 
base while measuring the associated changes of the potential using a combination 
electrode. Based on the Nernst equation (Eq. 1) the measured potentials can be 
converted into pH values, provided that certain conditions are fulfilled. 






 Eq. 1 
 
R: universal gas constant, T: temperature, z: number of transferred 
electrons, F: Faraday constant, a(ox/red): activity of oxidized/reduced 
species, E: measured potential, E0: standard potential of the electrode 
 
Important requirements are constant ionic strength and temperature throughout the 
titration, allowing for the replacement of activities by concentrations in Equation 1. In order 
to keep the ionic strength constant, an inert electrolyte is used in excess. By inserting the 
respective values and, additionally, converting natural to common logarithm, the Nernst 
equation is simplified to: 
 E = E0 − 0.059 V ∙ pH Eq. 2 
For the conversion of potential to pH by Equation 2, the standard potential E0 of the 
electrode has to be determined prior to each measurement. In case of a simple ligand 
titration, there are two components necessary to describe the system, the ligand L and 
protons H. These again form the adducts LH, LH2 etc., where charges are usually omitted 
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for clarity. The corresponding equilibria can be expressed as either cumulative protonation 
(β) or stepwise deprotonation (K) constants. 
Table 4. Comparison of cumulative protonation and stepwise deprotonation reactions. 
 Cumulative protonation Stepwise deprotonation 
1. L +  H ⇌  LH β1 =
[LH]
[L][H]




2. L + 2 H ⇌ LH2 β2 =
[LH2]
L [H]2





Usually, the described constants are given as their common logarithm, i.e. as log βx or -
log Kx (pKax). From this set of equations the following correlations can be derived: 
 
log β1 = − logK2 = pKa2 Eq. 3 
 log β2 = (− logK1) + (−log K2) = pKa1 + pKa2 Eq. 4 
These relations can be easily extended to systems with any number of protonation steps. 
Based on the cumulative protonation constants an equation system including all relevant 
protonated species can be set up. Together with the measured potentials, the 
concentrations of all compounds involved, the autoprotolysis equilibrium of water and 
suitable start values for log β, the system can be solved iteratively using a computer 
program like Hyperquad.[156,160,161] 
As soon as the pKa values of the ligand are determined, metal-ligand titrations can be 
performed to evaluate the thermodynamic stability of the corresponding metal complex. In 
case of basic ligand systems the competition between the Lewis acids M (metal cation) 
and H is used to assess the stability constant KML of the complex ML. The pH decrease in 
comparison to the titration of the metal-free ligand is a quantitative measure for the 
complex stability, i.e. the lower the pH, the more stable the metal complex. Depending on 
the system and the pH range covered during titration, various species like protonated 
metal complexes (MLH), hydroxy compounds (MLH-1), or oligonuclear species might need 
to be included to describe the system.[156] Many metal ions tend to hydrolyze and hence, 
the corresponding hydrolysis reactions have to be considered when working with these 
cations.[162] 
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The stability constant of highly stable metal complexes, that are required for nuclear 
medicine applications, can often not be determined by direct titration as described above. 
A key requirement for these measurements is a noticeable complex dissociation of at 
least 20 % within the range for accurate pH detection (2-12). If this is not the case, ligand-
ligand competition titrations can be performed. Therefore, a competing ligand L’ with a 
comparable affinity for the respective metal ion is needed. Moreover, the sums of the 
protonation constants of the ligands L and L’ must be appreciably different. For the 
determination of the ML complex stability by this method, it is necessary that the pKa 
values of L and L’, as well as the complex formation constant of L’ with the metal ion are 
known.[156,163] 
 
In addition, the pM value is determined as an alternative criterion for metal ion affinity: 
 pM = −log [Mn+] Eq. 5 
The pM value is defined as the negative common logarithm of the free metal ion 
concentration under specified conditions (usually 1 µM total metal, 10 µM total ligand, 
pH 7.4, 25 °C). Comparisons of different ligand systems are straightforward, i.e. the larger 
the pM value, the higher the affinity of the chelate for the respective metal ion. The pM 
value is calculated from the stability constant log KML, taking into account ligand basicity 
(pKa values), metal ion hydrolysis, and (physiological) pH. This condition-dependent value 
is consequently considered more relevant for predicting in vivo stabilities than log KML 
values.[48,158,164-166] 
In the case of copper(I/II) systems, RORABACHER et al. could show a correlation between 
redox potentials and CuIIL stabilities.[167] They found that CuIL/CuIIL potentials are 
inversely related to the common logarithm of copper(II) complex formation constants by 
investigating a wide range of ligand types. A negative potential consequently indicates a 
stable CuII complex. The identified correlation implies that the stability constants of 
copper(I) complexes with different ligands are relatively uniform. From this it can be 
concluded that CuI, as a d10 electronic system, exhibits little preference for specific 
coordination geometries or donor atoms. Provided that the amount of uncomplexed 
copper ion in both oxidation states is negligible, Equation 6 can be formulated for a 
temperature of 25 °C. The underlying relations are illustrated in the square scheme shown 
in Figure 10. Considering that log K(CuIL) is nearly constant (see above) and that the 
ML     +     HnL’ ML’     +     HmL     +     (n-m) H
State of the art 
 21 
potential E(CuI/CuII) is a known value, one can calculate the CuIIL stability constant from 
the corresponding CuIL/CuIIL potential.[167,168] 
 
E(CuIL/CuIIL) = E(CuI/CuII) − 0.059 V · log
K(CuIIL)
K(CuIL)
 Eq. 6 
As redox potentials are easily accessible, this correlation is a useful tool for approximate 
estimations of copper(II) complex stabilities. However, a change of solvent can lead to 
significant changes as solvent molecules compete for the coordination sites on both CuI 
and CuII ions. Furthermore, only ligands that are uncharged in their unprotonated form 
were considered by RORABACHER et al. to exclude the influence of electrostatic 
effects.[167,168] 
 
Figure 10. Correlation between redox potentials and stability constants for CuIL/CuIIL 
couples. Adapted from references [168,169]. 
Radiolabeling experiments 
In further studies, usually the radiolabeling performance of the chelator with the respective 
metal ion is investigated as a function of concentration, temperature, and time. Ideally, 
one can radiolabel a small quantity of the ligand with a high amount of radioactive nuclide 
as this leads to a high specific activity of the resulting radiometal complex. Furthermore, 
fast radiolabeling at mild temperature (10-15 minutes, 25-37 °C) is best, especially with 
short-lived nuclides like, for example, gallium-68 (t1/2 = 1.1 h[27]). However, even with 
longer half-life radionuclides, rapid labeling kinetics are desirable with respect to safety 
considerations and convenience of radiopharmaceutical preparation (“kit-type“ 
formulations[150,170]).[48] The radiolabeling process is usually monitored by thin layer 
chromatography (TLC) and / or high performance liquid chromatography (HPLC). Chelator 
CuII  +  L
log K(CuIIL)
CuIIL
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and radiometal ion are combined and after a defined time, an aliquot of the sample is 
taken and analyzed by radio-TLC or radio-HPLC. For radio-TLC, an impregnated paper 
strip in combination with a suitable mobile phase is used to separate the formed 
radiolabeled ligand from the uncomplexed, “free“ radiometal ions. The TLC plate is then 
measured in a well counter (e.g. a gamma well counter) in order to determine the intensity 
distribution. From that, the radiochemical yield (RCY), expressed as the percentage of 
radioactivity bound to the chelate, can be derived. In case of radio-HPLC, a column is 
used for separation (e.g. a C18 column) as well as a radiation detector for subsequent 
analysis, usually attached after the UV detector in the liquid line. The number and intensity 
of the peaks in the HPLC trace provide information on the radiochemical purity, i.e. the 
presence or absence of other radioactive compounds, whereas peak integration reveals 
the RCY.[144] 
Competition assays 
Challenges to the integrity of a metal complex can be either tested using other chelators 
with high affinity for the respective metallic center or metal ions that compete for the metal 
binding site of the ligand system under investigation. The usual procedure is to first 
radiolabel the chelator under the optimized conditions determined in previous labeling 
experiments. When quantitative radiolabeling (RCY > 99 %) is confirmed by TLC or 
HPLC, different competition assays can be carried out. One approach is the incubation of 
the preformed radiometal-ligand complex with strong metal chelators like cyclam (L3) or 
EDTA (L9).[171-173] Here again, TLC or HPLC is used to determine the ratio of radiometal-
ligand to radiometal-(competing ligand) complex and thus the amount of transchelation. 
Therefore, a suitable system consisting of mobile phase and TLC plate or HPLC column, 
respectively, has to be found in order to clearly separate those two compounds. 
Experiments more relevant to in vivo conditions involve the use of blood serum or 
individual native biochelators (e.g superoxide dismutase and transferrin).[58,158,172-177] From 
a functional point of view, blood can be designated as “liquid tissue“ as it consists of cells 
(erythrocytes, leukocytes, and lymphocytes) and plasma, a protein and electrolyte 
containing fluid. The liquid remaining after blood clotting is called serum, which is plasma 
without the coagulation factor fibrinogen.[178] Normally, human blood plasma has a total 
protein concentration between 65 to 80 g/L and consists of roughly 100 proteins including 
transport proteins such as ceruloplasmin, albumin, metallothionein, and transferrin, 
storage proteins like ferritin, as well as metal containing enzymes like extracellular 
superoxide dismutase (only small amounts).[178-180] By incubation of a radiolabeled ligand 
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with a biologically relevant mixture like blood serum, the stability of the complex to 
transchelation, and thus radiometal loss, can be evaluated over time using size exclusion 
chromatography (SEC)[58,158,174,181] or gel electrophoresis.[182] 
Aside from proteins, the human body contains various metal ions such as Na+, K+, Ca2+, 
Mg2+, Zn2+, Cu2+, and Fe3+ in high (major elements) to low (trace elements) 
concentrations.[179,183] Hence, the radiometal-ligand complex needs to be stable in the 
presence of competing cations. Furthermore, selectivity of the chelator for the respective 
radiometal ion is crucial, as these often comprise metallic impurities depending on the 
production and purification method.[48,184,185] An important aspect to consider in general is 
the concentration ratio: usually radiopharmaceuticals are applied in very small quantities 
(nano- to picomolar levels) and under highly dilute conditions, so that competing chelators 
or metal ions (even if also only present in low concentrations) could be in excess of the 
radiolabeled drug, and thus exchange reactions may be favored.[39,48,184] 
Lipophilicity and biodistribution studies 
Although it might be possible to simulate extracellular conditions to a certain extent during 
in vitro experiments, actual uptake, distribution, and clearance of a radiopharmaceutical in 
living systems is complicated. These pharmacokinetic properties can be correlated with 
the lipophilicity of the drug and therefore 1-octanol-water partition coefficients are 
determined as an index of a compound’s lipophilic character.[186,187] The partition 
coefficient Po/w is defined as the concentration of an unionized substance in the lipid 
phase (1-octanol) divided by its concentration in the aqueous phase (water) and is usually 
given in form of the common logarithm (log Po/w). In the case of ionized compounds, e.g. 
transition metal ion complexes, the degree of ionization (dependent on the pKa value of 
the substance and the pH of the system) must be considered. The distribution coefficient 
Do/w is thus the concentration ratio of the sum of both ionized and unionized forms of the 
respective compound between the two immiscible phases. It is important to note that 
log Do/w, in contrast to log Po/w values, are pH-dependent properties and for in vivo 
applications, the most significant distribution coefficients are those at a pH of 7.4, the pH 
of blood serum.[186,188] A widely used method to determine the lipophilicity of a substance 
is the so-called shake-flask procedure, often in combination with radionuclides for 
analysis. Therefore, the compound to be examined is dissolved in either organic or 
aqueous phase and radiolabeled. Equilibrium partition is then achieved by agitation, 
before separating both phases and analyzing the amount of radiotracers present.[172,189,190] 
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Figure 11. Illustration of 1-octanol-water partition. Adapted from reference [186]. 
Even though general predictions of biological behavior are difficult, one can state that 
rather low lipophilicity (log D < 0) often leads to renal clearance, whereas non-renal 
excretion is predominant at higher lipophilicity (log D > 0).[186,191] Based on such 
observations QSPR (quantitative structure-property relationships) models are developed 
in order to predict the biological properties of new conjugates. These approaches are 
useful tools, as they help to reduce the number of animal experiments and conserve 
resources.[186,188,192]  
However, the ultimate test for radiopharmaceutical stability is carried out in vivo. 
Biodistribution studies in healthy animals (often mice or rats) are performed on radiometal-
ligand complexes without conjugated vectors in order to gain information on uptake and 
clearance behavior, organ distribution, and complex stability under physiological 
conditions. Stable complexes are typically cleared rapidly from the animal via the renal 
(kidneys-bladder-urine) or the hepatobiliary (digestive system-liver-feces) tracts, 
depending on lipophilicity and metabolism. In case of unstable complexes, substantial 
uptake is observed in organs and tissues where the released radiometal ion is known to 
accumulate (e.g. CuII in the liver, GaIII and the lanthanides in the bone).[48,113]  
What is the further procedure from this stage onwards? After the introduction of a vector 
moiety, the stability of the conjugate needs to be examined as a basis for the potential 
application in nuclear medicine. In this case, tumor-bearing animals are used for the 
investigation of targeting and accumulation behavior of the radiolabeled drug. If the results 
are promising, clinical studies on patients (phase I-III) can be initiated with the ultimate 
goal to obtain market approval of the radiopharmaceutical. The typical time frame for this 
process is in the range of 5 to 10 years.[24,48] 
In this introductory chapter the structure and use of receptor targeting radiometal labeled 
pharmaceuticals was presented. The individual components of such metal-based agents 
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radionuclide or bifunctional chelator (BFC) that is optimal for all nuclear medicine 
applications in either imaging or therapy.[95] For this reason, new versatile ligand systems 
need to be developed and investigated with metal ions relevant for radiopharmaceutical 
purposes. The focus in the present thesis is hence on the metal-ligand unit of radiolabeled 
drugs. Therefore, new ligands are synthesized and evaluated with different metal ions. In 
the following chapters these radiometals (Chapter 1.2) as well as the ligand class of 
bispidines (Chapter 1.3) are considered in detail. 
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1.2 Selected radiometal ions – nuclear properties and coordination 
chemistry with emphasis on medical applications 
A selection of metallic radionculides with interesting properties for nuclear medicine will be 
presented including copper-64, gallium-68, indium-111, lutetium-177, and actinium-225. 
The main focus of this discussion will be on radiometal production and decay 
characteristics as well as on non-radioactive coordination chemistry and radiopharma-
ceutical applications. 
1.2.1 Copper-64 
There are a number of radioactive copper isotopes suitable for nuclear imaging and 
therapy, i.e. 60Cu, 61Cu, 62Cu, 64Cu, 66Cu, and 67Cu.[146] Copper-64 is the most versatile of 
these radionuclides because of its unique decay properties involving β– decay to 64Zn 
(39 %), as well as electron capture (44 %) and positron emission (17 %) to 64Ni with a 
maximum β+ energy of 653 keV.[27,146,193] The copper isotope 64Cu can hence be used for 
either therapeutic or diagnostic purposes, whereby the main application is PET 
imaging.[38,194,195] In contrast to PET radionuclides like 11C (t1/2 = 20.4 min[27]) and 
18F (t1/2 = 109.8 min[27]), copper-64 displays a comparably long half-life of 12.7 hours and 
is thus compatible with small as well as large molecular carriers.[38,146,194] Together with the 
pure β– emitter 67Cu (t1/2 = 2.6 d[27]) copper-64 builds a “matched pair“ for combined 
imaging and therapy.[49-51] 64Cu is commercially available and can be produced by 
biomedical cyclotrona via the 64Ni(p,n)64Cu nuclear reaction.[21,196,197] Therefore, 
12 MeV proton irradiation of enriched 64Ni is performed, followed by separation of 64Cu 
and other contaminants like cobalt isotopes from the 64Ni target using anion exchange 
chromatography.[196-199] 
The coordination chemistry of copper in the oxidation state +II has been extensively 
investigated and offers an excellent starting point for the development of copper-based 
radiopharmaceuticals.[137,153,200] However, certain special features have to be considered 
when working with this transition metal cation: according to the HSAB principle, copper(II) 
is classified as a “borderline” element and as such prefers nitrogen-containing donors like 
amines and pyridines.[138,139,200] Copper(II) has a d9 electron configuration and builds 
paramagnetic metal complexes with coordination numbers (CN) of four to six 
corresponding to ionic metal radii between 57 and 73 pm.[148,200] Typical coordination 
modes of copper(II) approximate pseudo square planar, trigonal pyramidal, square 
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pyramidal and octahedral geometries.[200] Copper(II) is a JAHN-TELLER active system and 
in the case of 6-coordinate CuII ions this effect is often observed as an axial 
elongation.[2,200,201] 
Copper(II) and its complexes are prone to reduction under physiological conditions, 
whereby the estimated threshold for typical bioreductants is –0.40 V vs. the normal 
hydrogen electrode (NHE).[137] The CuII/CuI reduction is suggested to be a cause for 
radiocopper loss in vivo since d10 copper(I) is significantly more labile towards ligand 
exchange.[21,200] It is hence important that a ligand selected for use with 64Cu can either 
coordinate both CuI and CuII or stabilizes copper(II) in a way that prevents reduction.[194] 
Thereby it must be considered that CuI, in contrast to CuII, prefers soft polarizable ligands 
with sulfur and phosphorus donor atoms.[200] The redox behavior of copper can be 
exploited for imaging of oxygen deficiency (hypoxia) using bis(thiosemicarbazone) 
chelates like ATSM (L11, N2S2-type ligand).[202-204] The proposed mechanism involves 
formation of CuI species from copper(II) complexes like CuII-ATSM in hypoxic cells, 
followed by retention of the reduced compounds.[205] 
A variety of different ligand systems has been investigated for the combination with the 
PET nuclide copper(II)-64 (see Figure 12).[48,137,146,194,200] To evaluate the potential of the 
chelates for nuclear medicine applications, radiolabeling and stability studies were 
performed. Macrocycles of varying size and substitution pattern were shown to form highly 
stable copper(II) complexes.[137,194] Tri- and tetraazamacrocycles were functionalized with 
carboxylic acid (L4, NOTA; L5, DOTA, and L6, TETA), phosphonic acid (L13, DOTP and 
L17, TETP) and picolinic acid pendent arms (L12, NO1PA2PY; L14, DO1PA, and L18, 
TE1PA).[115,116,124,125] The incorporation of an ethylene linker into the marcocyclic ring led 
to the corresponding cross-bridged derivatives like CB-TE2A (L20) or CB-TE2P (L22). 
Furthermore, substitution with different functional groups was also tested (e.g. L21, CB-
TE1A1P).[122,123,126,206] In addition, various bifunctional systems with suitable linker moieties 
were developed.[48] The octadentate N4O4 macrocyclic chelate TETA (L6) has 
predominantly been examined for radiopharmaceutical purposes with copper(II)-64.[48] 
However, Anderson et al. showed in experiments on rats that 64CuII-TETA-D-Phe1-
octreotide (64CuII-TETA-OC) is relatively unstable and undergoes significant transchelation 
towards native proteins like superoxide dismutase (SOD).[207] The abovementioned cross-
bridged versions CB-TE2A (L20), CB-TE1A1P (L21), and CB-TE2P (L22) are therefore 
especially interesting as they show improved in vivo stability and radiolabeling kinetics in 
comparison to TETA.[208] 
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Sarcophagine hexaazamacrobicyclic cryptands are well-known for their fast and extremely 
strong copper(II) binding. The Sar-cage DIAMSAR (L24, N6) and its derivatives have 
hence been investigated as chelates for 64CuII-based radiopharmaceuticals.[209-214] The 
lipophilicity of such nitrogen-rich ligands can have a negative impact on the biodistribution 
including accumulation in the liver and the digestive tract.[48] For this reason, Sar-
derivatives with additional carboxylic acid functionalities have been developed.[215-217] 
Another type of cyclic chelator are dioxotetraaza macrocycles, bearing amine and amide 
functions. Recently, COMBA and coworkers incorporated a bispidine moiety into this ligand 
scaffold. By subsequent variation of the ring size and flexibility, they found BBDT (L25) to 
form copper(II) complexes, which are stable in the presence of SOD and human serum. 
As with most macrocyclic systems, the radiolabeling properties of L25 are not ideal since 
heating to 50 °C for more than 30 minutes is required.[177] In contrast to that, the bispidine 
system itself provides a suitable platform for the development of 64CuII chelators showing 
fast labeling kinetics. Examples for such bispidine ligands are N2py4 (B3), (p-MeO)B4, 
and B5, depicted in Figure 12.[172,173,218] The application of bispidine ligands in nuclear 
medicine, especially for PET imaging, will be discussed in Chapter 1.3. 
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Figure 12. Selected copper(II) chelators. 
As mentioned before, high complex stability is crucial to prevent radiometal loss in vivo. 
After iron and zinc, copper is the third most abundant trace metal in the human body.[146] 
As such, its metabolism is tightly regulated and there are a number of copper-binding 
biomolecules that can potentially compete with a chelator for 64CuII coordination, including 
serum albumin, transcuprin, ceruloplasmin, metallothionein, and superoxide 
dismutase.[146,180] When excess CuII ions are injected into the blood stream, they 
immediately become bound to serum copper transport proteins like albumin or 
transcuprin. These proteins deposit the metal in the liver resulting in its rapid clearance 
from the blood. In the liver the copper is predominantly taken up by ceruloplasmin and in 
this form returns to the blood stream to be transferred to other organs.[146,219] Knowledge 
of the natural biodistribution of ionic CuII is essential for comparison with the 
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1.2.2 Gallium-68 
For the application in nuclear medicine the gallium isotopes 67Ga and 68Ga are 
promising.[220] Accelerator-produced gallium-67 (t1/2 = 3.3 d[27]) disintegrates by electron 
capture with emission of γ rays suitable for scintigraphy and additionally emits low energy 
AUGER and conversion electrons.[53,221] When coordinated to deprotonated citric acid 
(L26), gallium-67 can be used for the detection of tumors and inflammations.[17,221] 
However, the current research is predominantly focused on the short-lived isotope 
gallium-68 (t1/2 = 1.1 h[27]), as it can be produced in a commercially available 68Ge / 68Ga 
generator system.[222,223] These generators produce 68Ga through electron capture decay 
of its “parent” radionuclide 68Ge. Efficient separation of both metals is achieved by ion 
exchange chromatography with the parent 68Ge remaining on the column and the 
daughter 68Ga being eluted using concentrated hydrochloric acid.[223] The long half-life of 
germanium-68 of 271 days allows the generator to be used for up to 1 year.[21,27,223] 
Gallium-68 decays by 89 % positron emission with a maximum β+ energy of 1.9 MeV to 
68Zn.[27,222] The generator-based production of 68Ga provides thus a feasible route to a 
PET nuclide without the need for an on-site cyclotron. In analogy to the successful 
application of the generator-produced radionuclide 99mTc for nuclear imaging, 68Ga is 
expected to pose great potential for future developments.[194,223] 
In aqueous solution, the only stable and relevant oxidation state of gallium is GaIII, which 
exists in its hydrated form as [Ga(H2O)6]3+ under acidic conditions.[21,194] This small and 
highly charged cation is a classic hard Lewis acid and consequently, has a strong affinity 
for hydroxides.[137-139] In the pH range of 3-7 insoluble Ga(OH)3 is formed in the absence of 
suitable ligands and is hydrolyzed to the gallate anion [Ga(OH)4]– above pH 7.[21,194] 
Gallium(III) typically builds metal complexes with coordination numbers (CN) of four to six 
in which the radius of the cation is in the range of 47-62 pm.[137,148] The development of 
ligand systems for GaIII is focused on hexadentate chelators in order to ensure full 
encapsulation of the metal ion in a (distorted) octahedral geometry.[137] As a hard acidic 
cation, gallium(III) forms thermodynamically stable complexes with ligands containing 
anionic oxygen, and nitrogen donors, but was also found to exhibit a good affinity for 
thiolates.[137,194] 
Due to the close similarity of the trivalent metal ions GaIII and FeIII, transchelation of 
gallium(III) by native iron binding proteins is a major issue for in vivo applications.[194] The 
strong affinity of GaIII for the biological iron transporter transferrin is well known.[165] It is 
hence important that radiogallium(III) complexes are sufficiently stable in presence of this 
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blood serum protein to prevent ligand exchange, resulting in the accumulation of 67/68GaIII 
in the liver, lungs, and bone.[223,224] 
Because of its short half-life, 68GaIII is predominantly used with small vector molecules like 
peptides.[54,71] Suitable gallium(III) chelators are needed for the incorporation of the 
radiometal ion into biomolecules and a selection thereof is presented in Figure 13. The 
macrocyclic frameworks NOTA (L4) and DOTA (L5) have been extensively investigated 
with 68GaIII and can be designated as “gold standards” for this radiometal.[48,54] The 
smaller-sized cycle NOTA is better suited for gallium(III) and the thermodynamic stability 
of GaIII-DOTA is significantly lower than that of GaIII-NOTA.[225] Nevertheless, conjugates 
such as 68GaIII-DOTA-TOC and 68GaIII-DOTA-TATE showed high in vivo stability.[226,227] In 
order to improve their gallium(III) binding properties for radiopharmaceutical application, 
derivatives of these macrocycles have been synthesized. In the case of the 
triazacyclononane-based chelator TRAP (L27, N3O3-type ligand), phosphinic acid arms 
with additional distal carboxylic acid groups have been introduced into the macrocyclic 
scaffold.[228,229] Of particular interest is the improved selectivity of L27 for GaIII in the 
presence of competing metal ions when compared to NOTA.[230] Another important feature 
is the potential of L27 to be radiolabeled with 68GaIII under the highly acidic conditions of 
the 68Ge / 68Ga generator eluent, which is possible due to the low pKa of < 1 of the 
phosphinic acids.[229] A general problem when using macrocycles to complex short-lived 
radionuclides like 68GaIII is the often unfavorable chelation kinetics including either long 
reaction times or harsh conditions.[48,194] The heptadentate macrocyclic chelate PCTA 
(L28, N4O3) incorporates pyridine into the DOTA framework instead of a secondary 
amine.[231] Originally evaluated as a potential MRI contrast agent,[232] L28 has been 
recently investigated with 68GaIII. L28 was thereby found to perform radiolabeling in less 
than 30 minutes at ambient temperature whilst maintaining the high stability associated 
with macrocycles.[233,234] 
With regard to their fast complex formation, non-macrocyclic chelators are of special 
interest for application with 68GaIII. Derivatives of the preorganized ligand system AAZTA 
(L29, N2O4 or N3O3) are promising new gallium(III) chelates with rapid radiolabeling 
kinetics and good preliminary stability results.[235,236] Another prominent ligand class is the 
so-called “pa-family” which uses picolinic acids (pa) as central binding units.[237-240] The 
first “pa” ligand to have been investigated for radiochemical purposes was the 
hexadentate scaffold H2dedpa (L30, N4O2) showing ideal properties for 67/68GaIII.[241-243] 
Due to the hardness of gallium(III), oxygen-rich chelators are quite suitable for this metal 
cation. The bacterial siderophore desferrioxamine B (DFO, L31, O6) natively binds FeIII 
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and also forms stable GaIII complexes of high thermodynamic stability.[244,245] The tripodal 
tris(hydroxypyridinone) chelator CP256 (L32, O6) is another pure oxygen donor ligand and 
can be radiolabeled with 68Ga in 5 minutes at room temperature.[246] In addition, 68GaIII-L32 
displayed high inertness to transferrin in competition studies.[246] It is expected that the 
further development of these promising acyclic ligand systems will have significant impact 
on 68GaIII PET imaging in the future.[194] 
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1.2.3 Indium-111 
After 99mTc, 111In is the most widely used metallic radionuclide for single photon emission 
computed tomography (SPECT). With a half-life of 2.8 days, 111In decays via electron 
capture (EC) to 111Cd emitting γ rays of 171 and 245 keV, and is hence ideally suited for 
nuclear imaging.[21,27] In addition, 111In emits AUGER electrons and an 111InIII radiolabeled 
peptide conjugate has been successfully evaluated for the treatment of neuroendocrine 
tumors.[44,247,248] 111In is commercially produced by irradiation of a natural cadmium target 
with a proton beam via the 111Cd(p,n)111In or the 112Cd(p,2n)111In reaction. The subsequent 
separation of 111In from the cadmium target is performed by either ion exchange or solvent 
extraction.[137] 
As in the case of gallium, the only stable indium oxidation state under aerobic aqueous 
conditions is +III.[137] In comparison to GaIII, InIII has a relatively large size with 62-92 pm 
for coordination numbers (CN) of 4-8.[148] Within the element group the “hardness” of a 
metal cation decreases with increasing ionic radius[138,139] and indium(III) hence displays a 
slightly enhanced affinity for softer donor atoms.[137] Furthermore, InIII attains CN of 7 or 8 
in its complexes compared to predominantly 6-coordinate GaIII complexes.[137] Such 
differences in the coordination chemistry of metal ions can have a significant impact on 
their in vivo behavior.[249] A selection of prominent indium(III) chelators is presented in 
Figure 14. 
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The macrocycle DOTA (L5) and the acyclic ligand DTPA (L34) are the “gold standards” 
for 111InIII radiolabeling.[48,137] The indium(III) DOTA complex is highly stable,[158,250] but 
requires elevated labeling temperatures to obtain high molar activities, which is 
problematic in combination with heat-sensitive biomolecules as vector moieties.[48,251] 
Despite the accumulating studies of the InIII-DOTA complex regarding its application as a 
radiopharmaceutical no X-ray structural data are available.[137,250-254] However, the solid 
state structure of the indium(III) complex based on the amide-substituted DOTA derivative 
DOTA-AA (L33) has been reported and is shown in Figure 15 .[255] The central indium(III) 
ion is coordinated by the N4O4-ligand DOTA-AA by four amine-nitrogen, one carbonyl-
oxygen, and three carboxylate-oxygen atoms. The N4 coordination plane and the O4 plane 
are twisted by an angle of ~28 ° with respect to each other resulting in a geometry 
between prismatic (theoretical twist angle of 0 °) and antiprismatic (45 °).[255] Such 
structures are referred to as twisted square-antiprismatic.[137] 
 
Figure 15. ORTEP plot of the complex InIII(DOTA-AA) (CCDC 228929).[255] Ellipsoids are 
shown at the 50 % probability level; co-crystallized solvent molecules, and hydrogen 
atoms are omitted for clarity.[256] 
In contrast to the macrocyclic ligand DOTA, DTPA (L10) shows fast radiolabeling with 
111InIII within 5-10 minutes at room temperature.[48] Solid state X-ray analyses revealed that 
DTPA forms 7- or 8-coordinate indium(III) complexes with distorted pentagonal-
bipyramidal or square-antiprismatic geometries, respectively (see Figure 16).[137,257-259] In 
the case of sevenfold coordination, one acetate arm is protonated and, in this form, is not 
involved in metal ion complexation.[257,259] Despite the non-optimal in vivo stability, 
derivatives of DTPA are incorporated in two approved 111InIII-labeled radiopharma-
ceuticals, known under the trade names OctreoScan® and ProstaScint®.[21,48,127-129,260,261] 
Whereas OctreoScan® (111InIII-DTPA-octreotide) is based on a tumor-targeting peptide, 
In
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ProstaScint® (111InIII-pendetide-capromab) uses a monoclonal antibody for the detection of 
prostate cancer.[127-129,260,261] Inspired by the successful application of DTPA in 111InIII 
SPECT imaging, the preorganized cyclohexyl derivative CHX-AII-DTPA (L34, N3O5-type 
ligand) was developed, showing improved stability over DTPA with different metal 
ions.[48,130,131,262] However, as a consequence of the preorganization of the ligand scaffold 
the radiolabeling kinetics of CHX-AII-DTPA with 111InIII are less favorable than those of 
DTPA. While DTPA can be labeled within 5-10 minutes at room temperature, CHX-AII-
DTPA requires mild heating (25-60 °C) and extended reaction times of 30-60 minutes.[48] 
  
7-coordinate 8-coordinate 
Figure 16. ORTEP plot of the complex anions of C(NH2)3[InIII(DTPA)] (left, CCDC 
1312572)[257] and Na2[InIII(DTPA)] (right, CCDC 1213339).[258] Ellipsoids are shown at the 
50 % probability level; co-crystallized solvent molecules, counterions, and hydrogen 
atoms are omitted for clarity.[256] 
Another promising indium(III) chelator is the picolinic acid-based ligand H4octapa (L35, 
N4O4), which displays high in vivo stability as well as fast radiolabeling behavior.[58,158,240] 
So far, the solid state structure of the indium(III) octapa complex could not be determined. 
NMR studies in deuterated water and density functional theory (DFT) calculations, 
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1.2.4 Lutetium-177 
Since the beginning of the past decade rapidly growing interest in lutetium-177 as a 
therapeutic radionuclide has been observed.[263,264] The increased use of 177Lu is mainly 
attributed to its favorable radiochemical properties and its ease of production with high 
specific activity.[264] Lutetium-177 decays with a half-life of 6.7 days to stable hafnium-177 
via the emission of β– particles with low energies of 177, 385, and 498 keV used for 
radiotherapy.[27,264] Depending on the size, location, and characteristics of a specific 
tumor, the choice of the β– emitting radionuclide for targeted therapy might be different.[111] 
For example, high energy β– emitters such as 90Y (t1/2 = 2.7 d[27]) are preferable for the 
treatment of large solid tumors, whereas the low energy β– emissions of 177Lu are better 
suited for smaller tumors and metastases.[111,263] In addition, lutetium-177 also emits γ rays 
with maximum energies of 113 and 208 keV suitable for SPECT imaging and dosimetry 
calculations.[21,27] Another advantage of 177Lu is that its long half-life allows for the 
distribution to users in remote regions with minimal activity loss from radioactive 
decay.[44,263] The most popular therapeutic radionuclide is iodine-131 (t1/2 =8.0 d[27]), which 
has been routinely used as sodium iodide-131 (Na131I) for the treatment of thyroid cancer 
for more than 60 years.[43] Radioiodine therapy is based on the highly selective uptake of 
free iodide from the blood to the thyroid gland via the sodium iodide symporter.[43,265] As a 
consequence of this unique biological mechanism, 131I will continue to be the radionuclide 
of choice for the therapy of thyroid diseases. However, due to the similar nuclear 
characteristics of 131I and 177Lu, the radiolanthanide can be considered as the metallic 
analog of 131I and might replace it in some non-thyroid applications.[264] 
Lutetium-177 can be produced by charged particle acceleration in a cyclotron, but neutron 
irradiation using a nuclear reactor is the preferred route in terms of practicability and cost-
effectiveness. Production of 177Lu in a nuclear reactor can be performed in two ways, i.e. 
by the direct activation of enriched 176Lu or through the indirect route by irradiation of 176Yb 
followed by β– decay to 177Lu.[264] 
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Figure 17. Selected lutetium(III) chelators. 
Lutetium is the heaviest member of the lanthanide group and as such possesses the 
smallest radius due to the lanthanide contraction.[44,264] The ionic radii reported for 
lutetium(III) complexes with coordination numbers of 6, 8, and 9 are 86, 98, and 103 pm, 
respectively.[148] As a typical lanthanide the only common oxidation state of lutetium is 
+III.[44,264] The coordination chemistry of the hard Lewis acid lutetium(III) is characterized 
by its tendency to form complexes with hard donors like oxygen, nitrogen, and fluoride. 
Furthermore, LuIII prefers polydentate ligand systems usually resulting in 8- or 
9-coordinate metal complexes.[264] In Figure 17 a few examples of commonly used 
lutetium(III) chelators are depicted. The ubiquitous DOTA (L5) for instance acts as an 
octadentate ligand for lutetium(III) through the four nitrogen atoms of the macrocycle and 
the four oxygen atoms of the carboxylic acids.[266] A water molecule occupies a ninth 
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Figure 18. ORTEP plot of the complex anion of Na[LuIII(DOTA)(H2O)] 
(CCDC 1221968).[266] Ellipsoids are shown at the 50 % probability level; co-crystallized 
solvent molecules, counterions, and hydrogen atoms on carbon atoms are omitted for 
clarity.[256] 
Despite the preference of lutetium(III) for high coordination numbers, the hexadentate 
chelate EDTMP (L36, N2O4-type ligand) was successfully evaluated with 177LuIII for the 
treatment of metastatic bone cancer.[267-270] In some countries 177LuIII-EDTMP is already 
used as an agent for metastatic bone pain palliation.[263] However, to this day, the 
macrocycle DOTA is the most widely used chelator for 177LuIII. Despite the relatively long 
half-life of 177LuIII, DOTA-peptide conjugates have been evaluated for radiotherapy.[264] 
Very promising results were found for 177LuIII-DOTA-TATE (Lutathera®), which efficiently 
targets neuroendocrine tumors.[271,272] Due to the relatively slow radiolabeling kinetics of 
DOTA with 177LuIII and the need for elevated reaction temperatures,[251,264] there is an 
increasing interest in acyclic chelators like DTPA (L10),[273,274] CHX-AII-DTPA (L34),[274-277] 
and H4octapa (L35)[58] for the potential application with the radiolanthanide. Although the 
nuclear properties of 177LuIII are highly suitable for application involving monoclonal 
antibodies (mAbs) as targeting vectors, the clinical use of 177LuIII-radiolabeled antibodies is 
not as widespread as that of the respective peptide-based agents. This might be 
explained by the more challenging preparation and characterization of antibodies in 
comparison to small peptides.[263] However, there are a number of mAbs, often 
functionalized with DOTA, which are currently in clinical trials for application with 
177LuIII.[264] A promising example is the development of 177LuIII-DOTA-rituximab for 
radioimmunotherapy of Non-HODGKIN’s lymphoma.[278,279] 
Lu
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1.2.5 Actinium-225 
The ultimate goal of nuclear therapy is to create a “magic bullet” that specifically targets 
and destroys malignant cells without harming surrounding healthy tissue.[40,41] To this end, 
the properties of α particle-emitting nuclides, with their high linear energy transfer (LET) 
and short path length resulting in highly selective cytotoxicity, are ideal.[41,147] A promising 
radionuclide for molecular targeted α therapy (TAT) is actinium-225, which disintegrates 
with a half-life of 10.0 days producing six radionuclidic daughters in the decay cascade to 
virtually stable bismuth-209 (t1/2 = 1.91019 y[280]).[27,281] As shown in Figure 19, four of 
these daughters are short-lived α emitters and 225Ac can hence be designated as an α 
particle nanogenerator.[281] In addition to the net four α emissions, the decay of 225Ac 
yields three β– disintegrations, and two useful γ emissions of which the 213Bi 440 keV 
γ emission is suitable for imaging and dosimetry studies.[281,282] 225Ac can be obtained 
either from the natural decay of 233U or from neutron irradiation of 226Ra followed by 
successive capture decay reactions via 227Ac, 228Th to 229Th.[281] 
 
Figure 19. Decay scheme of uranium-233.[27,283] 
There are no stable isotopes of actinium and the knowledge about the coordination 
chemistry of this element is hence limited. The properties of actinium(III) were usually 
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LaIII and AcIII, LaIII has been used as surrogate for AcIII in the development of synthetic or 
analytical procedures.[284] However, it has been shown that there are significant 
electronical differences between lanthanides and actinides.[285-287] As a consequence of 
the limited understanding of actinium chemistry, the development of suitable AcIII 
chelators is challenging. The ionic radius of actinium(III) was reported as 112 pm in 
six-fold coordination and the large size of the cation is likely suited to ligands with high 
denticity.[119-121,148,284,288] An important prerequisite for any 225AcIII chelator is the ability to 
stably bind the radionuclide as well as its daughters.[281] A selection of chelates studied for 
225AcIII coordination is depicted in Figure 20. 
 
Figure 20. Selected actinium(III) chelators. 
Due to the large ionic radius of actinium(III) the 15- and 18-membered macrocycles PEPA 
(L7, N5O5-type ligand)[117] and HEHA (L8, N6O6),[118] were evaluated for the application 
with 225AcIII.[119-121,281] In biodistribution studies in healthy mice 225AcIII-radiolabeled PEPA 
showed an inadequate stability resulting in the substantial accumulation of activity in the 
liver, while 225AcIII-HEHA proved to be exceptionally stable.[119] Inspired by these results, 
the antibody conjugate HEHA-mAb201B was prepared and labeled with 225AcIII for 
targeted radioimmunotherapy (RIT) of lung tumors in mice. Although the radioconjugate 
effectively delivered large doses of 225AcIII to the tumors, the treatment also led to death of 
the laboratory animals within days.[289] More recently, the smaller macrocycle DOTA (L5, 
N4O4) has been shown to be the most suitable 225AcIII chelator so far based on different 
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HuM195 that targets the CD30 antigens on acute myeloid leukemia cells and the resulting 
radioconjugate 225AcIII-DOTA-HuM195 has shown promise in clinical trials.[281,291] Due to 
the long half-life of actinium-225 of 10 days, the radionuclide is best suited for the 
application with antibodies as vectors. However, the conditions required for the labeling of 
the described macrocycles with 225AcIII are incompatible with antibody stability and 
retention of function. Therefore, a two-step procedure was developed for the preparation 
of a radiolabeled DOTA-antibody conjugate involving complexation of 225AcIII by a 
bifunctional DOTA derivative (50-60 °C, 30-60 min) followed by coupling of 225AcIII-DOTA-
NCS to the respective antibody.[288] Although the radioconjugate is accessible by this 
route, the presented method is not convenient for standard clinical use. For this reason, 
acyclic ligand systems, known for their fast radiolabeling kinetics with many metal ions at 
ambient temperature,[48] were also investigated with 225AcIII.[119,121,288] However, the linear 
polyaminocarboxylic acids DTPA (L10, N3O5) and CHX-AII-DTPA (L34, N3O5) do not 
appear to be suitable 225AcIII chelators as evidenced by inadequate stability in YIII 
challenge assays and animal studies.[119,121,288]  
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1.3 Bispidine ligands for nuclear medicine 
The general term “bispidine” for the 3,7-diazabicyclo[3.3.1]nonane framework was derived 
from its chemical structure consisting of two condensed piperidine rings 
(bis-piperidine).[292] Bispidine derivatives with a keto or alcohol function at C9 are 
designated as bispidones or bispidols, respectively (see Figure 21). However, the term 
bispidine is often used as the general designation for compounds with the characteristic 
bicyclic backbone regardless of their substitution pattern. The bispidine scaffold occurs in 
nature in the form of the cyclic alkaloid sparteine (4), for example, which can be isolated 
from lupines and displays antiarrhythmic and antimicrobial activity.[293,294] 
 
Figure 21. From left to right: Chemical structures of sparteine, bispidine, bispidone and 
bispidol. 
The standard procedure for the bispidone synthesis goes back to Mannich and Mohs, who 
described it in 1930 and is still used to date.[159,292] The bispidine system is built up in two 
consecutive double Mannich reactions starting from a primary amine, two aldehydes and 
dimethyl-1,3-acetonedicarboxylate as CH-acidic compound.[292,295,296] The resulting 
piperidone is usually obtained in the form of keto-enol tautomers, as shown in 
Figure 22.[295,297] Subsequently, it is reacted in a second condensation with formaldehyde 
and another amine to the respective bispidone.[292,295,296] By varying the residues R1 and 
R2 at the amine groups, a large number of differently substituted bispidones with variable 
denticity and donor atoms is accessible.[298] Due to the keto group at C9, bispidones are 
prone to ring opening via retro Michael reaction. This unfavorable side reaction can be 
avoided by reduction of the carbonyl function to the corresponding alcohol.[298,299] 
Furthermore, hydration of the C9 ketone upon coordination of the bispidone to a metal ion 
is observed frequently.[298] In addition to the C9 reduction to a monool, the ester groups 
can be either hydrolyzed[173] or reduced resulting in a triol.[300] The reductions, particularly 
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bispidine scaffold and consequently influence the stability of corresponding metal 
bispidine complexes.[301-303] 
 
Figure 22. Standard bispidone synthesis via two double Mannich reactions.[298] 
As diaza-derivatives of adamantane, bispidines possess a very rigid structure, which is 
highly preorganized for the coordination of metal ions. The first transition metal bispidine 
complexes were published by Stetter and Haller in 1957 and 1969.[304,305] Since then 
numerous bispidine compounds with different metal ions, such as vanadium(IV/V),[306] 
chromium(III),[307] manganese(II),[308,309] iron(II/III),[310,311] cobalt(II/III),[312-314] nickel(II),[315] 
copper(I/II),[218,316,317] zinc(II),[303] ruthenium(II),[318] and platinum(II)[319-321] have been 
reported. There are three isomers of the unsubstituted bispidine scaffold differing in the 
conformation of the two condensed piperidine rings (see Figure 23).[298] However, the only 
conformation suitable for metal ion coordination is the chair-chair form, which, in general, 
is energetically favored compared to the chair-boat or the boat-boat conformation.[132,298] 
With sterically demanding residues at N3 and N7, chair-boat isomers can be stabilized[298] 
and even a boat-boat form has been recently observed.[322] In the case of substituents in 
C2 and C4 position, there are additionally different possible configurations. Depending on 
the orientation of the residues one can distinguish between the exo-exo isomer (all axial), 
the endo-exo isomer (axial and equatorial) and the endo-endo isomer (all equatorial). The 
achiral endo-endo configuration is needed for the formation of metal complexes, as it 
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Figure 23. Conformational isomers of the bispidine scaffold with different axial (a) and 
equatorial (e) substituents at C2 and C4 of the chair-chair isomer. 
By using different amines in the bispidone synthesis (Figure 22), numerous tetra-, penta- 
and hexadentate ligand systems have been synthesized, which adopt distorted square 
pyramidal or octahedral geometries upon metal ion coordination.[298] An important feature 
of the bispidine framework is the structural difference between N3 and N7. In metal 
bispidine complexes, the M-N7 bond is part of two six-membered chelate rings and hence 
more flexible than the M-N3 bond as part of two rigid five-membered chelates.[298,323] This 
usually leads to a longer bond from the metal center to N7 than to N3, but isomers with a 
short M-N7 and a longer M-N3 bond have also been reported.[307,324] Bispidine ligands are 
consequently preorganized for metal ions that favor tetragonal coordination geometries, 
i.e. for JAHN-TELLER-active systems such as copper(II).[303,325] For CuII bispidine complexes 
a pseudo JAHN-TELLER elongation has been observed along all three coordination 
axes,[326-329] which suggests that the corresponding minima are close to degenerate.[323] 
Hole size calculations[330] on bispidine ligands indicate that they have a relatively large 
metal binding site with averaged metal-donor distances of more than 2.1 Å and hence 
preferably stabilize lower as compared to higher oxidation states.[302] 
An immense variety of bispidine derivatives together with their metal coordination 
chemistry and diverse applications have been described.[298,323,331,332] Transition metal 
bispidine complexes are used in copper(II)-catalyzed aziridination reactions,[333,334] in 
nickel-catalyzed C-C bond formation reactions using a nickel(II) precatalyst[335] and in the 
enantionselective copper(II)-catalyzed Henry reaction.[336] Further applications include 
oxygen activation by copper(I)[316,325,337-341] and cobalt(II),[312,314] as well as oxidation 
reactions by high-valent iron[342] and manganese[343] bispidine complexes. An interesting 
approach in medical chemistry is the investigation of bispidine analogs of cisplatin as 
potential cytostatic agents in cancer therapy.[319-321] In addition, bispidines provide a 
suitable platform for the development of new in vivo radiotracers.[323,331] For the application 
as bifunctional chelator (BFC) in nuclear medicine, the bispidine system must be 
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possible positions, i.e. at the ester groups,[173] at the C9 keto function,[344] or at the tertiary 
amines of the ligand backbone.[172,345] 
 
Figure 24. Possible functionalization sites at the bispidone scaffold. 
Due to the high complementarity of bispidines and copper(II), these ligands are well-suited 
for the use as BFCs in 64CuII PET imaging. The first bispidine to be investigated in this 
regard was the hexadentate ligand N2py4 (B3).[173,302] Preliminary investigations of B3 with 
64CuII have shown fast radiolabeling under mild conditions and high stability in the 
presence of competing ligands as well as in rat plasma. After C9 reduction and ester 
hydrolysis of B3, the resulting bispidol B6 was attached to a stabilized bombesin (BBN) 
analog, yielding the respective B6-BBN conjugate (see Figure 26). The radiopharma-
cological investigation of the 64CuII-labeled bispidine-bombesin conjugate was then 
performed by biodistribution and small animal PET studies.[173] 
direct introduction of a linker
moiety or functionalization of 
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Figure 25. Classical bispidines investigated for nuclear medicine applications. 
 
Figure 26. Bispidine-bombesin conjugate for tumor imaging studies.[173] 
While studying tetra- and pentadentate bispidines COMBA et al. observed a correlation 
between the basicity of the aromatic donor groups at C2 and C4, and the stability of the 
corresponding copper(II) complexes.[172,317] In a systematic survey, tetradentate bispidines 
with different substituents in either the ortho-, meta-, or para-position of the pyridine 
donors were synthesized and their CuII complexes investigated by cyclic voltammetry.[317] 
It was shown that the increase of electron density upon introduction of a methoxy group in 
para-position of the pyridines resulted in a more stable copper(II) bispidine complex. A 
para-substituted nitro group, on the other hand, decreased the basicity of the pyridines 
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methoxy substituted pentadentate bispidol ligand (p-MeO)B4, which showed promising 
results in initial radiochemical investigations.[172] 
Charbonnière et al. also work on pentadentate bispidol systems for 64/67CuII-based radio-
pharmaceuticals, but use a methylene carboxylic acid substituent instead of a picolyl 
group at N7 of the ligand backbone.[218] The high selectivity of B5 for copper(II) and the 
kinetic inertness of the complex inspired the development of the recently published 
bifunctional version B7.[218,346] As a proof of principle, coupling of B7 to biotin and to a 
model peptide was performed, but further studies are needed to evaluate the in vivo 
stability of these conjugates.[346] 
In terms of dual imaging, bispidine systems were attached to fluorescent probes like the 
BODIPY (boron-dipyrromethene) chromophore,[344] the green rhodamine dye ATTO532, 
and the red cyanine dye Cy5.5.[345] The bispidine-dye conjugates were investigated with 
regard to combined PET and optical imaging.[344,345] The nuclear component can thereby 
be used to localize the diseased tissue followed by fluorescence-guided biopsy or 
surgery.[347,348] 
Apart from the bispidines, discussed so far, there are also macrocyclic systems 
incorporating bispidine units like the cyclam-based tetraazamacrocycle L37.[349] Cyclic 
dioxotetraaza frameworks with a bispidine core and two amides have been investigated 
for medical applications. Three derivatives thereof have been reported with the benzene-
appended macrocycle BBDT (L25) being the most promising copper(II) chelator for 64CuII 
PET imaging.[177] Due to deprotonation of the amides upon metal ion coordination, 
CuII-L25 is a neutral complex and redox chemistry indicates that +II as well as +III copper 
oxidation states are accessible. As expected for macrocyclic systems, radiolabeling is 
relatively slow, requiring heating to 50 °C for 30 minutes. Both challenge experiments and 
biodistribution studies performed on the copper(II)-64 L25 complex confirm its high 
stability.[177] To further evaluate the potential of L25, the ligand was then modified by 
introduction of a carboxylic acid linker at the aromatic bridge yielding L38.[169] For a proof 
of concept study, this linker was coupled to the somatostatin analog TATE and the 
conjugate 64CuII-L38-TATE was investigated in preliminary animal studies with tumor-
bearing mice.[350] In the next step this conjugate was combined with a fluorescent dye[351] 
and the corresponding investigations are currently in progress. 
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It has previously been demonstrated that the highly preorganized and rigid bispidine 
ligands represent excellent copper(II) chelators for 64CuII PET imaging.[172,173,218,346] In this 
study, picolinic acid groups, known to be excellent metal-binding moieties,[124,125,157,241,352-
358] were incorporated into the bispidine backbone to further improve these ligands. The 
combination of the very versatile bispidine scaffold and picolinic acids (pa) leads to a new 
class of chelators, the so-called “bispa” ligands. Depending on the substitution pattern, 
different bispa derivatives are accessible as shown in Figure 28. The synthesis of the 
hexadentate bispa ligand Hbispa1a (B1a) was developed within the frame of a master 
thesis and first investigations with respect to metal complex stability were promising.[359] 
Building on these findings, the objective of the present thesis was to synthesize further 
bispa ligands with different structural features and denticities. The synthetic routes to 
these picolinic acid-based ligands and their characterization are described in Chapter 3. 
 
Figure 28. Bispa ligands consisting of a bispidine scaffold (black) and picolinic acid 
moieties (orange). 
In a second step, the coordination chemistry of the newly synthesized bispa ligands was 
investigated regarding potential nuclear medicine applications. At the beginning of the 
bispa project, the bispidine ligands studied for 64CuII PET imaging mainly contained 
nitrogen donors.[172,173] The attachment of a picolinic acid moiety to the bispidine backbone 
involves the introduction of a carboxylate function, which might facilitate the coordination 
of hard metal ions such as gallium(III). One central aim of the present thesis was therefore 
to extend the scope of the bispidine ligands to other promising radiometal ions relevant for 































ligands were expected to be well-suited for 64CuII, but were also investigated with 68GaIII as 
presented in Chapter 4. The octadentate chelator H2bispa2 (B2), on the other hand, was 
expected to be interesting for use with larger metal ions such as 111InIII, 177LuIII, or 225AcIII 
(see Chapter 5). Furthermore, amine-substituted picolinates are rigid tridentate ligands 
and reduce the overall charge of metal complexes. As charge and hydrophilicity of a 
compound have an impact on the biodistribution, it is convenient for in vivo applications to 
have compounds with various charges at hand. For example, bispidines that only possess 
neutral nitrogen donors form copper(II) complexes with an overall charge of +2, whereas 
the charge of the new copper(II) bispa complexes is +1. 
The final goal of the described project is to use bispa ligands as chelating unit in 
radiometal-based pharmaceuticals. To this end, the potential of the unfunctionalized bispa 
ligands was tested in various radiochemical studies, including radiolabeling experiments 
and competition assays, as well as lipophilicity and biodistribution studies. These 
investigations were performed in order to obtain information about radiolabeling kinetics, 
complex stability and in vivo behavior of the compounds. 
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3 Synthesis of picolinic acid-based bispidine ligandsiv 
The synthetic route to the new picolinic acid-based bispidine ligands proceeds via the 
build-up of the respective bispidine scaffold, which is then coupled to a suitable picolinic 
acid derivative. For the coupling to the bispidine fragment, the picolinic acid must be 
modified by protection of the carboxylic acid and by introduction of a substitutable unit, 
e.g. a halide. Due to the standard preparation of bispidones via Mannich reactions, the 
bispidine backbone contains two methyl ester groups.[292] To avoid their hydrolysis, a tert-
butyl protecting group is used for the picolinic acid, as this group can be removed 
selectively in the presence of methyl esters. The tert-butyl ester protected picolinic acid 
derivative 11 was synthesized in two steps according to a slightly modified literature-
known procedure, as shown in Figure 29.[360] The commercially available starting material 
6-methylpicolinic acid 8 was first esterified to 10 using tert-butyl-2,2,2-trichloroacet-
imidate 9 and then transformed to the alkyl bromide derivative 11 with N-bromo-
succinimide (NBS) and the radical initiator azobis(isobutyronitrile) (AIBN). This protected 
fragment was then coupled to a secondary amine of the bispidine scaffold, as described in 
the following chapters. 
 
Figure 29. Synthesis of the protected picolinic acid fragment tert-butyl 6-
(bromomethyl)picolinate 11 starting from 6-methylpicolinic acid 8. 
  
                                                
iv Reproduced in part with permission from P. Comba, L. Grimm, C. Orvig, K. Rück, H. Wadepohl, 
Inorg. Chem. 2016, 55, 12531-12543, Copyright 2016 American Chemical Society.; Parts of this 
chapter will be published in P. Comba, U. Jermilova, C. Orvig, B. O. Patrick, C. F. Ramogida, 
K. Rück, C. Schneider, M. Starke, Chem. Eur. J., submitted manuscript. 
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3.1 Synthesis and characterization of hexadentate bispa ligands 
Hexadentate bispa ligands are accessible by introduction of picolinic acid at either N7 or 
N3 of the bispidine backbone. Further derivatives can be synthesized by functionalization 
of the pyridines attached to the C2 and C4 positions. The synthesis and characterization 
of the hexadentate bispa ligands, shown in Figure 30, are presented in the following. 
 
Figure 30. Hexadentate bispa ligands. 
3.1.1 Synthesis of Hbispa1a 
In Hbispa1a (B1a) the picolinic acid moiety is connected to N7 of the bispidine scaffold and 
the numbering scheme for this ligand is shown in Figure 30. The synthesis of B1a was 
developed within the frame of a master thesis[359] and is therefore only briefly reviewed 
here. Standard piperidone P1[361] and bispidone B8[296] were synthesized by slightly 
modified literature procedures.[317] The piperidone P1 is obtained as a mixture of its keto 
and its enol form, but only the main keto tautomer is depicted in the reaction scheme. 
Previous attempts in the COMBA group to introduce a secondary amine directly at N7 of 
the bispidine backbone, by using ammonia in the second Mannich reaction, failed. For this 
reason, a benzyl protected amine was inserted in step (i) of the synthetic route.[362] To 
prevent ligand decomposition by a retro Michael reaction, the bispidone B8 was reduced 
with sodium borohydride to the alcohol B9.[298,363] The benzyl protecting group was then 
removed by hydrogenation with palladium on activated charcoal.[309,362] In the next step, 
bispidol B10 was coupled to the picolinic acid derivative 11 via nucleophilic substitution 
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intermediate with trifluoroacetic acid H(TFA), B1a was obtained as trifluoroacetate (TFA) 
salt.[359] 
 
Figure 31. Synthesis of Hbispa1a (B1a). (i) THF, reflux, 30 min; (ii) NaBH4, 
1,4-dioxane / water (3:1), –5 °C, 30 min, 0 °C, overnight; (iii) 1 bar H2, Pd/C, EtOAc, 
90 °C, overnight; (iv) Na2CO3, MeCN, reflux, 24 h; (vii) H(TFA), CH2Cl2, rt, 24 h. 
After repeated bispa syntheses crystals of B1aH(TFA) suitable for solid state X-ray 
analysis were obtained from one batch. The general notation ligandH(TFA) indicates that 
one molecule trifluoroacetic acid is present per ligand. In the case of the bispa ligands, the 
bispidol framework is usually protonated and hence positively charged, and TFA acts as a 
counterion. The ligand crystallizes in a chair-chair conformation, where the pyridine 
donors adopt the favored equatorial position with respect to the six-membered N3 aza-
cyclohexane (see Figure 32). Bispidines in general are highly preorganized for 
complexation to metal ions.[298,313] As the bispa ligand was isolated as TFA salt, one of the 
amine functions, namely N7, is protonated. It is probably for this reason and due to the 
carboxylate group, which allows for hydrogen bonding, that in the solid state structure of 
B1aH(TFA) the pyridine donors and the picolinate point towards the putative metal 
binding site. The distance between the nitrogen donors N3 and N7 of the bispidine 
backbone is a measure for the size of the metal coordination site and is roughly 2.9 Å for 
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Figure 32. ORTEP plot of B1aH(TFA). Ellipsoids are shown at the 50 % probability level; 
co-crystallized solvent molecules, counterions, and hydrogen atoms are omitted for 
clarity.[256] 
The hydrogenation of B9 to B10 in step (iii) was only feasible in small scales and 
upscaling to more than 3 grams led to incomplete conversion. For this reason, the 
reduction of the C9 keto function and the removal of the benzyl protecting group, steps (ii) 
and (iii) in Figure 31, were carried out in reverse order. This allowed for the conversion of 
higher amounts of B8 (up to 10 grams) with consistent yields in both steps in comparison 
to the previous reported procedure.[359] Compounds B11[309] and B10[359] are literature-
known. 
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3.1.2 Synthesis of (p-MeO)Hbispa1a 
COMBA et al. found that the stability of bispidine metal complexes is increased by 
introducing a methoxy group in the para-position of the pyridines at C2 and C4 of the 
bispidine backbone.[317] Inspired by these findings, a para-methoxy substituted derivative 
of Hbispa1a (B1a) was synthesized. To this end, 4-methoxypicolinaldehyde 16 was 
prepared in a four-step sequence, shown in Figure 34.[317] First, picoline-N-oxide 12 was 
nitrated in position 4 with sulfuric acid and fuming nitric acid yielding 4-nitropicoline-N-
oxide 13.[364,365] In a Boekelheide rearrangement, using trifluoroacetic anhydride, 13 was 
subsequently converted to the corresponding alcohol 14,[366-370] which was then reacted 
with sodium methoxide to afford 15 via nucleophilic ipso-substitution.[371] In the last step, 
15 was oxidized by selenium dioxide to the 4-substituted picolinaldehyde 16.[317] 
 
Figure 34. Synthesis of 4-methoxypicolinaldehyde 16. (i) H2SO4 / HNO3, 120 °C, 3 h;  
(ii) (CF3COO)2O, CH2Cl2, rt, 3 d; (iii) NaOMe, MeOH, 80 °C, 24 h, (iv) SeO2, 1,4-dioxane, 
85 °C, 3 h.[317] 
The other starting materials for the synthesis of the para-methoxy substituted 
piperidone P2, i.e. dimethyl-1,3-acetonedicarboxylate and methylamine, are commercially 
available. Piperidone P2 is literature-known and was mainly obtained as the enol-
tautomer.[317] 
 
Figure 35. Synthesis of the para-methoxy substituted piperidone P2.[317] 
In analogy with the synthesis of B1a, described in the previous chapter, the substituted 
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scheme depicted in Figure 36. All intermediates as well as the TFA salt of the final ligand 
(p-MeO)B1aH(TFA) were characterized by standard analytical methods, i.e. 1H- and 
13C-NMR spectroscopy, high resolution mass spectrometry (HR-MS) and elemental 
analysis (EA). For the compounds B12, B13, B14, and (p-MeO)(tBu)B1a, a solid state 
structure could be determined by X-ray analysis. Bispidone B12 crystallized in the chair-
chair conformation, required for metal ion complexation, with the two pyridine donors in 
equatorial position (endo-endo). The following transformations did not influence this 
orientation and the preorganization of the bispidine scaffold was thus preserved. Also in 
the case of (p-MeO)B1a, performing steps (ii) and (iii) in reverse order would probably 
improve the synthesis, but this has not yet been tested. 
 
Figure 36. Synthesis of (p-MeO)Hbispa1a ((p-MeO)B1a). (i) THF, reflux, 30 min;  
(ii) NaBH4, 1,4-dioxane / water (3:1), –5 °C, 30 min, 0 °C, overnight; (iii) 8 bar H2, Pd/C, 
EtOAc, 95 °C, overnight; (iv) Na2CO3, MeCN, reflux, 24 h; (vii) H(TFA), CH2Cl2, rt, 
overnight. 
3.1.3 Synthesis of Hbispa1b 
Different structural isomers of bispidines are accessible by simply exchanging the 
substituents at N3 and N7 of the ligand backbone with each other. An example are 
pentadentate bispidones possessing a picolyl pendent arm at either N3 or N7.[326] Metal 
complexes of these isomers display surprisingly different properties with respect to 
stability and reactivity.[303,372] Due to these findings, the hexadentate bispa ligand Hbispa1b 
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is attached to N7 of the bispidine scaffold, whereas in B1b, the additional group is 
introduced at N3. 
In the case of B1b, the secondary amine for coupling to the picolinic acid fragment is 
required at position N3 and could be directly introduced by using ammonia in the 
synthesis of piperidone P3.[296] In the second Mannich reaction bispidone B15[373] is build 
up and then subsequently reduced with sodium borohydride to afford bispidol B16.[300] The 
protected picolinic acid fragment tert-butyl 6-(bromomethyl)picolinate 11 is then coupled 
via nucleophilic substitution to B16 yielding (tBu)bispa1b, (tBu)B1b. This step is followed 
by hydrolysis of the ligand precursor to the TFA salt of B1b using trifluoroacetic acid. 
 
Figure 37. Synthesis of Hbispa1b (B1b). (i) THF, reflux, 3 h; (ii) NaBH4, 1,4-dioxane / 
water (3:1), –5 °C, 30 min, 0 °C, overnight; (iii) Na2CO3, MeCN, reflux, 24 h;  
(iv) H(TFA), CH2Cl2, rt, 24 h. 
The newly synthesized compounds (tBu)B1b and B1bH(TFA) were investigated by 1H- 
and 13C-NMR spectroscopy, high resolution mass spectrometry (HR-MS), and elemental 
analysis (EA). B1bH(TFA) was further characterized by solid state X-ray analysis and the 
obtained structure is depicted in Figure 38. Similar to B1a, the isomer B1b adopts the 
required chair-chair conformation with the pyridine donors in the equatorial position, only 
the picolinic acid moiety is not yet pointing towards the metal coordination site. According 
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backbone. The distance between the nitrogen donors N3 and N7 is 2.664(2) Å in B1b and 
hence similar to the N3-N7 distance determined for B1a (2.684(2) Å). 
 
Figure 38. ORTEP plot of B1bH(TFA). Ellipsoids are shown at the 50 % probability level; 
co-crystallized solvent molecules, counterions, and hydrogen atoms are omitted for 
clarity.[256] 
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3.2 Synthesis and characterization of an octadentate bispa ligand 
In addition to the hexadentate bispa ligands discussed so far, an octadentate derivative 
can be synthesized by attaching picolinic acid groups at both, N3 (pa3) and N7 (pa7) of 
the bispidine scaffold. The structure of the octadentate bispa ligand H2bispa2 (B2) is 
shown in Figure 39 together with the corresponding numbering scheme. 
 
Figure 39. Structure of the octadentate bispa ligand H2bispa2 (B2). 
In the first step of the synthesis of the octadentate ligand B2, two consecutive double 
Mannich reactions lead to the formation of the bispidine scaffold B17 (Figure 40). As a 
secondary amine at N7 of the bispidine backbone cannot be introduced directly, a 
protecting group is needed. Benzyl amine, which was used in the syntheses of B1a and 
(p-MeO)B1a, proved to be unsuitable for the preparation of B2, as the subsequent 
removal of the benzyl moiety with hydrogen (1 bar) in the presence of palladium on 
charcoal support only led to partial conversion. Additionally, the desired product could not 
be isolated from the reaction mixture. An increase of the hydrogen pressure to 7 bar did 
not lead to full conversion, but resulted in an inseparable mixture of various side products. 
Instead of the benzyl protecting group, 2,4-dimethoxybenzyl (DMB) was then chosen for 
the synthesis of B2. The DMB moiety had already been used successfully for the 
preparation of bispidones by Kolanowski et al. [311] 
Using commercially available starting materials, the literature-known piperidone P3[296] 
was synthesized and subsequently reacted with formaldehyde and 2,4-dimethoxy-
benzylamine to afford the protected bispidone B17.[374] In order to prevent ring opening by 
a retro Michael reaction, the C9 keto group of B17 was reduced with sodium borohydride, 
yielding bispidol B18. Straightforward deprotection with trifluoroacetic acid led to 
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possesses two secondary amines suitable for coupling via nucleophilic substitution to tert-
butyl 6-(bromomethyl)picolinate 11. The tert-butyl ester groups of the resulting precursor 
(tBu)2bispa2, (tBu)2B2, were consequently removed by treatment with trifluoroacetic acid 
to obtain B2H(TFA). 
 
Figure 40. Synthesis of H2bispa2 (B2). (i) THF, reflux, overnight (DMB = dimethoxy-
benzyl);  (ii) NaBH4, 1,4-dioxane / water (3:1), –5 °C, 30 min, 0 °C, overnight; (iii) H(TFA), 
CH2Cl2, reflux, 2 d; (iv) Na2CO3, MeCN, reflux, overnight; (v) H(TFA), CH2Cl2, rt, overnight. 
Compounds B19H(TFA), (tBu)2B2, and B2H(TFA) were characterized by 1H- and 
13C-NMR spectroscopy, high resolution mass spectrometry (HR-MS), elemental analysis 
(EA), and solid state X-ray analysis. The solid state structure of intermediate B19H(TFA) 
shows protonation at N7 of the bispidine scaffold, as observed for B1a and B1b. In 
addition to the synthesis of B2, the bispidol fragment B19H(TFA) might present a 
versatile building block for other bispidine systems. Due to the two secondary amines in 
the ligand backbone, simultaneous attachment of similar residues at N3 and N7 can be 
performed easily by nucleophilic substitution. This is especially interesting in cases in 
which the direct introduction via Mannich reaction is difficult. 
Crystallization of the tert-butyl ester protected ligand precursor (tBu)2B2 from ethyl 
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sodium complex of (tBu)2B2 with a bromide as counterion. The protected picolinic acid 
moiety at N3 (pa3) is disorderd at the ester group, which is not depicted in Figure 41 for 
improved clarity. Without considering the disordered oxygen atoms, the bond lengths 
between the central sodium cation and ligand donor atoms are in a range of 2.394(5) Å 
(Na-Npa3) to 2.793(5) Å (Na-Opa7). The Na-Npy1 distance, in contrast, is with 
3.2154(35) Å significantly elongated. The solid state structure is in agreement with the EA, 
which confirms the presence of one molecule sodium bromide per (tBu)2B2. 
 
Figure 41. ORTEP plot of the complex cation of [NaI((tBu)2B2)]Br. Ellipsoids are shown at 
the 50 % probability level; disorders, co-crystallized solvent molecules, counterions, and 
hydrogen atoms are omitted for clarity.[256] 
Crystals of B2H(TFA) suitable for solid state X-ray analysis were obtained by slow 
evaporation from a methanolic solution. The ligand crystallizes as a zwitterion with seven 
water molecules in the asymmetric unit, forming an extensive hydrogen-bonded network. 
The solid state structure further reveals that the tertiary nitrogen atoms N7 and Npa3 are 
protonated, and that the two azacyclohexane rings of the bispidine scaffold are oriented in 
chair-chair conformations with an N3-N7 distance of 2.766(3) Å. In contrast, the elemental 
analysis indicates the presence of one molecule of trifluoroacetic acid and thus three 
acidic protons. The stoichiometry was verified by potentiometric titration of the ligand, 
which determined an average of 2.93 equivalents of acidic protons per ligand (see 
Experimental Section for details). The non-stoichiometric number of protons is explained 
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Figure 42. ORTEP plot of B2. Ellipsoids are shown at the 50 % probability level; co-
crystallized solvent molecules and all hydrogen atoms on carbon atoms are omitted for 
clarity.[256]  
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3.3 Acid-base properties of the bispa ligands 
With regard to potential nuclear medicine applications, the stabilities of metal-ligand 
complexes were investigated. To this end, potentiometric acid-base titrations are 
performed to measure complex formation constants. Therefore, the pKa values of the 
respective ligands must be determined initially. In order to measure the protonation 
constants of the hexadentate bispa ligands Hbispa1a (B1a) and Hbispa1b (B1b), 
potentiometric titrations in aqueous solution at 25 °C and at an ionic strength of 0.1 M 
(KNO3) were performed. Hexadentate bispa ligands have six basic centers consisting of 
five nitrogen donors (two tertiary amines and three pyridines) and one carboxylate group. 
Therefore, the compounds possess six pKa values but, as the fully protonated ligands are 
expected to be very strong acids, not all of these constants are accessible by 
potentiometric titration. The pKa values are 7.73, 3.94 and ~1.83 for B1a, and 9.05 and 
6.10 for B1b. The first protonation of the ligand occurs at a pKa value of about 8 for B1a 
and 9 for B1b and is associated with proton addition to one of the tertiary amines of the 
bispidine scaffold. This is confirmed by the solid state structures of the protonated bispa 
ligands. The species distribution for B1a and B1b as a function of the pH is depicted in 
Figure 43. L denotes the respective ligand with completely deprotonated basic centers 
and the charges of the species are generally omitted for clarity. The diagrams clearly 
demonstrate the different protonation properties of the isomeric bispa ligands B1a and 
B1b: At physiological pH of 7.4 B1b almost exclusively exists in its single protonated form, 
whereas at the same pH the species distribution of B1a already displays a significant 
amount of completely deprotonated ligand. As the deprotonated form is required for metal 
ion coordination, this might have an impact on the complexation behavior of the two bispa 
ligands. 
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Figure 43. Species distribution diagrams of B1a (left) and B1b (right) in aqueous solution 
for c(L) = 10-3 M. 
The protonation constants of H2bispa2 (B2) were also determined by potentiometric 
titration of aqueous ligand solutions (25 °C, 0.1 M KCl). The pKa values for B2 are 7.45, 
5.62, and 3.31. The highest pKa value of 7.45 is assigned to the protonation of a tertiary 
amine of the bispidine backbone. A comparison of different bispidine systems shows that 
the first protonation generally occurs in the pKa range of 6.68(8) to 9.13(7),[302,303] where 
the value for B2 is at the lower end of the scale. The proton addition to the tertiary amine 
is presumably followed by protonation of the carboxylates of the two picolinic acid 
moieties (pKa values of 5.62 and 3.31). Additional ligand protonation constants, i.e. more 
acidic pKa values, were not accessible. 
 
Figure 44. Species distribution diagram of B2 in aqueous solution for c(B2) = 10-3 M. 
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Table 5. Overall (βx) and stepwise (Kx) protonation constants in log units for B1a, B1b and 
B2. 
equilibrium reaction(a) B1a B1b B2 
  log βx  
L + H ⇌ LH 7.73(3) 9.05(7) 7.45(1) 
L + 2 H ⇌ LH2 11.68(5) 15.15(14) 13.07(2) 
L + 3 H ⇌ LH3 13.50(12)  16.37(3) 
  pKax  
L + H ⇌ LH 7.73 9.05 7.45 
LH + H ⇌ LH2 3.95 6.10 5.62 
LH2 + H ⇌ LH3 1.82  3.31 
(a) L denotes the respective ligand with completely deprotonated basic centers; the charges of the 
species are omitted for clarity. 
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4 Investigation of the hexadentate bispa ligands 
Building on the promising results obtained for bispidines regarding the application with 
copper(II)-64,[172,173,218,346] the new hexadentate bispa ligands were also investigated using 
this diagnostic radiometal ion. Additionally, studies with gallium(III)-68, another versatile 
PET nuclide, were conducted. The corresponding radiochemical measurements are 
presented in detail in Chapter 4.2. Prior to the experiments with radionuclides, the 
suitability of the bispa ligands for the metal ions copper(II) and gallium(III) was 
investigated in studies with the respective non-radioactive isotopes (see Chapter 4.1). In 
addition, the coordination chemistry of the bispa systems with other transition metal ions, 
i.e. cobalt(II), nickel(II) and zinc(II) was studied. 
4.1 Coordination chemistry of the hexadentate bispa ligandsv 
 
Figure 45. Complexation reactions of the hexadentate bispa ligands B1a, (p-MeO)B1a, 
and B1b with the metal ions Co2+, Ni2+, Cu2+, Zn2+, and Ga3+, respectively (Mn+).  
                                                
v Reproduced in part with permission from P. Comba, L. Grimm, C. Orvig, K. Rück, H. Wadepohl, 
Inorg. Chem. 2016, 55, 12531-12543, Copyright 2016 American Chemical Society. 
Mn+Mn+
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Complexation reactions of the hexadentate bispa ligands B1a, (p-MeO)B1a, and B1b 
were carried out with cobalt(II), nickel(II), copper(II), zinc(II), and gallium(III). Equimolar 
solutions of the TFA salts of B1a, (p-MeO)B1a, or B1b and the respective metal salt in 
methanol (CoII, NiII, CuII, ZnII) or in a mixture of methanol and water (GaIII) were combined 
and stirred at room temperature (CoII, NiII, CuII, ZnII) or at 60 °C (GaIII). In the case of the 
colored complexes, an immediate color change was observed upon addition of the ligand 
solutions to the dissolved metal salts. The formation of the metal complexes was 
confirmed by high resolution mass spectrometry (HR-MS). The isolated metal complexes 
were investigated by elemental analysis (EA), solid state X-ray analysis, 
NMR spectroscopy, UV-vis-NIR spectroscopy, ESR spectroscopy, cyclic voltammetry, and 
potentiometric titrations where appropriate. 
The formation of the gallium(III) complex of (p-MeO)B1a was confirmed by HR-MS, but 
the purification of [GaIII(p-MeO)B1a](X)2 (GaIII-(p-MeO)B1a) was not successful and 
hence no further characterization could be performed. The gallium(III) complex based on 
B1b was not stable under the conditions of electrospray ionization (ESI) MS. However, 
the formation of [GaIIIB1b](NO3)2 (GaIII-B1b) was confirmed by X-ray analysis, 
NMR spectroscopy, and EA (see Experimental Section). As mentioned before, the bispa 
ligand B1a was developed within the scope of a master thesis as potential chelator for 
copper(II)-64 and gallium(III)-68.[359] In this previous study B1a was reacted with non-
radioactive CuII and GaIII as a proof of concept and the respective metal complexes could 
be isolated and identified. However, a detailed characterization of the complexes as well 
as the radiochemical investigation of B1a were conducted as part of the present thesis. 
4.1.1 Solid state X-ray analysis 
For all metal complexes of B1a and B1b, as well as for the copper(II) and zinc(II) complex 
of (p-MeO)B1a crystals suitable for solid state X-ray analysis could be obtained. The 
single crystals were either prepared by diffusion of diethyl ether into complex solutions of 
methanol or acetonitrile, or by slow evaporation of the solvent consisting of a mixture of 
methanol and water (2:1). As expected the structures of the metal complexes show 
distorted octahedral coordination geometries (see Table 6 and Table 7). Because of the 
frequent presence of different types and amounts of crystal solvent, there is no unique 
packing motif for the complexes even with the same type of ligand. 
 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 46. From top to bottom: ORTEP plots of the complex cations of [CuII(B1a)](TFA), 
[CuII((p-MeO)B1a)](TFA), and [CuII(B1b)](TFA). Ellipsoids are shown at the 50 % 
probability level; co-crystallized solvent molecules, counterions, and hydrogen atoms are 
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Figure 46 shows the molecular cations of the CuII complexes of B1a, (p-MeO)B1a, and 
B1b. All three d9 systems display the expected pseudo JAHN-TELLER elongation. In the 
case of [CuII(B1a)]+ (CuII-B1a) and [CuII((p-MeO)B1a)]+ (CuII-(p-MeO)B1a) the distortion is 
along the N7-Cu-Opa axis, whereas in [CuII(B1b)]+ (CuII-B1b) the axis Nyp1-Cu-Npy2 is 
elongated. The structural data of the other metal-bispa complexes are also given in 
Table 6 and Table 7. 
Similar to the tetra-, penta- and hexadentate bispidines studied by COMBA et al. so far, the 
bispa-type ligands are very rigid and preorganized for tetragonally distorted complexes, in 
particular for JAHN-TELLER active systems such as CuII.[298,302,303,375] In general, the bond 
from the metal center to N7 is more flexible (part of two six-membered chelates) than that 
to N3 (part of two rigid five-membered chelates), and this usually leads to a longer and 
more flexible bond for M-N7 compared to M-N3. For the B1a- and the (p-MeO)B1a-based 
complexes, as well as for the corresponding pentadentate all-N ligands,[298,302,303,375] the 
flexibility of the M-N7 bond is restricted by a five-membered chelate ring to the third 
pyridine group (picolinate-pyridine in B1a and (p-MeO)B1a). However, the elongation 
along M-N7 is clearly shown for all structures of B1a and (p-MeO)B1a as depicted in 
Table 6. Obviously, for CuII this leads to an electronic stabilization, for CoII, this is not 
unfavorable but for NiII, ZnII, and GaIII it is. For the pentadentate bispidines it was 
observed that the CuII complex exhibits the highest stability, followed by the CoII complex 
and the respective NiII system.[303] This finding is in contrast to the predictions from the 
Irving-Williams series.[376,377] The structural analyses of the all-N pentadentate and 
hexadentate bispidines were accompanied by computational modeling.[302,303] Comparing 
the thus obtained stabilities and overall shapes with the structures of B1a and 
(p-MeO)B1a, it appears that for these bispa ligands the situation is very similar to the 
bispidine systems.  
For B1b, the situation is somewhat different, i.e. for all five structures of the metal 
complexes, the differences of bond distances from the metal center to N3 and N7 are 
smaller than for both B1a and (p-MeO)B1a. In the case of the copper(II), zinc(II), and 
gallium(III) complexes of B1b, the bond to N3 is even larger than that to N7 (see 
Figure 46). This binding motif has been observed and discussed in detail for bispidine 
ligands, i.e. there are two potential locations for the metal ion in the rigid bispidine cavity, 
and the stability of the two isomers depends on the size and electronic structure of the 
metal ion.[375] Also, for the CuII complexes of the pentadentate bispidines, JAHN-TELLER 
isomers have been reported.[329,378] The solid state structure of CuII-B1b shows an 
elongation along py1-Cu-py2 and similar bonds from CuII to N3 and N7. This structural 
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trend, as well as the similar overall shapes of B1b with the other metal ions CoII, NiII, ZnII, 
and GaIII, indicate that B1b is also highly preorganized and complementary for CuII. 
4.1.2 NMR spectroscopy 
The newly synthesized bispa ligands as well as the respective zinc(II) and gallium(III) 
complexes were studied by 1H- and 13C-NMR spectroscopy (see Experimental Section 
and Appendix A). Two-dimensional correlation experiments (1H-1H and 1H-13C) were 
performed to allow the accurate assignment of all signals. Comparison of the NMR 
spectra of the metal-free ligands and the respective metal complexes shows significant 
changes of the proton chemical shifts associated with coordination of the ligands to the 
metal ions. The spectra confirm the formation of a single complex in solution with ZnII and 
GaIII, and these spectra are in accordance with the structures determined by solid state 
X-ray analysis. In Figure 47 the spectral changes in the 1H-NMR spectrum of bispa ligand 
B1a upon complexation of zinc(II) are depicted. 
 
Figure 47. Overlay of the 1H-NMR (600.13 MHz, 22 °C, D2O) spectra of B1aH(TFA) and 
[ZnII(B1a)](TFA). 
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Except for [GaIII(B1b)](NO3)2, all metal complexes, as well as the bispa ligands have a 
trifluoroacetate (TFA) as counterion. In proton decoupled 13C-NMR spectra of these 
compounds, signals for the two carbon atoms of TFA coupling to the three fluorine nuclei 
(I = 1/2) are expected. However, these signals are often too weak to be observed, but are 
resolved in the 13C-NMR spectra of (p-MeO)B1aH(TFA) and [ZnII((p-MeO)B1a)](TFA). 
4.1.3 UV-vis-NIR spectroscopy 
The spectroscopic data of the bispa complexes in the ultraviolet (UV), visible (vis) and 
near-infrared (NIR) region of the electromagnetic spectrum are given in Table 8, together 
with reported values for complexes of the known hexadentate bispidine N2py4 (B3).[302] 
The solution electronic spectra were measured at room temperature in MeOH (NiII and 
CuII) or dimethyl sulfoxide (DMSO; CoII). The experimental spectra and the deconvolution 
of unresolved transitions with Gaussian fits are summarized in Appendix D. For each 
metal center, the spectra of the complexes of the four ligands are as similar as expected, 
showing the higher asymmetry for the bispa compared to the B3 systems. The bispidine 
ligand B3 comprises only pyridines and tertiary amines as donor groups and those 
possess very similar ligand field parameters.[140,379] Because of the significant π donation 
of the carboxylates, the ligand field emerging from the three bispa ligands is smaller than 
that of B3. 
Table 8. Spectroscopic data of the metal complexes of B1a, (p-MeO)B1a, B1b, and B3. 
 UV-vis-NIR (dd transitions)(a) ref. 
[CoII(B1a)](TFA) 470 (123), 557 (43), 993 (5)  
[CoII((p-MeO)B1a)](TFA) 467 (173), 541 (37), 1030 (6)  
[CoII(B1b)](TFA) 475 (117), 516 (9), 544 (23), 584 (7), 677 (6), 920 (6)  
[CoII(B3)](PF6)2 397 (170), 493 (67), 551 (27) sh [302] 
[NiII(B1a)](TFA) 515 (12), 558 (11), 819 (20), 923 (25)  
[NiII((p-MeO)B1a)](TFA) 521 (12), 585 (10), 866 (38)  
[NiII(B1b)](TFA) 512 (18), 796 (13), 877 (36)  
[NiII(B3)](ClO4)2 304 (443) sh, 532 (18), 815 (30) [302] 
[CuII(B1a)](TFA) 672 (93), 1284 (34)  
[CuII((p-MeO)B1a)](TFA) 673 (106), 1227 (36)  
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[CuII(B1b)](TFA) 651 (78), 904 (18)  
[CuII(B3)](ClO4)2 620 (110) [302] 
(a) Measurements at 25 °C in MeOH (NiII and CuII complexes of B1a, (p-MeO)B1a, and B1b), 
DMSO (CoII complexes of B1a, (p-MeO)B1a and B1b), or in MeCN (B3). 
For an octahedral cobalt(II) complex three dd-transitions are expected, i.e. 4T1g→4T2g, 
4T1g→4A2g, and 4T1g(F)→4T1g(P). Metal bispa complexes are less symmetrical than Oh and 
this leads to further splitting of the terms. Due to limited resolution, not all transitions can 
be distinguished. For CoII-B1a and CoII-(p-MeO)B1a three transitions can be resolved, 
whereas the spectrum of CoII-B1b shows six maxima in the absorbance spectra. 
As a rough approximation the metal ion in bispa complexes is coordinated in a slightly 
distorted tetragonal geometry. For a nickel(II) complex with Oh symmetry transitions from 
the electronic 3A2g ground state to the three excited states 3T2g, 3T1g (F), and 3T1g (P) are 
expected. Often there is an additional spin-forbidden transition to the 1Eg state observable. 
If only the coordinating ligand atoms are considered in the nickel(II) bispa complex 
cations, i.e. five similar nitrogen donors and one negatively charged oxygen, a pseudo 
C4v symmetry can be deduced. The transition from Oh to C4v symmetry results in a splitting 
of the excited electronic states. For NiII-B1a and NiII-B1b there are two signals around 
900 nm in the absorbance spectra and this might be associated with a splitting of the 
3A2g→3T2g transition. However, the assignment in this region is difficult due to the often 
relatively intense band resulting from the spin-forbidden transition (~900-1000 nm). For 
NiII-(p-MeO)B1a there is only one broad band at 866 nm, which is not further resolved. 
The same applies for the 3A2g→3T1g (F) transition, which can either be observed as two 
separate signals or as one broad band around 500 nm. The third transition is obscured by 
strong ligand-metal charge transfer (CT) bands occurring at wavelengths below 400 nm. 
A d9 metal ion such as copper(II) possesses an electronic gap or “hole” on its d level and 
can hence be treated as an “inverse” d1 ion. For systems with only one d electron (or one 
electronic “hole”) the orbital model can be applied.[380] For tetragonal copper(II) 
complexes, a d orbital splitting as depicted in Figure 48 can be derived. Due to the 
pseudo JAHN-TELLER effect, one axis in the CuII-bispa systems is elongated and this axis 
is usually designated as the z axis. Because of the elongation of the z axis all orbitals with 
z character are lowered energetically. For the copper(II) bispa complexes two signals 
around 651-672 nm and 904-1284 nm, respectively, were observed. According to the 
d orbital splitting in Figure 48 the broad band at lower energy (higher wavelength) can be 
assigned to the dz2→dx2-y2 transition. Further electronic transitions are possible from the 
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dxy, dxz and dyz orbitals to the dx2-y2 level, but those are not resolved in the UV-vis-NIR 
spectra of the complexes and thus only one additional signal was detected. 
 
Figure 48. Coordination geometry of the copper(II) complexes based on the bispa ligands 
B1a and B1b (left) and the corresponding scheme of the d orbital splitting (right). Adapted 
from reference [381]. 
4.1.4 ESR spectroscopy 
The ESR spectra of the copper(II) complexes based on B1a, (p-MeO)B1a, and B1b were 
recorded and simulated as frozen solutions. The experimental spectra depicted in 
Appendix E show the characteristic hyperfine coupling to copper with a nuclear spin of 
I = 3/2. The form of ESR signals of metal complexes depends on their coordination 
geometry. The dependency of the anisotropic g tensors of axial symmetric 
CuII compounds is for example as follows: gx = gy and gz > gx, gy. The same considerations 
apply for the corresponding A tensors. An axial ESR spectrum hence indicates a 
tetragonal symmetry of the copper(II) complex.[382] The Spin Hamiltonian parameters 
derived by simulation of the ESR spectra using the software package XSophe[383,384] are 
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Table 9. Results of the simulation of the ESR spectra of the copper(II) complexes based 
on B1a, (p-MeO)B1a, B1b, and B3. 
 simulated ESR parameters(a)  
 gx, gy, gz Ax, Ay, Az [10-4 cm] ref. 
[CuII(B1a)](TFA) 2.059, 2.059, 2.243 13, 13, 145  
[CuII((p-MeO)B1a)](TFA) 2.057, 2.057, 2.244 10, 10, 170  
[CuII(B1b)](TFA) 2.016, 2.068, 2.236 27, 21, 145  
[CuII(B3)](ClO4)2 2.069, 2.069, 2.208 -, -, 169 [302] 
(a) Measurements at 8 K in MeOH (B1a, (p-MeO)B1a, and B1b) or at 130 K in DMF / water 2:1 
(B3). 
In agreement with the solid state structures and the analysis of the UV-vis-NIR spectra, 
the simulated ESR parameters indicate that the solution structures are similar to those in 
the solid state. The coordination geometries derived from the solid state structures of the 
copper(II) complexes based on B3,[302] B1a, and B1b are depicted schematically in 
Figure 49. In the case of [CuII(B3)]2+ (CuII-B3) there are only tertiary amine and pyridine 
donors which possess very similar ligand field properties.[140,379] One of the three 
coordination axes in CuII-B3 is elongated due to the JAHN-TELLER effect and this results in 
identical gx and gy parameters and a higher value for gz.[302] Axial symmetry is also 
observed for CuII-B1a and CuII-(p-MeO)B1a) where the axis N7-Cu-Opa is elongated. 
Similar gx and gy parameters are again obtained for the nitrogen donors in the x,y plane. 
The para-substitution in CuII-(p-MeO)B1a) does not have a big influence on the Spin 
Hamiltonian parameters (see Table 9). The simulation of the ESR spectrum of the 
copper(II) complex based on B1b reveals different g parameters (gx ≠ gy ≠ gz) and hence 
points to a rhombic site geometry. The obtained value of gz is higher than gx and gy due to 
the elongation of the Npy1-Cu-Npy2 axis. Furthermore, the carboxylate in the x,y plane 
leads to a larger asymmetry and hence to different gx and gy parameters. 
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Figure 49. From left to right: Coordination geometries derived from the solid state 
structures of the copper(II) complexes based on B3, B1a, and B1b with the pseudo JAHN-
TELLER elongated axes highlighted in orange. 
4.1.5 AOM analysis 
For the copper(II) complexes of the bispa ligands B1a and B1b an angular overlap model 
(AOM) based ligand field analysis of the electronic and ESR spectra has been carried out. 
This study was performed for a detailed comparison of the solid state structures and the 
structures in solution as well as to understand differences in the degree of preorganization 
of the two isomeric ligands for the JAHN-TELLER labile CuII ion. 
Term energies of transition metal complexes are governed by the metal center, the donor 
atoms and the coordination geometry.[385] The AOM uses a simplified molecular orbital 
(MO) approach to calculate the spectroscopic properties of such complexes.[386-388] In this 
model metal-ligand (M-L) bonds are described by covalent σ, π and δ interactions using 
two-atom overlap integrals of the metal d orbitals and the donor orbitals. Each M-L 
interaction has to be parameterized individually with the respective eσ, eπ and eδ values. 
These parameters are positive for donor atoms and negative for acceptors, and their 
values decrease in the order |eσ| > |eπ| > |eδ|. The interaction between a free electron pair 
at the ligand and a metal orbital with suitable symmetry has a destabilizing effect resulting 
in an upward shift in energy of the metal atomic orbital and eσ is thus always positive. The 
π parameter, on the other hand, can adopt both signs, depending on the character of the 
bond with respect to π-forward and π-backward donation. In the case of an anisotropic 
π bond, eπ is divided into two parts, i.e. eπx and eπy. Due to the minor overlap integral of 
δ bonds, the values for eδ are relatively small and are hence often neglected. Moreover, 
the ligand systems investigated here do not possess orbitals suitable for the formation of 
δ bonds. The AOM parameters depend on the metal-ligand distance r in a way that their 
values approximately decrease with the sixth power of r.[386-389] In tetragonally distorted 
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interaction with the metal 4s orbital. This effect, known as ds mixing, is considered in the 
AOM by assigning each ligand an additional bonding parameter eds with eds = 1/4 eσ.[330,390] 
The AOM calculations reported here were performed with the computer program 
CAMMAG.[391] The coordinates of the CuII center and the donor atoms were taken from 
the X-ray structures of CuII-B1a and CuII-B1b. In both cases, the z axis was defined along 
the pseudo JAHN-TELLER elongated axis (see also Figure 49). Details of the AOM 
analysis together with examples of input-files are given in Appendix F. AOM eσ, eπ and 
eds parameters are not transferable in principle but in a series of studies, it has been 
shown that the error made by assuming transferability generally is acceptable.[315,379,392] 
However, with published parameters for CuII-amine, CuII-pyridine and CuII-carboxylate 
bonds, adjusted to the observed CuII-donor distances with 1/r6,[385,390,393] the computed and 
experimentally determined electronic transitions are only in fair agreement. Thus, 
modifications of the ligand field parameters were introduced and led to acceptable 
predictions of the dd transitions and EPR g tensor parameters as shown in Table 10. One 
reason for the discrepancy between the published and moderately adjusted AOM 
parameters is that those for the carboxylates are merely the result of an ad-hoc 
parameterization for one particular set of complexes,[393] while the parameterization for 
amines and pyridines were deduced from a larger set of spectroscopic studies.[385] Also, 
transferability is an assumption with limited applicability, and electron transfer from anionic 
ligands may be problematic in this context.[394] In addition and most importantly, small 
structural changes upon dissolution of the complexes, in particular along the JAHN-TELLER 
vibration, may lead to significant changes of the ligand field. However, while the 
adjustments to the AOM parameters seemed to be necessary for esthetic reasons, the 
qualitative interpretation that there are only minor structural changes upon dissolution of 
the complexes does not change with the two sets of parameters used.  
The structural data suggest that CuII-B1a is elongated along the N7-Cu-Opa axis, while 
the elongation observed for CuII-B1b is along Npy1-Cu-Npy2. Based on both sets of AOM 
parameters, the solid state structure is confirmed to also be the structure in solution and 
this has some implication for the relative stabilities (see below). The splitting of the three 
dπ orbitals is not resolved for either isomer but, from the relative line width of the 
dxy,xz,yz→dx2-y2 transitions, it appears that the splitting is slightly larger for CuII-B1a, and this 
agrees with the geometry observed in the solid state structures, which for CuII-B1a 
suggests interaction of the carboxylate π donor with the CuII dxz,yz orbitals. The in-plane 
carboxylate in CuII-B1b leads to a relative destabilization of the dπ orbitals and a 
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stabilization of the dx2-y2 orbital with respect to CuII-B1a with an axial carboxylate, 
emerging in a generally lower ligand field but a higher energy dz2→dx2-y2 transition. 
The conservation of the solid state structures in solution, i.e. the different orientations of 
the pseudo JAHN-TELLER axes, is also well supported by the g values resulting from 
simulation of the frozen solution X-band ESR spectra. As already discussed in 
Chapter 4.1.4, tertiary amines and pyridine donors exhibit very similar ligand field 
parameters,[140,379] while those for carboxylate are significantly different and therefore lead 
to a larger in-plane asymmetry in CuII-B1b. 
In metal complexes the donor atoms N7 and N3 of the bispidine scaffold are part of rather 
flexible six- and very rigid five-membered chelate rings, respectively.[375] This structural 
difference in general leads to long M-N7 and shorter M-N3 bonds and therefore to a rigid 
bispidine ligand shape that is highly complementary for copper(II). For the N2py3-type 
isomers similar to B1a and B1b this results in distinct stability differences between the two 
corresponding isomeric CuII complexes and an interesting CuII selectivity for one of the 
two isomers.[303] However, “JAHN-TELLER isomerism” was observed for the CuII complexes 
of a number of bispidine derivatives,[329,378] and the ligand field properties of the two 
isomers CuII-B1a and CuII-B1b as well as the stronger CuII-Opa interaction in CuII-B1b 
suggest that this isomer might lead to a slightly more stable CuII complex. 
Table 10. Comparison of experimental and calculated (AOM) spectroscopic data of the 
copper(II) complexes based on B1a and B1b. 
  UV-vis-NIR (dd transitions)  ESR 
  λ [cm-1] gx, gy, gz 
[CuII(B1a)](TFA) exp. 14880, 7790 2.059, 2.059, 2.243 
 AOMpub (a) 17870, 17330, 15640, 9110 2.029, 2.038, 2.136 
 AOMadj (b) 16131, 15668, 13421, 8114 2.028, 2.046, 2.154 
[CuII(B1b)](TFA) exp. 15360, 11060 2.016, 2.068, 2.236 
 AOMpub (a) 18530, 18260, 17440, 11200 2.014, 2.055, 2.120 
 AOMadj (b) 17306, 16978, 15713, 10681 2.015, 2.060, 2.128 
(a) For AOMpub published AOM parameters were used.[385,390,393] (b) AOMadj gives data based on 
moderately adjusted parameters offering improved matching to the spectroscopic data (see 
Appendix F). 
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4.1.6 Cyclic voltammetry 
The electrochemical measurements of the metal complexes were performed at ambient 
temperature in dimethylformamide. The obtained redox potentials are summarized in 
Table 11 and the corresponding cyclovoltammograms are depicted in Appendix G. With 
the bispa complexes of NiII and CoII two signals corresponding to the NiII/I (CoII/I) and NiIII/II 
(CoIII/II) couples were detected, and for the CuII systems a single wave for CuII/I was 
observed in the measurable range as permitted by the solvent. It is known that the stability 
constants of CuI complexes are relatively uniform, while those of CuII vary over a wide 
range.[168] Therefore, CuII/I redox potentials are linearly correlated to the thermodynamic 
stability of the corresponding CuII complexes,[167] and this correlation has been used to 
predict approximate stability constants of CuII bispidine complexes.[303,395] In comparison to 
other CuII bispidine systems only bearing nitrogen donors, the reversible redox potentials 
of CuII-B1a, CuII-(p-MeO)B1a, and CuII-B1b are significantly lower, indicating higher CuII 
complex stabilities, in particular compared to the hexadentate CuII-B3 system.[302] The 
reason for these strongly negative redox potentials is the coordination of the carboxylate 
group to the copper(II) center. The anionic oxygen donor transfers electron density to the 
metal ion and this results in a decrease of the CuII/I redox potential. According to the 
obtained potentials listed in Table 11, CuII-B1b is predicted to be slightly more stable than 
CuII-B1a, which is in agreement with the spectroscopic analysis. 
Comparing the bispidine complexes of all three investigated metal ions there is a general 
trend observed with the B3 complexes having significantly higher redox potentials than 
the bispa systems, whereas the values for the B1b isomer are slightly more negative than 
that for the respective B1a and (p-MeO)B1a complexes, i.e. M-B3 > M-B1a > 
M-(p-MeO)B1a > M-B1b. This order can be explained by means of structural and 
electronic considerations: The para-methoxy groups in M-(p-MeO)B1a increase the 
electron density at the pyridine nitrogens and hence on the copper(II) center, which leads 
to a more negative redox potential in comparison to M-B1a. A structural difference 
between the B1a and (p-MeO)B1a metal complexes on the one hand and M-B1b on the 
other hand is the distinct orientation of the elongated pseudo JAHN-TELLER axes. Due to 
the elongation of the N7-Cu-Opa axis in the B1a and (p-MeO)B1a complexes, the metal-
carboxylate bond in M-B1b is slightly shorter and this consequently decreases the redox 
potential. 
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Table 11. Electrochemical data of the metal complexes based on B1a, (p-MeO)B1a, B1b, 
and B3. 
 redox potentials E1/2 vs. fc/fc+ [V] (a)  
 MII/I MIII/II ref. 
[CoII(B1a)](TFA) –1.94 –0.37  
[CoII((p-MeO)B1a)](TFA) –1.97 –0.41  
[CoII(B1b)](TFA) –2.09 –0.52  
[CoII(B3)](PF6)2 - 0.22 [302] 
[NiII(B1a)](TFA) –2.18 0.76 (irrev.)  
[NiII((p-MeO)B1a)](TFA) –2.24 0.71 (irrev.)  
[NiII(B1b)](TFA) –2.27 (irrev.) 0.71  
[NiII(B3)](ClO4)2 –1.28 (irrev.) 1.39 (irrev.) [302] 
[CuII(B1a)](TFA) –1.02 -  
[CuII((p-MeO)B1a)](TFA) –1.08 -  
[CuII(B1b)](TFA) –1.17 -  
[CuII(B3)](ClO4)2 –0.66 - [302] 
(a) Measurements at 25 °C in DMF and 0.1 M (n-Bu4N)(ClO4) (B1a, (p-MeO)B1a, and B1b) or in 
MeCN and 0.1 M (n-Bu4N)(PF6) (B3). 
4.1.7 Potentiometric titrations 
The stability constants of the isomeric CuII-bispa complexes CuII-B1a and CuII-B1b were 
determined under similar experimental conditions as those used in the protonation 
experiments (see Chapter 3.3). As the stability constants were not accessible via direct 
potentiometry, ligand-ligand competition titrations were performed in a ratio of 1:1:1 (CuII / 
L / L’, with L = B1a or B1b and L’ = EDTA (L9)). Back-titrations were carried out in order 
to screen for complete equilibration of the system. When titrating the metal-ligand 
solutions up to a pH of 11, a shift between the titration curve and the back-titration was 
observed. By lowering the final pH value to 10, both curves became congruent, which 
indicates decomposition processes in basic media (pH > 10). Therefore, only data points 
in the pH range of 2-10 were considered in the fitting procedures. The main species 
formed in solution are CuL and CuLH (see Appendix C for species distribution plots). Only 
the 1:1 complexation was modeled, which is in agreement with the spectroscopic and 
structural data. Logarithmic complex stability constants of 18.9 for CuII-B1a and 19.4 for 
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CuII-B1b were obtained, i.e. the CuII-B1b complex is slightly more stable than its isomer 
and this is in accordance with the structural, spectroscopic and electrochemical analyses. 
Both ligands lead to significantly larger CuII complex stabilities than the known 
hexadentate ligand B3 by around three orders of magnitude (16.3).[302] The species 
distribution diagrams of copper(II) in the presence of B1a and B1b are shown in 
Appendix C. 
Table 12. Copper(II) complex stability constants and pM7.4 values of B1a and B1b (H2O, 
25 °C, 0.1 M KNO3). 
equilibrium reaction (a) stability constant log β B1a B1b 
Cu + L ⇌ CuL log βCuL 18.88(10) 19.44(18) 
Cu + L + H ⇌ CuLH log βCuLH 21.07(6) 21.77(21) 
 pM7.4 value (b) 19.3 18.7 
(a) L denotes the respective ligand with completely deprotonated basic centers; the charges of the 
species are omitted for clarity. (b) Calculated for 10 µM total ligand and 1 µM total metal ion 
concentration at pH 7.4 and 25 °C. 
The pM values at pH 7.4 (pM = -log [Mn+]) are also given in Table 12. These define the 
complex stabilities at a particular pH value and for PET chelators the pM values at 
physiological pH are of particular relevance. Interestingly, based on the log β values and 
spectroscopic as well as electrochemical data, B1b is a slightly better ligand than B1a 
(19.4 vs. 18.9). However, at pH = 7.4 this is reversed according to the calculated pM 
values of 18.7 and 19.3, respectively. The species distributions of the metal-free ligands, 
given in Figure 43 of Chapter 3.3, indicate that this is related to the relevant pKa values. 
These findings are therefore an excellent example for the importance of pM values to 
directly assess different ligands for a given metal ion. In Table 13 the stability parameters 
determined for the copper(II) bispa complexes are compared to various literature-known 
CuII chelators. To avoid the release of the radioisotope, the metal complex has to be 
stable in the presence of competing metal ions. In this context, stability studies of similar 
bispidine systems have already shown high stability of the corresponding CuII complexes 
and good selectivity of the ligands for CuII in comparison to CoII, NiII, and ZnII.[218,302,303] 
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Table 13. Comparison of the pKa, log βCuL and pCu7.4 values of bispa ligands and 
selected chelators from literature. 
ligand pKa log βCuL pCu7.4 (a) ref 
Hbispa1a (B1a) 7.73(3), 3.95(5), 1.82(12) 18.88(10) 19.3  
Hbispa1b (B1b) 9.05(7), 6.10(14) 19.44(18) 18.7  
N2py4 (B3) 6.68, 11.40 16.28 17.6 [302] 
Diol of B5 >12, 10.6(6), 4.5(1), 2.0(2), 0.82(1), <0.82 19.2(2) 17.0 [218] 
TETA (L6) 10.82(1), 10.10(2), 4.15(1), 3.21(1) 21.87(6) 16.7 [396] 
TE1PA (L18) 11.55(1), 10.11(1), 2.71(1), 1.7(1) 25.5(1) 19.6 [124] 
DOTA (L5) 11.14(1), 9.69(2), 4.85(2), 3.95(1) 22.72(4) 17.6 [396] 
DO1PA (L14) 10.46(1), 9.26(1), 3.23(1) 24.01(1) 20.0 [124] 
NOTA (L4) 11.73(2), 5.74(1), 3.16 21.63(2) 18.2 [116] 
(a) L denotes the respective ligand with completely deprotonated basic centers; the charges of the 
species are omitted for clarity. 
The comparison of copper(II) complexes based on different ligand systems reveals a 
certain deviation with regard to the bispa ligands (see Figure 50). The potentials of the 
copper(II) bispidine and bispa complexes were referenced against the redox couple 
ferrocene/ferrocenium (fc/fc+) by default.[303] To be able to directly compare these values 
with the redox potentials used by RORABACHER et al. for their potential-stability 
correlation,[167] the corresponding potentials were also referenced vs. fc/fc+. Therefore, an 
fc/fc+ redox potential of –0.4 V vs. the standard hydrogen electrode (SHE) was assumed 
based on the approximation that this value is invariant with solvent.[397,398] However, there 
are reports indicating that this assumption is not entirely correct.[399-401] A detailed list of 
redox potentials and stability constants used for the plot in Figure 50 is compiled in 
Appendix G. It is important to note that the potentials were determined in different 
solvents. For reasons of comparability the cyclovoltammetric measurements of bispidine 
ligands are usually performed in acetonitrile, but it was shown that the redox potentials 
assessed in water are in the same range for the investigated compounds (see 
Appendix G).[303] Due to solubility problems of the cobalt(II) and nickel(II) bispa 
complexes, dimethyl formamide was used as solvent for the electrochemical analyses of 
the bispa systems. However, it was observed that the CuII/I potentials of CuII-B1a 
measured in dimethyl formamide and in acetonitrile are comparable.[359] The presentation 
of the values in Figure 50 shows that the RORABACHER-correlation can be applied to the 
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neutral all-N bispidine ligands as indicated by the linear fit. The bispa ligands, in contrast, 
are considerably shifted from this line and this is probably due to their anionic character. 
For this reason, RORABACHER et al. only considered ligands uncharged in their 
deprotonated form in order to eliminate electrostatic effects.[167] The analysis of further 
monoanionic ligands might provide a similar correlation as that found for neutral systems. 
 
Figure 50. Plot of the potentials of CuII/IL redox couples as a function of the logarithmic 
values of the CuIIL formation constants. Blue squares represent various ligand systems 
used by RORABACHER et al.[167] Green circles represent bispidines investigated by COMBA 
et al.[303] Orange triangles represent the bispa ligands B1a and B1b. Linear fit including 
the ligands from the original RORABACHER-plot and the bispidines: y = –0.05718 ± 
0.00262; R2: 0.92609. 
In summary, the copper(II) complexes of B1a and B1b were shown to display high 
complex stabilities, which is an important prerequisite for radiopharmaceutical 
applications. In the light of the planned investigation of the bispa ligands with radioactive 
gallium(III) isotopes, the stability of the GaIII-bispa complexes is of crucial importance as 
well. A thorough discussion of the stability of these complexes in challenge experiments 
and biodistribution studies will be presented in Chapter 4.2.2. 
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4.2 Radiochemical investigations of the hexadentate bispa ligands 
In the previous chapter the hexadentate bispa ligands were shown to form complexes with 
the metal ions copper(II) and gallium(III). Therefore, the bispa ligands were investigated 
for potential radiopharmaceutical applications with the PET isotopes copper-64 and 
gallium-68. In the scope of the present thesis only the isomeric bispa ligands B1a and 
B1b were examined. The results of these studies are presented in the following. 
4.2.1 Radiochemistry with copper(II)-64 
The radiochemical investigations with copper(II)-64 were performed at the Institute of 
Radiopharmaceutical Cancer Research of the Helmholtz Zentrum Dresden-Rossendorf 
(HZDR). Radiolabeling experiments, in vitro competition assays and the determination of 
the partition coefficients log Do/w were carried out in the group of Dr. Holger STEPHAN by 
Karin LANDROCK and Janine PARTSCH. The biodistribution studies were performed by 
Prof. Dr. Jens PIETZSCH and coworkers. 
Radiolabeling experiments 
Prior to the experiments, the radiochemical purity of the 64CuII-radiolabeled bispa ligands 
B1a and B1b was determined by radio-high performance liquid chromatography (radio-
HPLC) to be > 99 %. The radiolabeling efficiency of B1a and B1b with copper(II)-64 was 
investigated as a function of time and concentration. Therefore, sample solutions with 
different amounts of the respective ligand and 64CuCl2 were prepared and allowed to 
radiolabel at ambient temperature. If not stated otherwise, the ligands were used in their 
protonated form with one trifluoroacetate (TFA) as the counterion. The experimental setup 
was carried out in a way to obtain final ligand concentrations of ~10-4 to 10-6 M and the 
studies were performed with starting activities of 10 and 100 MBq 64CuCl2, respectively. 
Depending on the molar activity of different 64CuII production runs, and the time of 
64CuII use after the end of bombardment (EOB), different aliquots of 64CuCl2 were added 
to obtain the desired starting activity. The degree of radiolabeling was assessed by radio-
thin layer chromatography (radio-TLC) at 5, 30 and 60 minutes after addition of 64CuCl2. 
The radio-TLC conditions described in the Experimental Section allowed for the clear 
separation of “free” copper(II)-64 and the two radiolabeled bispa ligands. While 64CuCl2 
remains at the origin, both 64CuII-bispa complexes move with an Rf-value of 0.8. The 
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radiochemical yield (RCY) was determined by integrating the peaks in the radio-thin layer 
chromatograms. In the case of B1a and B1b a total amount of 0.5 µg ligand per 100 µL 
(~510-6 M) could be radiolabeled quantitatively (RCY > 99%) within 5 minutes at room 
temperature using 100 MBq 64CuCl2. After decreasing the amount of ligand to 0.1 µg 
(~10-6 M) under the same conditions, only partial radiolabeling was observed, i.e. 
15 % RCY for 64CuII-B1a and 30 % RCY for 64CuII-B1b. 
The specific or molar activity of a compound is a measure of its ability to be radiolabeled 
by a certain amount of radioactivity and is given in detected activity per gram or mole of 
the substance.[135] Radiolabeling of B1a and B1b with copper(II)-64 yielded molar 
activities of ~100 GBq/µmol and ~200 GBq/µmol, respectively. Such high activities are 
desirable for nuclear medicine applications, as this means that a small quantity of ligand 
can be radiolabeled with a high amount of activity. As a consequence, the drug dose 
required for the patient is minimized. Altogether, a very efficient and rapid 
64CuII complexation of the bispa ligands was found under mild conditions. The other 
bispidine systems studied so far also displayed fast radiolabeling kinetics with 64CuII, but 
they were not investigated with activities as high as 100 MBq.[172,173] For this reason the 
maximum molar activity of these compounds could not be determined. 
Competition assays 
The stability of a radiolabeled metal complex towards transchelation is usually tested in 
challenge experiments with competing compounds or mixtures thereof. The standard 
procedure involves labeling of the ligand with the respective radiometal ion followed by 
incubation with the chosen competitor. After a certain time period, the amount of stable 
complex is then determined using a suitable analytical method. 
The first challenge experiments with the 64CuII-bispa complexes were performed in the 
presence of the competing ligands cyclam (L3) and EDTA (L9). Complete radiolabeling of 
B1a and B1b with copper(II)-64 (RCY > 99 %) was initially checked by radio-TLC 
analysis. The radiolabeled complexes were then incubated with a 100-fold molar excess 
of cyclam and EDTA, respectively. After incubation at room temperature for 2 and 
24 hours, the samples were assayed by radio-HPLC. The radio-HPLC protocol applied 
revealed well-separated signals for the metal complexes, hence providing information on 
the degree of transchelation. As expected, both 64CuII-B1a and 64CuII-B1b were stable by 
more than 99 % after 2 and 24 hours in the presence of cyclam as well as of EDTA. 
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To further study the kinetic stability of the 64CuII-bispa complexes, superoxide dismutase 
(SOD) challenge experiments were carried out. The copper / zinc enzyme SOD is mostly 
abundant in kidney and liver cells as well as erythrocytes. The major function of SOD is 
the cellular defense against oxidative damage, as it catalyzes the disproportionation of 
superoxide radicals to oxygen and hydrogen peroxide. This catalytic conversion takes 
place at the active site of the enzyme, which embeds the metal ions copper and 
zinc.[402,403] Several stability studies of 64CuII-labeled BFC-protein conjugates have shown 
transchelation of 64CuII to SOD.[207,208] For this reason, STEPHAN and coworkers developed 
a new SOD stability assay,[182] which was also used in the study presented here. Briefly, a 
3-fold excess of human SOD was added to the bispa complexes 64CuII-B1a and 
64CuII-B1b and the samples were then incubated for 1 hour at 37 °C. The subsequent 
analysis was performed using non-reducing and non-denaturing polyacrylamide gel 
electrophoresis (native PAGE). After electrophoresis, the gel was examined by electronic 
autoradiography with a radioluminography laser scanner. The different blackening 
intensities of the bands correlate with the amount of copper-64, which dissociates from the 
ligand upon incubation with SOD and is subsequently bound to the enzyme.[182] Following 
autoradiography, the gels were stained with colloidal Coomassie G-250 to visualize the 
protein bands. A representative gel is depicted in Figure 51 and the results obtained for 
64CuII-B1a and 64CuII-B1b are given in Table 14. The results are compared to prominent 
literature-known copper(II) chelators studied by STEPHAN et al. to show the potential of the 
newly-developed SOD assay.[182] The corresponding experiments were carried out under 
the same conditions applied in this study and the results can hence be directly compared. 
The 64CuII-bispa complexes displayed high resistance towards transchelation to human 
SOD with less than 1 % of incorporation. These values are in the same range as those 
observed for N2py4 (B3) and all macrocyclic ligands under investigation. However, 
64CuII-(p-MeO)B4 shows 4.3 ± 0.1 % transchelation ratio, which means that it is slightly 
less stable against SOD than the bispa complexes. In contrast, the acyclic radiolabeled 
chelator EDTA underwent an almost complete transchelation (85.4 ± 13.6 %) in the 
presence of SOD.[182] 
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Figure 51. Analysis of 64CuII transchelation to human erythrocyte superoxide dismutase 
(SOD) for 64CuII-B1a. Colloidal Coomassie stained native polyacrylamide gel (left) and 
autoradiography showing 64CuII-labeled bands of SOD (right). The respective analysis for 
64CuII-B1b is shown in Appendix H. 
Table 14. 64CuII transchelation [% of control] to human erythrocyte superoxide dismutase 
(SOD) for various 64CuII-labeled ligands after 1 h. Each value is given as mean ± standard 
deviation of three measurements. 
complex transchelation [% of control] ref 
64CuII-B1a 0.2 ± 0.1  
64CuII-B1b 0.4 ± 0.1  
64CuII-B3 0.7 ± 0.3 [173,177] 
64CuII-(p-MeO)B4 4.3 ± 0.1 [172,177] 
64CuII-TETA 1.3 ± 0.6 [182] 
64CuII-DOTA 1.7 ± 1.3 [182] 
64CuII-NOTA 1.4 ± 0.7 [182] 
64CuII-cyclam 1.0 ± 0.5 [182] 
64CuII-DIAMSAR 0.6 ± 0.1 [182] 
64CuII-EDTA 85.4 ± 13.6 [182] 
 
The ultimate in vitro stability test for radiometal ion complexes is the incubation of the 
compound in the presence of blood serum. In addition to the SOD challenge experiment 
described above, STEPHAN et al. also developed a complementary serum stability 
assay.[182] Instead of SOD, the radiolabeled ligands B1a and B1b were incubated with 
aliquots of human serum and the samples were analyzed by non-reducing sodium 
dodecyl sulfate (SDS) PAGE. The stained gels as well as the autoradiographic scans for 
64CuII-B1a and 64CuII-B1b are shown in Figure 52 and Appendix H. The prominent protein 
band in the size range of approximately 65 kDa most likely corresponds to 64CuII-labeled 
serum albumin. Other serum proteins with high affinity for copper(II) are not visible, 
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possibly due to their predominantly low abundance in human serum and the rather low 
activities of 64CuCl2 used in the experiments.[182] Quantitative analysis of the band 
intensities revealed 17.8 ± 1.1 % transchelation to human serum proteins for 64CuII-B1a 
and 6.0 ± 1.1 % for 64CuII-B1b. These high values were surprising, considering that the 
stability of radiolabeled ligands in SOD is usually observed to be in the same range as 
that in human serum.[182] Furthermore, the bands in the autoradiography were 
considerably smeared and this made the integration difficult. The autoradiography 
corresponding to the serum stability assay of 64CuII-B1b additionally shows a band at the 
top of the scan that cannot be assigned. 
 
Figure 52. Analysis of 64CuII transchelation to human serum proteins for 64CuII-B1a. 
Colloidal Coomassie stained native polyacrylamide gel (left) and autoradiography showing 
64CuII-labeled bands of human serum proteins (right). 
To validate the serum stability of 64CuII-B1a and 64CuII-B1b the respective experiments 
were repeated and then analyzed by radio-size exclusion chromatography (SEC) instead 
of gel electrophoresis. In both cases, the completely intact radiometal complexes (> 99 %) 
were eluted from the SEC column and no serum bound activity could be detected. This 
contradicts the results of the above-described serum challenge assays evaluated by gel 
electrophoresis. Finally, biodistribution studies were performed with the bispa-based 
complexes to provide clarity about their stability (see below). 
Lipophilicity studies 
Information about the lipophilicity of the 64CuII-labeled bispa ligands B1a and B1b were 
obtained using the shake-flask procedure.[189,190] The distribution ratio Do/w was determined 
as the concentration ratio of the respective 64CuII-bispa complexes between 1-octanol and 
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an aqueous phase at different pH. The distribution ratios are given as log Do/w values in 
Table 15. Similar to previously investigated bispidine systems,[172,173] the complexes 
64CuII-B1a and 64CuII-B1b are quite hydrophilic. Therefore, comparative biodistribution 
behavior, i.e. fast blood clearance and renal excretion, are expected for the 64CuII-labeled 
bispa ligands. The log Do/w values of 64CuII-B1b with a positive overall charge of one and 
of the twice positively charged 64CuII-B3 are in the same range.[173] Reduction of the C9 
keto group leads to a slight increase of hydrophilicity, which can be seen by comparison of 
the 64CuII-bispidine complexes based on B3 and B6.[173] The para-methoxy substitution of 
the pyridine groups in (p-MeO)B4, on the other hand, decreases the hydrophilicity.[172] 
Note that an efficient QSPR model was developed by COMBA et al. for the prediction of 
lipophilicities / hydrophilicities.[188,404] 
The distribution ratios of 64CuII-B1a are clearly more negative than those of 64CuII-B1b. 
This can be explained by the structural differences of the two copper(II) complexes, 
thoroughly discussed in Chapter 4.1. The lipophilic behavior of compounds is correlated to 
the respective charge distributions. The copper(II)-carboxylate bond length in the solid 
state structure of CuII-B1a is 2.3127(12) Å and therefore significantly larger than the 
respective distance in CuII-B1b with 2.0119(11) Å. In several spectroscopic studies it 
could be shown that the structures determined by X-ray analysis are preserved in solution. 
The positive charge at the central copper(II) ion and the negative charge of the 
carboxylate are apparently more separated in CuII-B1a resulting in a more hydrophilic 
complex. 
Table 15. Distribution ratios log Do/w of 64CuII-bispidine complexes at different pH. 
bispidine ligand  log Do/w at pH  ref 
 7.2 7.4 7.6  
Hbispa1a (B1a) (a) -3.79 ± 0.02 -3.78 ± 0.02 -3.77 ± 0.02  
Hbispa1b (B1b) (a) -2.70 ± 0.02 -2.74 ± 0.02 -2.74 ± 0.02  
N2py4 (B3) -2.73 -2.77 -2.69 [173] 
B6 -2.89 -2.88 -2.85 [173] 
(p-MeO)B4 -2.49 -2.44 -2.42 [172] 
(a) Values are given as mean ± standard deviation of four measurements. 
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Biodistribution 
The stability of the 64CuII-bispa complexes 64CuII-B1a and 64CuII-B1b was additionally 
tested in biodistribution studies on male Wistar Kyoto rats. The radiolabeled bispa ligands 
were injected into the tail vain of the rats and the animals were sacrificed 5 minutes, 
30 minutes, and 24 hours post injection (p.i.). Organs and tissues of interest were rapidly 
excised, weighed, and the accumulated radioactivity determined using a γ counter. When 
uncomplexed copper(II) ions in the form of 64CuCl2 are injected, an accumulation of 
radioactive species is observed in the liver, intestine and kidneys.[173] The biodistribution 
pattern of 64CuII-B1a and 64CuII-B1b, in contrast, show fast elimination via the kidney and 
no significant accumulation in other organs or tissues. The 64CuII radioactivity 
concentration was calculated as either the percentage of the injected dose per gram 
(%ID/g) or, for stomach, intestine, feces and urine, the percentage of injected dose (%ID). 
The biodistribution and elimination data of 64CuII-B1a and 64CuII-B1b are depicted in 
Figure 53 and Figure 54, and additionally given in Appendix H. Except for the kidneys, 
the activity uptake was less than 1 %ID/g tissue and this activity was eliminated after 
24 hours. As expected from the lipophilicity studies the 64CuII-bispa complexes are rapidly 
excreted via the renal pathway, i.e. kidneys and urine. Furthermore, the biodistribution 
shows no signs for demetalation of the complexes in vivo. On the contrary, they appear to 
be highly stable and this is in agreement with the results of the serum assays analyzed by 
radio-SEC. 
 
Figure 53. Biodistribution pattern of the 64CuII complex based on B1a at 5 min, 60 min, 
and 24 h p.i. (four Wistar Kyoto rats per time point and compound, mean value ± standard 



























































































Figure 54. Biodistribution pattern of the 64CuII complex based B1b at 5 min, 60 min, and 
24 h p.i. (four Wistar Kyoto rats per time point and compound, mean value ± standard 
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4.2.2 Radiochemistry with gallium(III)-68 
The radiochemical studies with gallium(III)-68 were also performed at the Institute of 
Radiopharmaceutical Cancer Research of the Helmholtz Zentrum Dresden-Rossendorf 
(HZDR). Except for the animal studies, the experiments were carried out in the group of 
Dr. Holger STEPHAN by Madlen MATTERNA and Dr. Kristof ZARSCHLER with assistance of 
Miriam STARKE. The biodistribution studies were performed by Prof. Dr. Jens PIETZSCH 
and coworkers. 
Radiolabeling experiments 
Initial radiochemical investigations with gallium(III)-68 were performed using the bispa 
ligand B1a. In the course of the radiolabeling studies different temperatures, ligand 
concentrations and activities were tested. The degree of radiolabeling was monitored by 
radio-TLC, allowing the clear separation of uncomplexed 68GaIII and 68GaIII-B1a. As B1a 
could not be radiolabeled with 68GaIII at room temperature, the experiments were 
performed at 37 °C while mixing the samples with 750 revolutions per minute (rpm) in a 
thermomixer. It was found that 30 µg ligand per 300 µL buffer solution (~10-4 M) were 
quantitatively radiolabeled with ~65 MBq 68GaCl3 within 30 minutes. At lower ligand 
concentrations of ~510-4 to 510-6 M only incomplete radiolabeling was observed under 
the described conditions and with 0.3 µg B1a (~10-6 M) the radiochemical yield (RCY) 
dropped to 0 %. The molar activity of B1a was calculated based on an experiment with 
1.5 µg ligand (~510-6 M) and 47.6 MBq 68GaCl3. After 15 minutes 55 % RCY were 
determined and this corresponds to a molar activity of ~12 GBq/µmol for B1a. For 
radiolabeling with starting activities of 80 MBq and higher, the reaction temperature had to 
be increased to 50 °C. 
Competition assays 
The stability of 68GaIII-B1a was investigated in the presence of either EDTA (L9) or human 
serum. For the EDTA challenge experiment, B1a was first radiolabeled with 68GaCl3 and 
then incubated with a 10-fold molar excess of EDTA at ambient temperature. The degree 
of transchelation was determined by radio-TLC after 1, 2 and 4 hours. At all time points 
the amount of radioactivity bound to EDTA was less than 1 %, which shows that 
68GaIII-B1a is stable against EDTA. 
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A serum stability assay similar to those described for 64CuII complexes was also 
performed with 68GaIII-B1a.[182] Radiolabeled B1a was incubated in the presence of human 
serum for 1 hour at 37 °C and the samples were then analyzed by gel electrophoresis and 
subsequent autoradiography. The stained gel and the autoradiographic scan are depicted 
in Figure 55. Blood serum contains the glycoprotein transferrin which possesses two iron 
binding sites. Due to the close similarity of FeIII and GaIII, transferrin also displays high 
affinity to the latter metal ion.[223,224] The intense band in the autoradiography of the gel 
can be assigned to human transferrin, which has a molecular weight of about 73 kDa.[405] 
Quantitative analysis of the bands revealed that 56.2 ± 2.6% of the gallium(III)-68 activity 
initially coordinated to B1a was now bound to transferrin. Even though 68GaIII-B1a showed 
no transchelation in the presence of EDTA, the complex is not stable against human 
serum. 
 
Figure 55. Analysis of 68GaIII transchelation to human serum proteins for 68GaIII-B1a. 
Colloidal Coomassie stained native polyacrylamide gel (left) and autoradiography showing 
68GaIII-labelled bands of human serum proteins (right). 
Biodistribution 
Analogous to the experiments described above for copper-64, a biodistribution study was 
performed with 68GaIII-B1a. The amount of activity in the organs and tissues was 
determined 5 and 60 minutes after intravenous application of the radiolabeled ligand. The 
values were calculated in %ID/g or %ID and are given in Figure 56 and Appendix H. In 
contrast to the biodistribution pattern of the 64CuII-bispa complexes, the data collected for 
68GaIII-B1a show substantial activity uptake in most tissues. In addition, the activity is not 
significantly eliminated from the organism, but rather increases in some parts, for example 
in the white adipose tissue (WAT) and the bone. The biodistribution and elimination 
behavior of 68GaIII-B1a is in agreement with the low stability of the complex in the 
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presence of human serum (see above). Due to these results no further stability studies 
with gallium(III) bispa complexes were performed and the isomeric bispa ligand B1b was 
also not investigated in radiochemical studies. 
 
Figure 56. Biodistribution pattern of the 68GaIII complex based on B1a at 5 min and 60 min 
p.i. (four Wistar Kyoto rats per time point and compound, mean value ± standard 
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4.3 Conclusion 
In Chapter 4.1 the coordination chemistry of the hexadentate bispa ligands B1a, 
(p-MeO)B1a, and B1b was investigated with the metal ions cobalt(II), nickel(II), copper(II), 
zinc(II), and gallium(III). Extensive structural and spectroscopic studies of the metal bispa 
complexes were performed and discussed with regard to nuclear medicine applications. 
The isomeric bispa ligands B1a and B1b were then further examined with the PET 
nuclides copper-64 and gallium-68.  
Bispa ligand B1a could not be radiolabeled with gallium(III)-68 at room temperature, but a 
labeling procedure at 37 °C was developed, which is compatible with the use of biological 
vectors. Challenge experiments with 68GaIII-B1a revealed that the complex is stable in the 
presence of EDTA (L9). However, incubation of 68GaIII-B1a with human serum resulted in 
56.2 ± 2.6% transchelation to transferrin after 1 h at 37 °C. The low stability of 68GaIII-B1a 
was also confirmed by biodistribution studies in rats. The bispa system hence proved to 
be inadequate for application as a 68GaIII-chelating unit in nuclear medicine. Due to these 
results no further studies with the bispa ligands and gallium(III)-68 were performed. 
Because the presence of only one oxygen donor seems to be insufficient for stable 
complexation of gallium(III), our group is currently working on improved bispidine ligands 
for this specific metal ion. 
The 64CuII-bispa complexes, on the other hand, showed very promising properties 
including fast radiolabeling, high stability, and favorable biodistribution behavior. In 
radiolabeling experiments, molar activities as high as ~100 and ~200 GBq/µmol were 
determined for 64CuII-B1a and 64CuII-B1b, respectively. Stability assays in the presence of 
EDTA, cyclam (L3), SOD and human serum revealed no transchelation of 64CuII to the 
competing ligands or proteins. The results of these in vitro studies were confirmed by 
biodistribution experiments showing very rapid blood and normal-tissue clearance of both 
64CuII-bispa complexes. The high stability of the complexes in vitro and in vivo is in 
agreement with their formation constants determined by potentiometric titration. The 
thermodynamic stability constants log β are 18.9 for CuII-B1a and 19.4 for CuII-B1b and 
this correlates with the respective CuII/I redox potentials of –1.02 and –1.17 V vs. fc/fc+. 
Based on these results, B1b appears to be a slightly better ligand than B1a. However, a 
parameter more relevant for in vivo applications than log β is the pM value at pH 7.4 (pM 
= –log [Mn+]). According to the calculated pM values of 19.3 and 18.7 for CuII-B1a and 
CuII-B1b, respectively, the stability order is reversed. Furthermore, the lipohilicity studies 
showed that 64CuII-B1a is slightly more hydrophilic than 64CuII-B1b and this is preferable 
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with regard to radiopharmaceutical applications. In summary, the hexadentate bispa 
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5 Investigation of the octadentate bispa ligandvi 
Bispidines represent an emerging ligand family for radiopharmaceutical applications, 
whereby the focus so far has been on acyclic hexadentate and macrocyclic tetradentate 
ligand systems and their CuII complexes.[172,173,218,346] In Chapter 3.2 the synthesis and 
characterization of the potentially octadentate bispa ligand H2bispa2 (B2) was reported. In 
this chapter studies on the complexation behavior of the N6O2-type ligand B2 with non-
radioactive InIII, LuIII, and LaIII are presented. The corresponding metal complexes were 
studied by nuclear magnetic resonance (NMR) spectroscopy, high resolution mass 
spectrometry (HR-MS), elemental analysis (EA), solid state X-ray analysis and 
potentiometric titrations. The coordination chemistry of B2 with LaIII was thought to be of 
interest due to some similarities of LaIII and AcIII, which does not have any stable 
isotope.[284] However, in terms of covalency, i.e. electronics and donor preference, there is 
a significant difference between lanthanides and actinides.[285-287] In addition to the “cold 
chemistry”, radiolabeling and radiostability studies were performed with 111InIII, 177LuIII, and 
225AcIII to evaluate the potential of B2 for the application as a chelator in nuclear medicine. 
 
Figure 57. Representation of the radiochemical investigation of bispa ligand B2 with the 
radioactive metal ions 111InIII, 177LuIII, and 225AcIII.  
                                                
vi  Parts of this chapter will be published in P. Comba, U. Jermilova, C. Orvig, B. O. Patrick, 
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5.1 Coordination chemistry of the octadentate bispa ligand 
5.1.1 Characterization of metal-bispa2 complexes 
In the light of potential radiopharmaceutical applications, the coordination chemistry of 
H2bispa2 (B2) with InIII, LuIII, and LaIII was studied. To this end, equimolar solutions of the 
ligand and the respective metal salts in methanol (LuIII and LaIII) or in a mixture of 
methanol and water (InIII) were combined. With InIII and LuIII the respective metal acetates 
were used, where acetate acts as a base for the deprotonation of the ligand. For the 
synthesis of the LaIII complex, the chloride was used instead of the acetate salt and, 
therefore, diluted sodium hydroxide solution was added. The formation of the metal 
complexes was confirmed by HR-MS as well as 1H- and 13C-NMR spectroscopy. 
Two-dimensional NMR correlation experiments (1H-1H and 1H-13C) were used to assign 
the signals unambiguously. 
The picolinate and pyridine donors of the ligand can rotate freely, leading to a simple 
1H-NMR spectrum (see Experimental Section and Appendix A). Upon coordination of the 
free ligand to the metal ions, significant changes in chemical shifts and coupling patterns 
of the NMR spectra are observed. The 1H-NMR spectrum of the [LaIII(B2)]+ (LaIII-B2) 
complex displays sharp and well-resolved diastereotopic splitting of the methylene protons 
associated with the picolinic acid arms. In addition, all previously equivalent sets of 
protons show different chemical shifts. A slightly different but altogether similar splitting 
pattern can be observed in the 1H-NMR spectrum of the corresponding LuIII complex. In 
contrast, the 1H-NMR of the [InIII(B2)]+ (InIII-B2) complex reveals changes in chemical 
shifts but shows no additional splitting of the signals. Furthermore, some peaks in the 
spectra of the complex become broad in comparison to the free ligand, suggesting some 
sort of fluxional behavior in solution.  
Crystals of the InIII complex suitable for solid state X-ray analysis were obtained by slow 
evaporation from a methanolic solution. The complex cation [InIII(B2)]+ crystallizes with 
one trifluoroacetate (TFA) as counterion and four molecules of water in the asymmetric 
unit. The central InIII ion is coordinated by seven donor atoms of the doubly deprotonated 
N6O2-type ligand, with bond lengths between 2.200(1) Å for In-Npa3 and 2.486(1) Å for 
In-N3. The pyridine nitrogen Npy1 has an In-Npy1 distance of 3.1073(11) Å and might 
hence be described as semi-coordinating since the pyridine lone pair is oriented towards 
the metal ion and efficiently shields the metal center from other donor groups, such as 
coordinating solvents or anions. The solid state structure of the complex cation [InIII(B2)]+ 
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is depicted in Figure 58 and the corresponding structural and crystallographic data are 
presented in Table 16 and Appendix B. 
 
Figure 58. ORTEP plot of the complex cation of [InIII(B2)](TFA). Ellipsoids are shown at 
the 50 % probability level; co-crystallized solvent molecules, counterions, and hydrogen 
atoms are omitted for clarity.[256] 
Table 16. Selected bond distances of H2bispa2 (B2) and [InIII(B2)](TFA). 
 H2bispa2 (B2) [InIII(B2)](TFA) 
distance [Å]   
In-N7  2.3867(10) 
In-N3  2.4859(10) 
In...Npy1  3.1073(11) 
In-Npy2  2.3784(10) 
In-Npa7  2.2201(10) 
In-Opa7  2.2599(9) 
In-Npa3  2.2000(10) 
In-Opa3  2.2270(9) 
N3...N7 2.766(3) 2.9355(14) 
Npy1...Npy2 4.679(3) 5.0052(15) 
 
The elemental analysis of the InIII-B2 complex confirms the presence of water molecules 
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for X-ray crystallography were obtained. However, NMR and HR-MS as well as the 
elemental analyses of the compounds confirm structures similar to the corresponding InIII 
complex, i.e. a 1:1 metal ion to ligand complex with TFA as a counterion and several 
water molecules. 
5.1.2 Potentiometric titrations 
The thermodynamic stabilities of the InIII-, LuIII- and LaIII-complexes based on B2 were 
measured by potentiometric titration (H2O, 25 °C, 0.1 M KCl), and the respective 
constants are listed in Table 17. While for LuIII and LaIII the stability constants were 
accessible by direct titration of equimolar ligand / metal ion solutions, a competing ligand 
was needed to determine the stability of the InIII-B2 complex. The acyclic chelator EDTA 
(L9) was used for the ligand-ligand competition titrations (see Experimental Section for 
details). 
Table 17. Metal complex stability constants (log β) and pM7.4 values of B2 (H2O, 25 °C, 
0.1 M KCl). 
model (a) InIII (b) LuIII LaIII 
ML 24.39(6) 8.51(3) 11.42(6) 
MLH  12.60(22) 15.49(13) 
MLH2  16.35(11)  
MLH-1   0.50(4) 
pM7.4 (c) 25.0 9.1 12.0 
(a) L denotes the respective ligand with completely deprotonated basic centers; the charges of the 
species are omitted for clarity. (b) Formation of InL was determined by ligand-ligand competition 
titrations. (c) Calculated for 10 µM total ligand and 1 µM total metal ion concentration at pH 7.4 and 
25 °C. 
The formation constants log βML and pM values (pM = -log [Mn+] at pH 7.4) for 
InIII complexes with several selected chelators are summarized in Table 18. The 
logarithmic stability constant of the InIII-B2 complex is 24.4 and therefore significantly 
larger than the respective stability constant observed for the InIII-transferrin complex 
(18.3). The iron-binding human serum protein is a main in vivo competitor for InIII.[406] 
Compared to other ligand systems relevant for nuclear medicine, InIII-B2 was found to 
have a higher stability constant than [InIII(DOTA)]- (23.9),[250] but to be less stable than 
[InIII(DTPA)]2- (29.0)[407] and [InIII(octapa)]- (26.8).[158] In this context, it is interesting to note 
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that InIII-DOTA is significantly more stable in vivo than InIII-DTPA, even though the log βML 
and pM7.4 values for InIII-DTPA are much higher than for the corresponding DOTA 
complex.[48] This demonstrates that these thermodynamic parameters can provide initial 
insight into the stability of metal ion complexes, but cannot be correlated directly with their 
in vivo behavior, where inertness rather than stability are of importance (kinetics vs. 
thermodynamics). In addition, hydrolysis plays a major role considering the nM to pM 
concentrations of the complexes in comparison to the relatively high concentrations of 
hydroxides at physiological pH. The complex stabilities log βML of the complexes LuIII-B2 
and LaIII-B2 were also determined and are relatively small (8.5 and 11.4 respectively) in 
comparison to the corresponding complexes with other chelators (see Appendix C). The 
species distribution diagrams of B2 in the presence of the investigated metal ions are 
shown in Appendix C. 
Table 18. Stability constants (log βML) and pM7.4 values for selected InIII complexes. 
ligand log βML pM7.4 (a) ref 
DOTA (L5) 23.9(1) 18.8 [158,250] 
DTPA (L10) 29.0 25.7 [158,407] 
H4octapa (L35) 26.8(1) 26.5 [158] 
transferrin 18.30 18.7 [158,406] 
H2bispa2 (B2) 24.39(6) 25.0  
(a) Calculated for 10 µM total ligand and 1 µM total metal ion concentration at pH 7.4 and 25 °C. 
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5.2 Radiochemical investigations of the octadentate bispa ligand 
The novel bispidine ligand H2bispa2 (B2) was investigated with the radioactive metal ions 
111InIII, 177LuIII, and 225AcIII. These radiometal ions typically form complexes with chelators 
of high denticity, i.e. 7-12 coordinate, and are used for either diagnostic (111InIII) or 
therapeutic (177LuIII and 222AcIII) purposes.[21,48] The radiochemical studies were carried out 
at the Tri University Meson Facility (TRIUMF), Canada’s national laboratory for particle 
and nuclear physics and accelerator-based science in Vancouver. The radiolabeling and 
challenge experiments were performed by Dr. Caterina RAMOGIDA with assistance of Una 
JERMILOVA. 
5.2.1 Radiolabeling experiments 
Initial radiolabeling studies with 111InIII, 177LuIII, and 225AcIII with B2 were performed to 
assess the potential of the new octadentate bispidine as a ligand scaffold in nuclear 
medicine applications. The degree of radiolabeling was analyzed by radio-high 
performance liquid chromatography (radio-HPLC) or radio-thin layer chromatography 
(radio-TLC). Stringent mild and fast radiolabeling procedures were enforced throughout 
the initial experiments with all three nuclides in order to mimic the most favorable 
conditions employed in a radiopharmacy setting and which would be amenable to “kit-
type” labeling. Room temperature, rapid labeling at low ligand concentrations is an 
important condition for new ligands under investigation in radiopharmaceutical 
applications, and would present a particular advantage compared to the “gold standard” 
macrocyclic ligand DOTA (L5), which often requires heating samples at elevated 
temperatures for extended periods of time. For example, many of the aforementioned “pa” 
ligands like H2dedpa (L30) and H4octapa (L35) have the ability to quantitatively complex 
several radiometal ions in 10 minutes at ambient temperature. 
B2 was successfully radiolabeled with the commercially available SPECT isotope 111InIII 
(t1/2 = 2.8 d[27]) within 10 minutes at room temperature at ligand concentrations of ~10-4 to 
10-7 M. The radiochemical yield (RCY) was determined by radio-HPLC to be > 99 %. A 
representative chromatogram is shown in Figure 59. Radiolabeling of [111InIII(B2)]+ 
(111InIII-B2) yielded molar activities as high as ~70 GBq/µmol or 89 MBq/µg in 10 minutes 
at ambient temperature, when radiolabeled with 8.9 MBq 111InIII at 10-7 M ligand. At B2 
ligand concentrations of 10-8 M, the radiolabeling yield dropped to 0 % after 10 minutes at 
ambient temperature. Note that the molar activity is usually determined under conditions 
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yielding RCYs of less than 99 %, otherwise the observed activity is typically 
underestimated. As no radiolabeling was observed when decreasing the ligand 
concentration to 10-8 M, this error should be negligibly small. The results for B2 are 
comparable to those obtained for H4octapa, which quantitatively complexes 111InIII at 
ligand concentrations as low as 10-7 M.[158] Conversely, [111InIII(DOTA)]- (111InIII-DOTA) 
labeling at identical conditions resulted in only 40 % RCY.[158] 
 
Figure 59. Representative HPLC radiochromatogram of 111InIII-B2 (tR = 10.5 min, red line) 
reacted for 10 minutes at ambient temperature (0.1 µg ligand, ~10-7 M, 8.9 MBq, pH 4), 
and corresponding UV chromatogram of non-radioactive InIII-B2 (tR = 10.1 min, blue line). 
Small differences in retention times of radioactive and non-radioactive complex are 
caused by the instrument setup, i.e. sequential arrangement of UV-vis detector followed 
by radiation detector. 
Unlike the facile labeling kinetics observed for 111InIII, radiolabeling at 10-4 M B2 with the β– 
and γ emitter 177LuIII (t1/2 = 6.7 d[27]) required gentle heating to 40 °C for 1 hour to obtain 
quantitative labeling (RCY > 99 %). Quantitative radiolabeling of DOTA was also achieved 
under analogous conditions (40 °C, 1 h). With the same ligand concentration of 10-4 M B2 
the RCY was 49 % after 15 minutes at room temperature (see Figure 60). Under these 
conditions, radiolabeling with 3.7 MBq 177LuIII yielded a molar activity of 10 MBq/µmol. Due 
to the inability of B2 to quantitatively complex 177LuIII at ambient temperature at the highest 
ligand concentration, 177LuIII radiolabeling at lower ligand concentrations was not 
attempted. 
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Figure 60. HPLC radiochromatograms of 177LuIII-B2 (tR = 10.9 min). Reaction conditions: 
100 µg of B2, 1 h, 40 °C (red line, RCY > 99 %); 100 µg of B2, 15 min, room temperature 
(green line, RCY = 49 %); 100 µg of B2 as control (purple line, tR of 177Lu3+ = 3.3 min). 
Corresponding UV chromatogram of non-radioactive LuIII-B2 (tR = 10.6 min, blue line). 
Small differences in retention times of radioactive and non-radioactive complex are 
caused by the instrument setup, i.e. sequential arrangement of UV-vis detector followed 
by radiation detector. 
The α emitter 225Ac (t1/2 = 10.0 d[27]) is a promising candidate for labeling biomolecules in 
targeted α therapy (TAT). The high linear energy transfer (LET) of alpha particles renders 
their emitters ideal for treating small tumors with minimal chance of harming surrounding 
healthy tissue.[21] 225Ac radiolabeling chemistry is further complicated by its decay scheme 
which goes through predominantly six daughters, including 221Fr (t1/2 = 4.9 min[27]) and 
213Bi (t1/2 = 45.6 min[27]), meaning a chelator suitable for 225AcIII pharmaceuticals must 
stably bind the nuclide as well as control the fate of the daughters.[281] Preliminary room 
temperature 225AcIII labeling of B2 was attempted at ligand concentrations of ~10-4 to 
10-8 M in ammonium acetate buffer, pH 6. The radiochemical yield of [225AcIII(B2)]+ 
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developing in an appropriate solvent (see Experimental Section), and counting the activity 
on the plates immediately and the following day. Measuring the TLC plates the following 
day was necessary in order to allow any initial 213BiIII to decay and calculate corrected 
225AcIII radiolabeling yields. At ligand concentrations of ~10-4, 10-5, 10-6 and 10-8 M, 225AcIII 
RCYs were 98, 94, 64 and 2 %, respectively (see Figure 61). Radiolabeling of B2 with 
40 kBq 225AcIII hence yielded a molar activity of 20 MBq/µmol. These results present a 
substantial advantage over the current “gold standard” DOTA, which required heating 
samples above 60 °C in order to initiate 225AcIII labeling, even at the highest ligand 
concentration.  
 
Figure 61. TLC radiochromatograms of 225AcIII labeling reactions at B2 ligand 
concentrations of 10-4 (blue line), 10-5 (red line), 10-6 (green line), and 10-8 (purple line), 
reacted for 30 min at ambient temperature, pH 6. Peaks centered at 20 mm correspond to 
225AcIII-labeled species; peaks above 60 mm correspond to uncomplexed 225AcIII. 
5.2.2 Competition assays 
Serum contains many endogenous proteins, such as transferrin and metallothionein, 
which can compete for and displace chelator-bound metal ions in vivo. As such, any 
radiometal-ligand complex must be able to withstand transchelation to such proteins in 
order to successfully deliver the radiotracer to the desired molecular target. To investigate 
the stability of the 111InIII-, 177LuIII- and 225AcIII-B2 complexes, a competition experiment was 
performed in the presence of excess human serum. This assay is a popular method to 
predict the in vivo inertness of radiometal ion complexes. 
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In addition to human serum, the 225AcIII-B2 complex was challenged via a LaIII competition 
experiment. Because of their similar ionic radii, LaIII (103-116 ppm, CN = 6-9) and AcIII 
(112 ppm, CN = 6)[148] are often considered chemical surrogates.[284] Despite fundamental 
differences in coordination chemistry among trivalent actinides and lanthanides,[285-287] 
using non-radioactive metal ions such as LaIII as a competitor is a straightforward and 
widely used method to probe the kinetic off-rate of a pre-formed actinium(III) 
complex,[288,408] since many ligands that bind AcIII may also efficiently complex LaIII. 
For the serum stability assays the radiolabeled ligands were incubated in the presence of 
human serum at 37 °C. The degree of radiometal ion loss to serum proteins was then 
assayed by either size exclusion using PD-10 columns (111InIII and 177LuIII experiments) or 
by radio-TLC (225AcIII). The 111InIII-B2 complex showed respectable stability with 88, 87, 
and 87 % of 111InIII remaining chelate bound after 1 hour, 1 and 5 days against human 
serum at 37 °C (Table 19). These results suggest a small amount (~12 %) of the 111InIII 
has been transchelated from the ligand to serum rapidly after one hour, but then the 
remaining 111InIII-B2 complex remains stable over the following 1 and 5 day time points. 
Literature compounds [111InIII(octapa)]- (111InIII-octapa) and 111InIII-DOTA exhibited similar 
stabilities of 92 and 89 %, respectively, after 1 day.[158] Sampling after 5 days was not 
conducted in these experiments. [177LuIII(B2)]+ (177LuIII-B2) was incubated and analyzed in 
human serum over 7 days, where the complex remained moderately stable after 1 hour 
and 1 day, with 89 and 86 % intact, respectively. Thereafter, a small drop in stability was 
seen at later time points, where 69 % of the 177LuIII complex remained intact after 7 days. 
The [177LuIII(octapa)]- (177LuIII-octapa) and [177LuIII(DOTA)]- (177LuIII-DOTA) complexes were 
previously found to be comparably stable to 177LuIII-B2 after 1 day in human serum (~87 % 
for both literature compounds).[409] Later time points of either the DOTA or octapa 
complexes were not analyzed. Therefore, it is unknown whether their respective 
177LuIII complexes would also decline in stability over the course of 7 days. Finally, 225AcIII-
B2 and “gold standard” [225AcIII(DOTA)]- (225AcIII-DOTA) were incubated with human serum 
for one week, and the complex stability was assayed at several stages. The 225AcIII-B2 
complex was exceptionally stable over the course of 7 days remaining 89 % intact and 
this value is comparable to the 7 day stability of the “gold standard” 225AcIII-DOTA (85 % 
intact). 
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Table 19. Radiometal ion complex stability in human serum (n = 3 for each 111InIII complex 
and for 225AcIII-B2 , n = 2 for each 177LuIII complex and for 225AcIII-DOTA). 
complex 1 h [%] 1 d [%] 5 d [%] 7 d [%] ref 
111InIII-B2 88.4 ± 1.2 87.4 ± 0.6 87.4 ± 1.5 ND (a)  
111InIII-octapa 93.8 ± 3.6 92.3 ± 0.04 ND (a) ND (a) [158] 
111InIII-DOTA 89.6 ± 2.1 89.4 ± 2.2 ND (a) ND (a) [158] 
177LuIII-B2 88.9 ± 1.1 86.1 ± 0.5 76.7 ± 0.01 68.8 ± 0.7  
177LuIII-octapa 88.1 ± 1.2 87.7 ± 0.7 ND (a) ND (a) [409] 
177LuIII-DOTA 87.7 ± 0.7 87.4 ± 2.1 ND (a) ND (a) [409] 
225AcIII-B2 97.4 ± 0.5 92.3 ± 0.7 90.7 ± 0.5 (b) 88.9 ± 2.8  
225AcIII-DOTA 93.9 ± 4.5 90.9 ± 5.6 91.1 ± 6.1 84.7 ± 8.1  
(a) ND = not determined. (b) Stability data at 3 days.  
The LaIII exchange competition experiment (Table 20) serves as an additional stability 
assay of the 225AcIII-B2 complex and is compared directly to the results obtained for 
225AcIII-DOTA, analyzed under equivalent conditions. The stability of the 225AcIII-B2 
complex shows a very similar trend to the 225AcIII-DOTA complex, i.e. 72 and 77 % of the 
initial complex remained intact after one week, respectively. Results of both the human 
serum and LaIII exchange competition assays of the 225AcIII complex coupled with the mild 
and efficient radiolabeling protocol, suggest that B2 is a promising chelator for 
AcIII pharmaceuticals. 
Table 20. 225AcIII-ligand competition against LaIII exchange with the values represented as 
% intact complex (5:1 LaIII to ligand ratio added, n = 2). 
complex 0.2 d [%] 1 d [%] 2 d [%] 3 d [%] 6 d [%] 7 d [%] 
225AcIII-B2 95.5 ± 0.2 91.5 ± 0.7 88.8 ± 2.5 85.2 ± 1.7 74.4 ± 1.4 71.7 ± 2.7 
225AcIII-DOTA 94.5 ± 3.5 (a) 94.9 ± 2.9 86.2 ± 3.1 ND (b) ND (b) 77.1 ± 3.6 
(a) Stability data at 0.08 days. (b) ND = not determined. 
 
  
Investigation of the octadentate bispa ligand 
 110 
5.3 Conclusion 
In this chapter the non-radioactive coordination chemistry of the novel octadentate 
bispidine ligand H2bispa2 (B2) was described, as well as its evaluation for 
radiopharmaceutical applications. Therefore, B2 was reacted with the “cold” metal ions 
InIII, LuIII, and LaIII for structural and solution studies, after which the radiolabeling 
efficiencies and radiostabilities of B2 with 111InIII, 177LuIII, and 225AcIII were determined. The 
stability constants of the InIII-, LuIII- and LaIII-B2 complex assessed by potentiometric 
titration are quite different from one another. However, the in vitro studies in the presence 
of human serum reveal similar stabilities for all radioactive metal-B2 complexes. These 
findings show once again that thermodynamic parameters like complex stability constants 
cannot always be correlated with the behavior in such competition assays, especially 
considering the different experimental conditions.[158] Stabilities vs. human serum 
comparable or better to those of the corresponding metal-DOTA complexes were 
observed. Besides showing respectable stabilities, the complexes 111InIII-B2 and 
225AcIII-B2 can additionally be formed quantitatively at room temperature. This is 
particularly important, because long-lived radioisotopes like 111InIII and 225AcIII are often 
used in combination with heat-sensitive antibodies as targeting vectors. The next steps 
towards the development of a bispa-based radiopharmaceutical will be the introduction of 
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6 Conclusion and outlook 
In the course of the present thesis various picolinic acid-based bispidine ligands were 
synthesized and evaluated regarding their putative application in nuclear medicine. By the 
introduction of picolinic acid groups into the bispidine scaffold, it was intended to improve 
the thermodynamic stability of the respective copper(II) bispidine complexes and to extend 
the spectrum of the bispidines to other radiopharmaceutically relevant metal ions. The 
bispidine ligands studied for 64CuII PET imaging so far solely contained nitrogen donor 
atoms, as for example N2py4 (B3).[172,173] The incorporation of an anionic oxygen donor 
was hence meant to enable the new bispa ligands to also stably bind hard metal cations. 
Through the attachment of one or two picolinic acid moieties at the bispidine backbone, 
hexa- and octadentate bispa ligands were prepared (see Figure 62 and Figure 64). 
 
Figure 62. Portfolio of bispidine-based ligand systems for nuclear medicine 
applications.[173,177] 
First, the coordination chemistry of the isomeric hexadentate bispa ligands Hbispa1a (B1a) 
and Hbispa1b (B1b), as well as of the para-methoxy substituted B1a derivative 
(p-MeO)Hbispa1a ((p-MeO)B1a) was investigated with non-radioactive metal ions. To this 
end, the N5O-type bispa ligands were reacted in complexation studies with cobalt(II), 
nickel(II), copper(II), zinc(II), and gallium(III). The resulting metal complexes were then 
characterized using standard structural and spectroscopic methods. 
Due to the favorable nuclear properties of gallium(III)-68 (t1/2 = 1.1 h[27], β+ emission), the 
bispa ligand B1a was evaluated in initial radiolabeling and stability studies with this 
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the reaction temperature from 25 °C to 37 °C. In addition, the radiolabeled complex 
68GaIII-B1a was shown to be unstable in the presence of human serum as well as in 
biodistribution experiments in rats. As a consequence of the inadequate stability of the 
68GaIII-bispa complex no further studies with gallium(III)-68 were performed. The presence 
of one hard donor group is obviously insufficient for the stable coordination of the hard 
metal ion GaIII. Therefore, novel bispidine ligands are currently being developed for this 
specific metal ion. There are several possible approaches including the evaluation of other 
substituents like carboxylic acids and phosphonic acids at the bispidine backbone as well 
as the preparation of heptadentate ligand systems. 
Building on the promising results obtained for the all-N bispidine systems,[172,173] the 
hexadentate bispa ligands were also evaluated with the PET nuclide copper(II)-64 
(t1/2 = 12.7 h[27], β+ emission). Prior to the radiochemical studies, the non-radioactive 
copper(II) bispa complexes were investigated using X-ray crystallography, UV-vis-NIR and 
ESR spectroscopy, cyclovoltammetry, and potentiometry. These analyses pointed to a 
high preorganization of the bispa ligands for copper(II) complexation as well as to a high 
stability of the resulting complexes. The formation constants log βCuL determined by 
potentiometric titrations were ~19 for the copper(II) complexes based on B1a and B1b 
and hence roughly three orders of magnitude larger than the value for CuII-B3 of 16.3.[302] 
The high complex stability was confirmed by in vitro challenge experiments with the 
respective radiolabeled ligands. No demetallation was observed, neither after incubation 
with an excess of the competing ligands cyclam (L3) and EDTA (L9) nor in the presence 
of SOD or human serum. In addition, biodistribution studies with the 64CuII-bispa 
complexes in rats revealed excellent in vivo stability as well as favorable clearance 
behavior. Furthermore, the bispa ligands could be radiolabeled with copper(II)-64 in only 
5 minutes at ambient temperature with molar activities as high as ~100-200 GBq/µmol. 
These results are very promising regarding the putative application of bispa ligands as 
part of radiopharmaceuticals. As the 64CuII complex based on B1a was found to be the 
most hydrophilic, the focus of future research will be on this specific bispa ligand. The next 
crucial step towards the development of a bispa-based radiopharmaceutical should now 
be the functionalization of the ligand scaffold with a suitable group for coupling to 
biological vectors like peptides and antibodies. Current work concentrates on the 
introduction of a p-isothiocyanatobenzyl group via the C9 alcohol of the bispidine scaffold, 
which can subsequently be conjugated to an amine group of the respective vector moiety 
(see Figure 63). The resulting radiolabeled bispa-vector conjugate then needs to be 
further investigated in studies on tumor-bearing animals in order to evaluate its targeting 
and accumulation properties. 
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Figure 63. Illustration of the conjugation of a potential bifunctional bispa ligand to a vector 
moiety followed by labeling of the conjugate with a radiometal ion. 
With the novel hexadentate bispa ligands, the portfolio of bispidine-based compounds 
now includes neutral chelators (B3 and others[172,173]) as well as systems with negative 
charges of –1 (bispa ligands) and –2 (macrocycle L25, BBDT[177]) in their deprotonated 
form (see Figure 62). The corresponding copper(II) complexes consequently display 
overall charges of +2, +1, and 0, respectively. As the hydrophilicity and the charge of a 
substance strongly influence the in vivo behavior, it is highly convenient for 
radiopharmaceutical applications to have the possibility to choose from such a broad 
ligand spectrum.  
The octadentate bispa ligand H2bispa2 (B2) was studied with radionuclides relevant for 
therapeutic and diagnostic purposes, i.e. 111InIII (t1/2 = 2.8 d[27], emission of γ rays and 
AUGER electrons), 177LuIII (t1/2 = 6.7 d[27], β– particles and γ rays), and 225AcIII 
(t1/2 = 10.0 d[27], α particles). The coordination chemistry of the N6O2-type bispa ligand was 
first investigated with the non-radioactive metal ions indium(III), lutetium(III), and 
lanthanum(III). In Figure 64 the complexation reaction of B2 and InIII to [InIII(bispa2)](TFA) 
(InIII-B2) is shown. The central indium(III) ion is coordinated by eight ligand donor atoms, 
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Figure 64. Complexation reaction of the octadentate ligand H2bispa2 (B2) to the 
respective indium(III) complex.[256]
The complex stability constants of InIII-, LuIII- and LaIII-B2 were determined by 
potentiometric titrations. Although the values obtained varied greatly, the challenge 
experiments with the radioactive metal-B2 complexes in the presence of human serum 
gave similar stabilities. The radiolabeled bispa complexes were comparably or even more 
stable under these conditions than the respective complexes of the “gold standard” DOTA 
(L5) with the same radiometal ions. After an incubation time of 1 hour for example, 89 and 
88 % of 177LuIII-B2 and 177LuIII-DOTA remain intact, respectively. Unlike DOTA, B2 could 
be quantitatively radiolabeled with 111InIII and 225AcIII under ambient conditions, which is 
very important for applications involving monoclonal antibodies as vector moieties. In the 
case of 111InIII, room temperature radiolabeling yielded a high molar activity of 
~70 GBq/µmol within 10 minutes. 
Recently, hole size calculations have been performed to understand the steric part of the 
different thermodynamic stabilities of the B2-metal complexes.[410] Furthermore, the 
theoretical determination of log D values for these systems based on calculated charge 
distributions, as previously reported for copper(II) complexes,[188,404] is in the focus of 
ongoing research. The promising results of the presented radiochemical studies of bispa 
ligand B2 will certainly promote the development of a bifunctional derivative similar to that 
currently in preparation for B1a (see above). With the new octadentate bispa ligand, the 
scope of bispidine chelators is now extended to nuclear medicine applications beyond 
















7 Experimental Sectionvii 
7.1 Materials and methods 
Chemicals and procedures 
Chemicals and solvents were purchased from Sigma-Aldrich Chemie GmbH, Fisher 
Scientific GmbH, Merck KGaA, ABCR GmbH & Co., and Tokyo Chemical Industry Co. 
Ltd. and were of the highest available purity. Dry solvents were used as delivered without 
further purification. For HPLC separations, potentiometric titrations, and radiochemical 
studies, Milli-Q water was used. Some of the reactions reported were carried out under an 
inert gas atmosphere of argon or nitrogen by means of standard SCHLENK- or glovebox 
techniques. Glassware was heated and dried under vacuum prior to usage. 
Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectra were recorded on Bruker Avance I 200, Bruker Avance II 400, Bruker 
Avance III 600 (Heidelberg University), Bruker Avance 400inv and Bruker Avance 400dir 
(University of British Columbia, Vancouver) spectrometers. The 13C-NMR spectra were 
measured with 1H decoupling. DEPT-135 as well as two-dimensional correlation 
spectroscopy like COSY, HSQC, and HMBC were used to assign the signals. 1H- and 
13C-NMR chemical shifts δ are reported in ppm values relative to the known solvent peak 
references: δH = 7.27 ppm and δC = 77.0 ppm for CDCl3, δH = 3.31 ppm and 
δC = 49.2 ppm for MeOH-d4, δH = 1.94 ppm and δC = 1.4 ppm for MeCN-d3, and 
δH = 4.75 ppm for D2O. The following abbreviations were used to describe the multiplicity 
of the signals: s = singlet, bs = broad singlet, d = doublet, bd = broad doublet, t = triplet, 
dd = doublet of doublet, ddd = doublet of doublet of doublet, td = triplet of doublet, and 
m = multiplet. The software package ACD/Labs was used for data processing and to 
create the figures in Appendix A.[411] 
  
                                                
vii Reproduced in part with permission from P. Comba, L. Grimm, C. Orvig, K. Rück, H. Wadepohl, 
Inorg. Chem. 2016, 55, 12531-12543, Copyright 2016 American Chemical Society.; Parts of this 
chapter will be published in P. Comba, U. Jermilova, C. Orvig, B. O. Patrick, C. F. Ramogida, 
K. Rück, C. Schneider, M. Starke, Chem. Eur. J., submitted manuscript. 
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Mass spectrometry (MS) 
High resolution (HR) mass spectra were either recorded on a Bruker ApexQe FT-ICR 
instrument by Dr. Jürgen GROSS and coworkers (Heidelberg University) or on a 
Waters/Micromass LCT TOF-MS spectrometer by Dr. Yun LING and coworkers (University 
of British Columbia, Vancouver). 
Elemental analysis (EA) 
Elemental analyses were performed on a CHN-O-vario EL by the “Microanalysis 
Laboratory”, Institute of Organic Chemistry, Heidelberg University. 
High performance liquid chromatography (HPLC) 
A HPLC system consisting of a Waters 600 controller, a Waters 2487 dual wavelength 
absorbance detector, and a Waters delta 600 pump was used. The purification of the 
metal ion complexes [InIII(B2)](TFA) and [LaIII(B2)](TFA) was carried out using a 
semipreparative Phenomenex Synergi Hydro-RP column (250 mm x 21.2 mm, 80 Å, 
4 µm). 
Solid state X-ray analysis 
At Heidelberg University crystallographic data were collected and solved by Prof. Dr. 
Hubert WADEPOHL and coworkers. Data collection was performed on a Bruker AXS Smart 
1000 CCD diffractometer (Mo-Kα radiation, sealed X-ray tube, graphite monochromator) or 
on an Agilent Technologies Supernova-E CCD diffractometer (Mo- or Cu-Kα radiation, 
microfocus X-ray tube, multilayer mirror optics). The solid state structures of B2 and 
[InIII(B2)](TFA) were determined at the University of British Columbia, Vancouver, by 
Dr. Brian PATRICK. These measurements were performed on a Bruker APEX DUO 
diffractometer (Cu-Kα radiation) or a Bruker X8 APEX II diffractometer (Mo-Kα radiation) 
with cross-coupled multilayer optics, respectively. The experimental structures reported in 
this thesis are or will be deposited at the Cambridge Crystallographic Data Centre (CCDC) 
and can thus be obtained free of charge via https://www.ccdc.cam.ac.uk/structures/. The 
corresponding CCDC-reference codes are given in Appendix B. The plots of the solid 




UV-vis-NIR spectra were recorded at 25 °C on a Jasco V-570 spectrophotometer 
equipped with a Jasco ETC-505T cryostat or on an Agilent 8453 spectrophotometer 
equipped with an Unisoku USP-203-A cryostat. Prior to each measurement the baseline 
was recorded using pure solvents and subtracted automatically. In the spectra device-
related noise was smoothed using Origin (OriginLab). Unresolved transitions were fitted 
with Gaussian envelopes as shown in Appendix C. 
Electron spin resonance (ESR) spectroscopy 
ESR measurements were performed on a Bruker ELEX-SYS-E-500 instrument at 8 K, 
using methanol as solvent. The Spin Hamiltonian parameters were obtained by simulation 
of the experimental data with the XSophe software package.[383,384] Fourier filtering 
(HAMMING function) and SAVITZKY-GOLAY filtering were undertaken to increase the 
spectral resolution. The cutoff of the HAMMING function was adjusted so that the high 
frequency noise was minimized without distorting the spectrum. 
Angular overlap model (AOM) analysis 
Ligand field calculations were performed with the computer program CAMMAG.[391] The 
used published and adjusted parameters as well as examples of input-files are given in 
Appendix F. 
Cyclic voltammetry 
Cyclovoltammetric measurements were performed on a CH Instruments CHI660D electro-
chemical workstation, equipped with a CH Instruments Picoamp Booster and Faraday 
Cage. A three-electrode setup consisting of a glassy-carbon working electrode, a platinum 
wire auxiliary electrode and an Ag/AgCl reference electrode (3 M NaCl) was used. The 
complexes to be measured were dissolved in dry DMF with 0.1 M (n-Bu4N)(ClO4) as the 
electrolyte salt. The solutions were degassed, and a slight argon stream was set above 
the solution during the measurement (scan rate of 0.1 V/s). All values were referenced 





All potentiometric measurements were carried out using a Metrohm Titrando 905 device, 
equipped with a BlueLine 17 pH electrode (Schott instruments) and dosing systems 
(Dosino 800, Metrohm) containing the respective titrants. The addition of titrant as well as 
the data collection were automatically carried out by the software package tiamo 2.3 
(Metrohm). The potentiometric setup consisted of a water-jacketed glass vessel 
maintained at 25 °C using a Lauda ecoline E300 thermostat. To exclude atmospheric CO2 
from the titration cell, a slight argon stream was passed over the sample solution during 
the measurement. All pH titrations were performed at a constant ionic strength of 
µ = 0.1 M electrolyte salt and the solutions were prepared with Milli-Q water.  
The investigations of the hexadentate bispa ligands B1a and B1b as well as their 
copper(II) complexes were performed with KNO3 as the electrolyte salt. As titrants 
0.1 M KOH and 0.1 M HNO3 were used, respectively. Prior to and after each 
measurement, the standard potential of the electrode (E0) was determined by titration of a 
HNO3 solution and subsequent analysis of the titration curve using the computer program 
TITKURVE.[414] Aqueous stock solutions of the ligands were prepared at a concentration 
of 2 mM. The samples (20 mL, 0.04 mmol ligand) were placed in the glass vessel and 
0.1 M HNO3 was used to adjust the initial pH value. Measurements were carried out in the 
absence of metal ions and with a metal-to-ligand ratio of 1:1. Each titration curve 
consisted of 50-65 titration points at the 2-11 pH range and three replicate titrations were 
performed for each system. Backtitrations were always carried out to ensure that 
equilibrium was attained at each point. A measuring time of 120 s (determination of 
protonation constants) and 300 s (determination of copper(II) stability constants) per 
titration point proved to be sufficient to avoid hysteresis. For the determination of the 
stability constants with CuII, 1:1 ligand-ligand competition titrations were performed. 
K2H2EDTA was used as the competing ligand with known pKa values and complex 
stability constants (µ = 0.1 M, 25 °C; pKa: 10.19, 6.13, 2.69, 2.0; log KCuL: 18.78, 
log KCuLH: 3.1, log KCuLH-1: 11.4).[415]  
Potentiometric titrations of bispa ligand B2 and the corresponding metal complexes were 
performed with KCl as the electrolyte salt. Titrants used were 0.1 M KOH and 0.1 M HCl. 
Before each measurement, the standard potential of the electrode (E0) was determined by 
titration of a HCl solution and subsequent analysis with the computer program GLEE.[416] 
The ligand and metal ion concentrations were in the range of 0.5 to 2.0 mM for 
potentiometric titrations. Equilibrium times were 5 min for pKa titrations and 15 min for 
metal complex titrations. For determination of the acid dissociation constants of B2, the 
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initial pH of the ligand solution was adjusted by addition of 0.1 M HCl. The required metal 
ions indium(III), lutetium(III), and lanthanum(III) were purchased as atomic absorption 
standard (AAS) solutions. The exact amount of acid present in the AAS solution was 
determined by titration of equimolar solutions of the respective metal ion and K2H2EDTA. 
The complex stability constants of lutetium(III) and lanthanum(III) with B2 were accessible 
via direct potentiometric titration of sample solutions with a metal-to-ligand ratio of 1:1. In 
case of indium(III), ligand-ligand competition titrations were performed in a ratio of 1:1:0.5 
(InIII / B2H(TFA) / competing ligand). K2H2EDTA was used as the competing ligand with 
known protonation and complex stability constants (µ = 0.1 M, 25 °C; log KInL: 25.0, 
log KInLH: 1.7, log KInLH-1: 8.43).[415] The formation constants corresponding to the 
hydrolysis of the metal ions in solution were taken from the literature.[162,417] In the case of 
all three metal complex titrations, precipitations were observed at a pH > 10 and the 
respective data points were thus excluded from the analysis.  
Protonation constants and complex stability constants were calculated from the 
experimental data with the computer program HYPERQUAD (version hq2008).[160] The 
total concentrations of the compounds and the pKw value (13.78) were not refined. The 
values given in parentheses are the standard deviation of three measurements. Species 





7.2 Syntheses of picolinic acid-based bispidine ligands 
Synthesis of the protected picolinic acid 
The tert-butyl substituted picolinic acid derivative 11 was prepared in a two-step 
synthesis,[360] whereby AIBN was used as the radical initiator for bromination of 10 instead 
of benzoyl peroxide.[359] 
General procedure 1 (GP1) for the coupling of the bispidine scaffold and the 
protected picolinic acid 
The respective bispidol fragment (1.0 eq) was dissolved in MeCN. To this solution tert-
butyl 6-(bromomethyl)picolinate 11 (1.0-2.4 eq depending on the synthesis) and an 
excess of Na2CO3 (6.0-6.1 eq) were added. The suspension was heated to reflux 
overnight or for 24 h, and then the excess of Na2CO3 was removed by filtration. The 
filtrate was concentrated in vacuo and the yellow residue partitioned between equal 
volumes (100 mL) of water and CH2Cl2. In the next step the combined organic phases 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. The 
purification of the crude product was performed as described in the individual synthesis 
instructions. 
General procedure 2 (GP2) for the removal of the tert-butyl ester protecting group 
To the tert-butyl ester protected ligand precursor dissolved in CH2Cl2 an equivalent 
volume of trifluoroacetic acid, H(TFA), was added and the solution was stirred overnight or 
for 24 h at room temperature. The solvent was then evaporated and the crude product 
was purified to afford the final ligand as the corresponding TFA salt. 
7.2.1 Synthesis of Hbispa1a 
The syntheses of the following compounds were performed according to slightly modified 
literature procedures and are thus not reported in this thesis: piperidone P1,[317,361] 




7.2.2 Synthesis of (p-MeO)Hbispa1a 
The following compounds were synthesized corresponding to a literature-known 









Piperidone P2 (34.0 g, 76.8 mmol, 1.0 eq) was dissolved in 100 mL tetrahydrofuran and 
heated to 50 °C. Benzylamine (2.96 mL, 9.87 g, 92.1 mmol, 1.2 eq) and formaldehyde 
(13.9 mL, 37 % in MeOH / H2O, 184 mmol, 2.4 eq) were added successively via a 
dropping funnel. The reaction mixture was heated under reflux for 30 minutes. After 
cooling to room temperature the solvent was removed under reduced pressure and the 
remaining solid was recrystallized from hot MeOH yielding B12 as colorless crystals 
(31.3 g, 54.5 mmol, 71 %). 
1H-NMR (600.13 MHz, 25 °C, CDCl3): δ = 2.06 (s, 3 H, N3CH3), 2.58 (d, 2JH,H = 11.9 Hz, 
2 H, N7CH2ax,eq), 3.15 (d, 2JH,H = 11.9 Hz, 2 H, N7CH2ax,eq), 3.48 (s, 2 H, N7CH2), 3.81 (s, 
6 H, COOCH3), 3.86 (s, 6 H, p-CH3O), 4.64 (s, 2 H, N3CH), 6.68-6.69 (m, 2 H, Har), 7.25-
7.26 (m, 1 H, Har), 7.31-7.34 (m, 4 H, Har), 7.55 (s, 2 H, Har), 8.30 (d, 3JH,H = 5.7 Hz, 2 H, 
Har) ppm. 
13C-NMR (150.92 MHz, 25 °C, CDCl3): δ = 43.4, 52.4, 55.0, 58.7, 62.1, 62.5, 73.5, 107.8, 
110.7, 127.1, 128.4, 129.7, 136.1, 150.5, 159.9, 166.1, 168.7, 203.6 ppm. 
HR-ESI MS (pos, MeOH): [B12+Na]+ calcd. 597.23197, obsd. 597.23361; [B12+H]+ calcd. 









Elemental analysis (report no. 36927): [B12] calcd. C, 63.80, H 6.04, N 9.60 %; obsd. C, 
64.07, H 6.02, N 9.56 %. 









Bispidone B12 (1.86 g, 3.24 mmol, 1.0 eq) was dissolved in 80 mL of a 1,4-dioxane-water 
mixture (3:1) and cooled to –5 °C. A solution of sodium borohydride (61.2 mg, 1.62 mmol, 
0.5 eq) in 40 mL of a 1,4-dioxane-water mixture (3:1) was added dropwise within 30 min 
and the solution was stirred overnight at 0 °C. Concentrated sulfuric acid was added and 
the solution (pH 2) was stirred for 1 h at room temperature. An aqueous solution of 
sodium hydroxide (20 wt%) was added to adjust a pH of 10 and the solution was stirred 
for 1 h at room temperature before filtering off the precipitate, washing carefully with 
CH2Cl2. The liquid layers were separated and the aqueous phase was extracted with 
CH2Cl2 (3 x 50 mL). The combined organic layers were dried over Na2SO4, filtered and the 
solvent was removed in vacuo. The crude product was recrystallized from hot MeOH 
yielding B13 as colorless crystals (460 mg, 798 µmol, 43 %). 
1H-NMR (600.13 MHz, 25 °C, MeOH-d4): δ = 1.85 (s, 3 H, N3CH3), 2.38 (d, 
2JH,H = 12.3 Hz, 2 H, N7CH2ax,eq), 2.64 (d, 2JH,H = 12.3 Hz, 2 H, N7CH2ax,eq), 3.42 (s, 2 H, 
N7CH2), 3.63 (s, 6 H, COOCH3), 3.88 (s, 6 H, p-CH3O), 3.98 (s, 2 H, N3CH), 4.65 (s, 1 H, 
CHOH), 6.87 (dd, 3JH,H = 5.9 Hz, 3JH,H = 2.5 Hz, 2 H, Har), 7.28-7.31 (m, 1 H, Har), 7.34-









13C-NMR (150.92 MHz, 25 °C, MeOH-d4): δ = 44.6, 50.2, 52.7, 54.2, 56.1, 65.8, 73.3, 
76.1, 109.6, 112.0, 128.3, 129.7, 131.2, 138.6, 150.8, 162.4, 168.4, 173.7 ppm. 
HR-ESI MS (pos, MeOH): [B13+Na]+ calcd. 599.24762, obsd 599.24846; [B13+H]+ calcd. 
577.26568, obsd. 577.26618. 
Elemental analysis (report no. 36950): [B130.5(1,4-dioxane)] calcd. C, 63.86, H 6.50, N 
9.03 %; obsd. C, 63.77, H 6.52, N 9.03 %. 









To a solution of B13 (2.02 g, 3.50 mmol, 1.0 eq) in 60 mL EtOAc palladium on activated 
charcoal (202 mg, 10 wt%) was added and the suspension was stirred at 95 °C and 8 bar 
hydrogen overnight in an autoclave. Subsequently, the reaction mixture was concentrated 
under reduced pressure, the residue was diluted in CH2Cl2 and the catalyst was removed 
by filtration over a celite pad. After evaporation of the solvent, the crude product was 
recrystallized from hot MeOH to afford B14 as colorless crystals (730 mg, 1.50 mmol, 
43 %). 
1H-NMR (600.13 MHz, 25 °C, MeOH-d4): δ = 1.84 (s, 3 H, N3CH3), 2.95-3.15 (m, 4 H, 
N7CH2ax,eq), 3.60 (s, 6 H, COOCH3), 3.92 (bs, 6 H, p-CH3O), 4.03 (s, 2 H, N3CH), 4.78 (s, 
1 H, CHOH), 6.80 (bs, 1 H, Hpy), 6.95 (bs, 2 H, Hpy), 7.54 (bs, 1 H, Hpy), 8.24 (bs, 1 H, 
Hpy), 8.51 (bs, 1 H, Hpy) ppm. 
13C-NMR (150.92 MHz, 25 °C, MeOH-d4): δ = 42.5, 44.1, 52.3, 52.6, 56.4, 74.4, 76.4, 










HR-DART MS (pos, CH2Cl2): [2B14+H]+ calcd. 973.43018, obsd 973.43388; [B14+H]+ 
calcd. 487.21873, obsd. 487.21949. 
Elemental analysis (report no. 37093): [B14MeOH] calcd. C, 57.90, H 6.61, N 10.80 %; 
obsd. C, 57.81, H 6.62, N 10.92 %. 









According to GP1 the bispidol fragment B14 (1.21 g, 2.49 mmol, 1.0 eq) was dissolved in 
80 mL MeCN. To this solution tert-butyl 6-(bromomethyl)picolinate 11 (680 mg, 
2.49 mmol, 1.0 eq) and Na2CO3 (1.58 g, 14.9 mmol, 6.0 eq) were added. The work up 
was carried out after 24 h and recrystallization of the orange crude product from hot 
MeCN delivered (p-MeO)(tBu)B1a as colorless crystals (1.11 g, 2.49 mmol, 66 %). 
1H-NMR (600.13 MHz, 25 °C, MeCN-d3): δ = 1.54 (s, 9 H, COOC(CH3)3), 1.83 (s, 3 H, 
N3CH3), 2.40 (d, 2JH,H = 11.9 Hz, 2 H, N7CH2ax,eq), 2.56 (d, 2JH,H = 11.9 Hz, 2 H, N7CH2ax,eq), 
3.55 (s, 2 H, N7CH2), 3.58 (s, 6 H, COOCH3), 3.78 (d, 2JH,H = 5.8 Hz, 1 H, CHOH), 3.85 (s, 
6 H, p-CH3O), 3.95 (bs, 2 H, N3CH), 4.60 (d, 2JH,H = 5.8 Hz, 1 H, CHOH), 6.70 (dd, 
3JH,H = 5.7 Hz, 4JH,H = 2.6 Hz, 2 H, Hpy), 7.51 (d, 3JH,H = 7.7 Hz, 1 H, Hpy), 7.57 (d, 
4JH,H = 2.6 Hz, 2 H, Hpy), 7.82 (t, 3JH,H = 7.7 Hz, 1 H, Hpy), 7.99 (dd, 3JH,H = 7.7 Hz, 
4JH,H = 0.9 Hz, 1 H, Hpy), 8.17 (d, 3JH,H = 5.7 Hz, 2 H, Hpy) ppm. 
13C-NMR (150.92 MHz, 25 °C, MeCN-d3): δ = 28.3, 44.5, 49.9, 52.4, 53.6, 56.1, 66.0, 
73.1, 75.8, 82.2, 109.3, 110.7, 124.1, 127.9, 138.1, 150.6, 151.2, 158.7, 162.6, 165.5, 











HR-ESI MS (pos, MeCN-d3 / MeOH): [(p-MeO)(tBu)B1a+Na]+ calcd. 700.29530, obsd. 
700.29629; [(p-MeO)(tBu)B1a+H]+ calcd. 678.31335, obsd. 678.31466. 
Elemental analysis (report no. 37163): [(p-MeO)(tBu)B1a] calcd. C, 62.03, H 6.40, N 
10.33 %; obsd. C, 62.00, H 6.44, N 10.71 %. 
Solid state X-ray structure: co_kr20 (1547416). 








According to GP2 5 mL H(TFA) were added to (p-MeO)(tBu)B1a (211 mg, 311 µmol) in 
5 mL CH2Cl2. Upon addition of H(TFA) the reaction mixture turned purple. The work up 
was carried out after stirring at room temperature overnight. The crude product was 
recrystallized from an ethanolic solution, which was overlaid with Et2O, yielding 
(p-MeO)B1aH(TFA) as colorless solid (183 mg, 249 µmol, 80 %). 
1H-NMR (600.13 MHz, 25 °C, D2O): δ = 2.08 (s, 3 H, N3CH3), 2.52 (s, 2 H, N7CH2ax,eq), 
2.87 (s, 2 H, N7CH2ax,eq), 3.74 (s, 6 H, COOCH3), 3.81 (s, 2 H, N7CH2), 3.93 (s, 6 H, p-
CH3O), 4.75 (s, 2 H, N3CH), 4.85 (s, 1 H, CHOH), 7.06 (s, 2 H, Hpy), 7.51 (d, 
3JH,H = 7.7 Hz, 1 H, Hpy), 7.88 (bs, 2 H, Hpy), 8.03 (d, 3JH,H = 7.7 Hz, 1 H, Hpy), 8.10 (d, 
3JH,H = 7.7 Hz, 1 H, Hpy) ppm. 
13C-NMR (150.92 MHz, 25 °C, D2O): δ = 43.0, 49.0, 53.3, 57.3, 61.3, 69.0, 69.9, 111.8, 
112.3, 116.3, 123.6, 126.5, 140.5, 144.0, 151.7, 152.3, 156.4, 162.9, 170.7, 171.6 ppm. 
HR-ESI MS (pos, MeOH): [(p-MeO)B1a+Na]+ calcd. 644.23270, obsd. 644.23327; [(p-










Elemental analysis (report no. 37387): [(p-MeO)B1aH(TFA)] calcd. C, 53.88, H 4.93, N 
9.52 %; obsd. C, 53.70, H 4.95, N 9.43 %. 
7.2.3 Synthesis of Hbispa1b 
The syntheses of the piperidone P3,[296] the bispidone B15,[373] and the bispidol B16[300] 









According to GP1 the bispidol fragment B16 (620 mg, 2.28 mmol, 1.0 eq) was dissolved in 
50 mL of MeCN. To this solution tert-butyl 6-(bromomethyl)picolinate 11 (972 mg, 
2.28 mmol, 1.0 eq) and Na2CO3 (1.44 g, 13.67 mmol, 6.0 eq) were added. The work up 
was carried out after 24 h to obtain (tBu)B1b as an orange solid (4.58 g, 7.25 mmol, 
92 %). The product was used without further purification. 
1H-NMR (600.13 MHz, 22 °C, MeCN-d3): δ = 1.65 (s, 9 H, COOC(CH3)3), 2.15 (s, 3 H, 
N7CH3) 2.20 (s, 2 H, N7CH2ax,eq), 2.30 (bs, 2 H, N7CH2ax,eq), 3.57 (s, 6 H, COOCH3), 3.59 
(s, 2 H, N3CH2), 4.64 (d, 2JH,H = 3.2 Hz, 1 H, CHOH), 4.86 (s, 2 H, N3CH), 6.83 (d, 
3JH,H = 7.7 Hz, 1 H, Hpy), 7.16 (dd, 3JH,H = 6.7 Hz, 3JH,H = 5.3 Hz, 2 H, Hpy), 7.55 (t, 
3JH,H = 7.7 Hz, 1 H, Hpy), 7.69-7.72 (m, 3 H, Hpy), 8.03 (bd, 3JH,H = 5.3 Hz, 2 H, Hpy), 8.36 










13C-NMR (150.92 MHz, 22 °C, MeCN-d3): δ = 28.5, 46.2, 52.0, 52.4, 53.9, 59.3, 72.0, 
72.3, 82.4, 123.4, 123.5, 125.3 127.8, 136.8, 137.6, 149.2, 149.8, 159.0, 161.1, 165.5, 
173.3 ppm. 
HR-ESI MS (pos, MeCN-d3 / MeOH): [(tBu)B1b+Na]+ calcd. 640.27536, obsd. 640.27445; 
[(tBu)B1b+H]+ calcd. 618.29223, obsd. 618.29217. 








According to GP2 70 mL H(TFA) were added to (tBu)B1b (3.57 g, 5.78 mmol) in 70 mL 
CH2Cl2. Upon addition of H(TFA) the reaction mixture turned purple. The work up was 
carried out after 24 h and the crude product was washed with EtOAc to give B1bH(TFA) 
as a colorless solid (2.93 g, 5.22 mmol, 90 %). Crystals suitable for X-ray diffraction were 
obtained by recrystallization from hot MeOH. 
1H-NMR (600.13 MHz, 22 °C, D2O): δ = 3.09 (s, 3 H, N7CH3), 3.47 (d, 2JH,H = 13.0 Hz, 2 H, 
N7CH2ax,eq), 3.66 (s, 6 H, COOCH3), 3.80 (d, 2JH,H = 13.0 Hz, 2 H, N7CH2ax,eq), 3.89 (s, 2 H, 
N3CH2), 5.03 (s, 1 H, CHOH), 5.06 (s, 2 H, N3CH), 6.75 (d, 3JH,H = 7.9 Hz, 1 H, Hpy), 7.26 
(dd, 3JH,H = 7.6 Hz, 3JH,H = 4.9 Hz, 2 H, Hpy), 7.35 (d, 3JH,H = 7.6 Hz, 2 H, Hpy), 7.79 (td, 
3JH,H = 7.6 Hz, 4JH,H = 1.6 Hz, 2 H, Hpy), 7.97 (t, 3JH,H = 7.9 Hz, 1 H, Hpy), 8.04 (d, 
3JH,H = 7.9 Hz, 1 H, Hpy), 8.31 (d, 3JH,H = 4.9 Hz, 2 H, Hpy) ppm. 
13C-NMR (150.92 MHz, 22 °C, D2O): δ = 43.1, 50.6, 53.0, 53.5, 55.5, 69.4, 70.5, 123.9, 











HR-ESI MS (pos, MeOH): [B1b+Na]+ calcd. 584.21157, obsd. 584.21216; [B1b+H]+ calcd. 
562.22962, obsd. 562.22994. 
Elemental analysis (report no. 37961): [B1bH(TFA)] calcd. C, 55.11; H, 4.77; N, 10.37; 
obsd. C, 55.08; H, 4.82; N, 10.42 %. 
Solid state X-ray structure: co_kr23 (CCDC 1481465). 
7.2.4 Synthesis of H2bispa2 
The piperidone P3,[296,317] the bispidone B17, and the bispidol B18[374] were synthesized 
according to literature-known procedures. 








To B18 (2.31 g, 4.11 mmol) in 25 mL of CH2Cl2 25 mL H(TFA) were slowly added and the 
solution was refluxed for 2 d. After 30 min the reaction mixture turned purple. In the next 
step the solvent was removed in vacuo and the residue was refluxed in MeOH followed by 
hot filtration. The TFA salt of B19 was obtained as colorless crystals (1.82 g, 3.46 mmol, 
84 %) from the concentrated filtrate. 
1H-NMR (600.13 MHz, 25 °C, MeOH-d4): δ = 3.48 (dd, 2JH,H = 13.2 Hz, 3JH,H = 1.2 Hz, 2 H, 
N7CH2ax,eq), 3.62 (bd, 2JH,H = 13.2 Hz, 2 H, N7CH2ax,eq), 3.69 (s, 6 H, COOCH3), 4.76 (d, 
3JH,H = 1.4 Hz, 2 H, N3CH), 4.89 (s, 1 H, CHOH), 7.40 (ddd, 3JH,H = 7.7 Hz, 3JH,H = 4.8 Hz, 
4JH,H = 1.2 Hz, 2 H, Hpy), 7.49 (d, 3JH,H = 7.7 Hz, 2 H, Hpy), 7.85 (td, 3JH,H = 7.7 Hz, 












13C-NMR (150.92 MHz, 25 °C, MeOH-d4): δ = 41.4, 51.9, 53.2, 67.6, 73.3, 124.7, 125.3, 
139.0, 150.8, 158.2, 171.6 ppm. 
HR-ESI MS (pos, MeOH): [B19+H]+ calcd. 413.18195, obsd. 413.18221. 
Elemental analysis (report no. 39141): [B19H(TFA)] calcd. C, 52.47; H, 4.79; N, 
10.64 %; obsd. C, 52.72; H, 4.93; N, 10.57 %. 










According to GP1 the bispidol fragment B19H(TFA) (1.21 g, 2.49 mmol, 1.0 eq) was 
dissolved in 80 mL of MeCN. To this solution tert-butyl 6-(bromomethyl)picolinate 11 
(2.07 g, 7.61 mmol, 2.4 eq) and Na2CO3 (2.02 g, 19.1 mmol, 6.1 eq) were added. The 
work up was carried out after heating to reflux overnight. The residue was dissolved in 
ethyl acetate and the solution was overlaid with Et2O to obtain (tBu)2B2 as a colorless 
solid (1.57 g, 1.98 mmol, 63 %) at –18 °C. 
1H-NMR (600.13 MHz, 25 °C, MeCN-d3): δ = 1.63 (s, 9 H, COOC(CH3)3), 1.65 (s, 9 H, 
COOC(CH3)3), 2.47 (d, 2JH,H = 11.8 Hz, 2 H, N7CH2ax,eq), 2.87 (d, 2JH,H = 11.8 Hz, 2 H, 
N7CH2ax,eq), 3.55 (s, 6 H, COOCH3), 3.64 (s, 2 H, N3CH2), 3.78 (bs, 2 H, N7CH2), 4.26 (d, 
2JH,H = 6.0 Hz, 1 H, CHOH), 4.49 (s, 2 H, N3CH), 4.65 (d, 2JH,H = 6.0 Hz, 1 H, CHOH), 6.78 











7.58 (m, 3 H, Hpy), 7.61 (d, 3JH,H = 7.8 Hz, 1 H, Hpy), 7.97 (t, 3JH,H = 7.9 Hz, 1 H, Hpy), 8.13 
(d, 3JH,H = 7.9 Hz, 1 H, Hpy), 8.24 (d, 3JH,H = 4.9 Hz, 2 H, Hpy) ppm. 
13C-NMR (150.92 MHz, 25 °C, MeCN-d3): δ = 28.4, 28.5, 49.9, 52.9, 55.2, 63.6, 66.2, 
73.1, 74.1, 83.4, 84.2, 123.7, 124.3, 125.3, 126.1, 126.8, 128.8, 138.3, 138.7, 140.2, 
149.1, 149.3, 150.4, 158.0, 158.7, 159.0, 164.7, 165.2, 172.4 ppm. 
HR-ESI MS (pos, MeOH): [(tBu)2B2+H]+ calcd. 795.37120, obsd. 795.37184. 
Elemental analysis (report no. 39927): [(tBu)2B2NaBrH2O] calcd. C, 56.39; H, 5.72; N, 
9.18 %; obsd. C, 56.67; H, 5.61; N, 8.93 %. 
Solid state X-ray structure: co_kr33_sq (CCDC 1547418). 








According to GP2 10 mL H(TFA) were added to (tBu)2B2 (900 mg, 1.13 mmol) in 10 mL 
CH2Cl2. Upon addition of H(TFA) the reaction mixture turned purple. The work up was 
carried out after stirring at room temperature overnight. The crude product was 
recrystallized from hot MeOH yielding B2H(TFA) as colorless crystals (642 mg, 
806 µmol, 71 %). 
1H-NMR (400.19 MHz, 25 °C, D2O): δ = 3.66 (d, 2JH,H = 13.1 Hz, 2 H, N7CH2ax,eq), 3.69 (s, 
6 H, COOCH3), 3.87 (s, 2 H, N3CH2), 4.02 (d, 2JH,H = 13.1 Hz, 2 H, N7CH2ax,eq), 4.73 (s, 












7.23 (ddd, 3JH,H = 7.5 Hz, 3JH,H = 5.0 Hz, 4JH,H = 0.9 Hz, 2 H, Hpy), 7.36 (bd, 3JH,H = 7.9 Hz, 
2 H, Hpy), 7.80 (td, 3JH,H = 7.7 Hz, 3JH,H = 1.7 Hz, 2 H, Hpy), 7.90 (bd, 3JH,H = 4.4 Hz, 2 H, 
Hpy), 7.98 (t, 3JH,H = 7.9 Hz, 1 H, Hpy), 8.05-8.10 (m, 2 H, Hpy), 8.18 (t, 3JH,H = 7.7 Hz, 1 H, 
Hpy), 8.21-8.23 (m, 1 H, Hpy) ppm. 
13C-NMR (100.64 MHz, 25 °C, D2O): δ = 49.2, 53.2, 53.8, 56.2, 61.6, 69.8, 71.0, 124.4, 
125.3, 125.5, 126.3, 126.7, 130.3, 139.3, 140.3, 145.5, 147.2, 148.6, 149.4, 150.1, 152.9, 
153.6, 163.2, 168.4, 170.3 ppm. 
HR-ESI MS (pos, MeOH): [B2+H]+ calcd. 683.2460, obsd. 683.2452. 
Elemental analysis (report no. 39971): [B2H(TFA)] calcd. C, 55.78; H, 4.43; N, 10.55 %; 
obsd. C, 55.52; H, 4.08; N, 10.77 %. 




7.3 Metal complexes 
7.3.1 Metal complexes based on the hexadentate bispa ligands 
Cobalt(II) bispa complexes 
[CoII(B1a)](TFA) (C31H30F3N5CoO9, 732.54 g/mol).  
B1aH(TFA) (150 mg, 222 µmol, 1.0 eq) was dissolved in 10 mL of dry MeOH under inert 
gas atmosphere. Co(OAc)24H2O (55.3 mg, 222 µmol, 1.0 eq) was added, and the 
resulting red solution was stirred for 2 h at room temperature. After evaporation of the 
solvent, the residue was taken up in MeOH and subjected to Et2O diffusion at room 
temperature yielding [CoII(B1a)](TFA)0.5H2O as red crystals (55.8 mg, 71.9 µmol, 32 %).  
HR-ESI MS (pos, MeOH): [CoII(B1a)]+ calcd. 619.14717, obsd. 619.14725. 
Elemental analysis (report no. 38721): [[CoII(B1a)](TFA)0.5H2O] calcd. C, 50.54; H, 
4.31; N, 9.36 %; obsd. C, 50.65; H, 4.51; N, 9.64 %. 
UV-vis-NIR (DMSO, rt): λ [nm] (ε [M-1cm-1]) = 470 (123), 557 (43), 993 (5). 
CV (DMF, rt): E1/2 = –0.37 V, –1.94 V (vs. fc/fc+). 
Solid state X-ray structure: co_kr30 (CCDC 1481460). 
[CoII((p-MeO)B1a)](TFA) (C33H34CoF3N5O11, 792.59 g/mol) 
(p-MeO)B1aH(TFA) (150 mg, 204 µmol, 1.0 eq) was dissolved in 10 mL of dry MeOH 
under inert gas atmosphere. Co(OAc)24H2O (50.8 mg, 204 µmol, 1.0 eq) was added and 
the resulting pink solution was stirred for 2 h at room temperature. After evaporation of the 
solvent, the residue was redissolved in MeOH and subjected to Et2O diffusion at room 
temperature yielding [CoII((p-MeO)B1a)](TFA)3H2O as dark red crystals (110 mg, 
130 µmol, 64 %).  
HR-ESI MS (pos, MeOH): [CoII((p-MeO)B1a)]+ calcd. 679.16830, obsd. 679.16855. 
Elemental analysis (report no. 38722): [[CoII((p-MeO)B1a)](TFA)3H2O] calcd. C, 46.82; 
H, 4.76; N, 8.27 %; obsd. C, 46.98; H, 4.76; N, 8.27 %. 
UV-vis-NIR (DMSO, rt): λ [nm] (ε [M-1cm-1]) = 467 (173), 541 (37), 1030 (6). 




[CoII(B1b)](TFA) (C31H30F3N5CoO9, 732.54 g/mol).  
B1bH(TFA) (150 mg, 222 µmol, 1.0 eq) was dissolved in 10 mL of dry MeOH under inert 
gas atmosphere. Co(OAc)24H2O (55.3 mg, 222 µmol, 1.0 eq) was added and the 
resulting orange solution was stirred for 2 h at room temperature. After evaporation of the 
solvent, the residue was taken up in MeOH and subjected to Et2O diffusion at room 
temperature yielding [CoII(B1b)](TFA)0.5H2O as brown crystals (116 mg, 150 µmol, 
67 %). 
HR-ESI MS (pos, MeOH): [CoII(B1b)]+ calcd. 619.14717, obsd. 619.14728. 
Elemental analysis (report no. 38723): [[CoII(B1b)](TFA)0.5H2O] calcd. C, 50.54; H, 
4.47; N, 9.36 %; obsd. C, 50.40; H, 4.51; N, 9.53 %. 
UV-vis-NIR (DMSO, rt): λ [nm] (ε [M-1cm-1]) = 475 (117), 516 (9), 544 (23), 584 (7), 677 
(6), 920 (6). 
CV (DMF, rt): E1/2 = –0.52 V, –2.09 V (vs. fc/fc+). 
Solid state X-ray structure: co_kr31 (CCDC 1481466). 
Nickel(II) bispa complexes 
[NiII(B1a)](TFA) (C31H30F3N5NiO9, 732.30 g/mol). 
Solutions of B1aH(TFA) (100 mg, 150 µmol, 1.0 eq) and Ni(OAc)24H2O (37.3 mg, 
150 µmol, 1.0 eq) in 5 mL MeOH, respectively, were combined and the resulting violet 
solution was stirred overnight at room temperature. After evaporation of the solvent, the 
residue was taken up in MeOH and subjected to Et2O diffusion at 5 °C yielding 
[NiII(B1a)](TFA)2H2O as violet crystals (110 mg, 150 µmol, 85 %). Some of the crystals 
were redissolved in a mixture of MeOH and H2O (2:1) and violet plates suitable for X-ray 
diffraction were obtained by slow evaporation of the solvent mixture. 
HR-ESI MS (pos, MeOH): [NiII(B1a)]+ calcd. 618.14932, obsd. 618.14926. 
Elemental analysis (report no. 36295): [[NiII(B1a)](TFA)2H2O] calcd. C, 48.46; H, 4.46; 
N, 9.12 %; obsd. C, 48.36; H, 4.51; N, 9.24 %. 
UV-vis-NIR (MeOH, rt): λ [nm] (ε [M-1cm-1]) = 515 (12), 558 (11), 819 (20), 923 (25). 
CV (DMF, rt): E1/2 = 0.76 V irrev., –2.18 V (vs. fc/fc+). 




[NiII((p-MeO)B1a)](TFA) (C33H34F3N5NiO11, 792.35 g/mol) 
Solutions of (p-MeO)B1aH(TFA) (120 mg, 163 µmol, 1.0 eq) and Ni(OAc)24H2O 
(40.6 mg, 163 µmol, 1.0 eq) in 5 mL MeOH, respectively, were combined and gave a 
violet solution, which was stirred overnight at room temperature. After evaporation of the 
solvent, the residue was redissolved in MeOH and subjected to Et2O diffusion at 5 °C 
yielding [NiII((p-MeO)B1a)](TFA)MeOH as a violet solid (123 mg, 149 µmol, 91 %).  
HR-ESI MS (pos, MeOH): [NiII((p-MeO)B1a)]+ calcd. 678.1705, obsd. 678.108. 
Elemental analysis (report no. 37275): [[NiII((p-MeO)B1a)](TFA)MeOH] calcd. C, 49.54; 
H, 4.65; N, 8.50 %; obsd. C, 49.34; H, 4.53; N, 8.36 %. 
UV-vis-NIR (MeOH, rt): λ [nm] (ε [M-1cm-1]) = 521 (12), 585 (10), 866 (38). 
CV (DMF, rt): E1/2 = 0.71 V irrev., –2.24 V (vs. fc/fc+). 
[NiII(B1b)](TFA) (C31H30F3N5NiO9, 732.30 g/mol). 
Solutions of B1bH(TFA) (100 mg, 148 µmol, 1.0 eq) and Ni(OAc)24H2O (36.8 mg, 
148 µmol, 1.0 eq) in 5 mL MeOH, respectively, were combined and the resulting brown 
solution was stirred for 2 h at room temperature. After evaporation of the solvent, the 
residue was taken up in MeOH and subjected to Et2O diffusion at 5 °C yielding 
[NiII(B1b)](TFA)0.5MeOH as brown crystals (77.6 mg, 106 µmol, 72 %). 
HR-ESI MS (pos, MeOH): [NiII(B1b)]+ calcd. 618.14932, obsd. 618.14908. 
Elemental analysis (report no. 37469): [[NiII(B1b)](TFA)0.5MeOH] calcd. C, 50.56; H, 
4.31; N, 9.36 %; obsd. C, 50.43; H, 4.35; N, 9.47 %. 
UV-vis-NIR (MeOH, rt): λ [nm] (ε [M-1cm-1]) = 512 (18), 796 (13), 877 (36). 
CV (DMF, rt): E1/2 = 0.71 V, –2.27 V irrev. (vs. fc/fc+).  
Solid state X-ray structure: co_kr27 (CCDC 1481467). 
Copper(II) bispa complexes 
[CuII(B1a)](TFA) (C31H30CuF3N5O9, 737.15 g/mol).[359] 
Solutions of B1aH(TFA)MeOHH2O (107 mg, 147 µmol, 1.0 eq) in 4 mL MeOH and 
Cu(OAc)2H2O (29.3 mg, 147 µmol, 1.0 eq) in 6 mL MeOH were combined and the 
resulting turquoise solution was stirred for 2 h at room temperature. After evaporation of 
the solvent, the residue was redissolved in MeOH and subjected to Et2O diffusion at 5 °C 




HR-ESI MS (pos, MeOH): [CuII(B1a)]+ calcd. 623.14358, obsd. 623.14326.  
Elemental analysis (report no. 34995): [[CuII(B1a)](TFA)1.5MeOH1.5H2O] calcd. C, 
48.06; H, 4.84; N, 8.62 %; obsd. C, 47.83; H, 4.62; N, 8.77 %.  
UV-vis-NIR (MeOH, rt): λ [nm] (ε [M-1cm-1]) = 672 (93), 1284 (34).  
CV (DMF, rt): E1/2 = –1.02 V (vs. fc/fc+). 
Solid state X-ray structure: co_kr08 (CCDC 1481462). 
[CuII((p-MeO)B1a)](TFA) (C33H34CuF3N5O11, 797.20 g/mol) 
Solutions of (p-MeO)B1aH(TFA) (120 mg, 163 µmol, 1.0 eq) in 5 mL MeOH and 
Cu(OAc)2H2O (32.6 mg, 163 µmol, 1.0 eq) in 5 mL MeOH were combined and the 
resulting blue solution was stirred overnight at room temperature. After evaporation of the 
solvent, the residue was taken up in MeOH and subjected to Et2O diffusion at 5 °C 
yielding [CuII((p-MeO)B1a)](TFA)1.5H2O as blue crystals (128 mg, 155 µmol, 95 %). 
HR-ESI MS (pos, MeOH): [CuII((p-MeO)B1a)]+ calcd. 683.1647, obsd. 683.1649.  
Elemental analysis (report no. 34995): [[CuII((p-MeO)B1a)](TFA)1.5H2O] calcd. C, 
48.09; H, 4.52; N, 8.50 %; obsd. C, 48.16; H, 4.61; N, 8.41 %. 
UV-vis-NIR (MeOH, rt): λ [nm] (ε [M-1cm-1]) = 673 (106), 1227 (36). 
CV (DMF, rt): E1/2 = –1.08 V (vs. fc/fc+). 
Solid state X-ray structure: co_kr22. 
[CuII(B1b)](TFA) (C31H30CuF3N5O9, 737.15 g/mol). 
Solutions of B1bH(TFA) (100 mg, 148 µmol, 1.0 eq) and Cu(OAc)2H2O (29.6 mg, 
148 µmol, 1.0 eq) in 5 mL MeOH, respectively, were combined and the resulting blue 
solution was stirred for 2 h at room temperature. After evaporation of the solvent, the 
residue was redissolved in MeOH and subjected to Et2O diffusion at 5 °C yielding 
[CuII(B1b)](TFA)H2O as dark blue crystals (100 mg, 123 µmol, 84 %). 
HR-ESI MS (pos, MeOH): [CuII(B1b)]+ calcd. 623.14358, obsd. 623.14372. 
Elemental analysis (report no. 37467): [[CuII(B1b)](TFA)H2O] calcd. C, 49.31; H, 4.27; 
N, 9.27 %; obsd. C, 49.02; H, 4.43; N, 9.40 %. 
UV-vis-NIR (MeOH, rt): λ [nm] (ε [M-1cm-1]) = 651 (78), 904 (18). 
CV (DMF, rt): E1/2 = -1.17 V (vs. fc/fc+). 
Solid state X-ray structure: co_kr24 (CCDC 1481468). 
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Zinc(II) bispa complexes 
[ZnII(B1a)](TFA) (C31H30F3N5O9Zn, 738.98 g/mol). 
Solutions of B1aH(TFA) (100 mg, 150 µmol, 1.0 eq) and Zn(OAc)22H2O (32.9 mg, 
150 µmol, 1.0 eq) in 5 mL MeOH, respectively, were combined and the reaction mixture 
was stirred overnight at room temperature. After evaporation of the solvent, the residue 
was taken up in methanol and subjected to Et2O diffusion at 5 °C yielding 
[ZnII(B1a)](TFA)2H2O as colorless crystals (100 mg, 147 µmol, 98 %). Some of the 
crystals were redissolved in a mixture of MeOH and H2O (2:1) and colorless plates 
suitable for X-ray diffraction were obtained by slow evaporation of the solvent mixture. 
1H-NMR (600.13 MHz, 22 °C, D2O): δ = 2.22 (s, 3 H, N3CH3), 2.56 (d, 2JH,H = 12.9 Hz, 2 H, 
N7CH2ax,eq), 2.98 (d, 2JH,H = 12.9 Hz, 2 H, N7CH2ax,eq), 3.80 (s, 6 H, COOCH3), 4.01 (s, 2 H, 
N7CH2), 5.03 (s, 2 H, N3CH), 5.04 (s, 1 H, CHOH), 7.37-7.38 (m, 2 H, Hpy), 7.48-7.51 (m, 
2 H, Hpy), 7.64 (d, 3JH,H = 7.8 Hz, 1 H, Hpy), 8.02-8.05 (m, 4 H, Hpy), 8.26 (d, 3JH,H = 7.8 Hz, 
1 H, Hpy), 8.33 (d, 3JH,H = 7.8 Hz, 1 H, Hpy) ppm. 
13C-NMR (150.92 MHz, 22 °C, D2O): δ = 43.5, 50.3, 53.5, 61.6, 68.7, 68.8, 123.4, 124.9, 
126.2, 126.3, 141.8, 142.8, 146.5, 148.5, 152.1, 153.6, 169.3, 171.3 ppm. 
HR-ESI MS (pos, MeOH): [ZnII(B1a)]+ calcd. 624.14312, obsd. 624.14336. 
Elemental analysis (report no. 36296): [[ZnII(B1a)](TFA)2H2O] calcd. C, 48.04; H, 4.42; 
N, 9.04 %; obsd. C, 48.06; H, 4.25; N, 9.35 %. 
Solid state X-ray structure: co_kr11 (CCDC 1481463). 
[ZnII((p-MeO)B1a)](TFA) (C33H34F3N5O11Zn, 799.03 g/mol) 
Solutions of (p-MeO)B1aH(TFA) (120 mg, 163 µmol, 1.0 eq) and Zn(OAc)22H2O 
(35.8 mg, 163 µmol, 1.0 eq) in 5 mL MeOH, respectively, were combined and the reaction 
mixture was stirred overnight at room temperature. After evaporation of the solvent, the 
residue was taken up in MeOH and subjected to Et2O diffusion at 5 °C yielding 
[ZnII((p-MeO)B1a)](TFA)2H2O as colorless crystals (120 mg, 144 µmol, 88 %). 
1H-NMR (600.13 MHz, 22 °C, D2O): δ = 2.21 (s, 3 H, N3CH3), 2.55 (d, 2JH,H = 12.9 Hz, 2 H, 
N7CH2ax,eq), 2.93 (d, 2JH,H = 12.9 Hz, 2 H, N7CH2ax,eq), 3.79 (s, 6 H, COOCH3), 3.85 (s, 6 H, 
p-OCH3), 3.97 (s, 2 H, N7CH2), 4.88 (s, 2 H, N3CH), 4.97 (s, 1 H, CHOH), 6.83 (d, 
4JH,H = 2.5 Hz, 2 H, Hpy), 6.97 (d, 3JH,H = 6.3 Hz, 4JH,H = 2.5 Hz, 2 H, Hpy), 7.62 (d, 
3JH,H = 7.8 Hz, 1 H, Hpy), 7.81 (d, 3JH,H = 6.3 Hz, 1 H, Hpy), 8.24 (t, 3JH,H = 7.8 Hz, 1 H, Hpy), 
8.28 (d, 3JH,H = 7.8 Hz, 1 H, Hpy) ppm. 
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13C-NMR (150.92 MHz, 22 °C, D2O): δ = 43.3, 50.4, 53.3, 53.4, 56.2, 61.6, 68.5, 68.6, 
111.0, 111.4, 116.3, 123.3, 126.1, 126.3, 142.7, 146.6, 149.7, 153.5, 153.9, 162.8, 169.0, 
169.2, 171.3 ppm. 
HR-ESI MS (pos, MeOH): [ZnII((p-MeO)B1a)]+ calcd. 684.1643, obsd. 684.1643. 
Elemental analysis (report no. 39847): [[ZnII((p-MeO)B1a)](TFA)2H2O] calcd. C, 47.46; 
H, 4.59; N, 8.39 %; obsd. C, 47.27; H, 4.73; N, 8.41 %. 
Solid state X-ray structure: co_kr19. 
[ZnII(B1b)](TFA) (C31H30F3N5O9Zn, 738.98 g/mol). 
Solutions of B1bH(TFA) (100 mg, 148 µmol, 1.0 eq) and Zn(OAc)22H2O (32.5 mg, 
148 µmol, 1.0 eq) in 5 mL MeOH, respectively, were combined and the reaction mixture 
was stirred overnight at room temperature. After evaporation of the solvent, the residue 
was redissolved in MeCN and subjected to Et2O diffusion at 5 °C yielding 
[ZnII(B1b)](TFA)H2O0.5MeCN as colorless crystals (66.9 mg, 90.5 µmol, 61 %). 
1H-NMR (600.13 MHz, 22 °C, D2O): δ = 2.75 (d, 2JH,H = 13.3 Hz, 2 H, N7CH2ax,eq), 2.79 (s, 
3 H, N7CH3), 3.04 (d, 2JH,H = 13.3 Hz, 2 H, N7CH2ax,eq), 3.70 (s, 6 H, COOCH3), 4.28 (s, 
2 H, N3CH2), 5.08 (s, 1 H, CHOH), 5.29 (s, 2 H, N3CH), 6.98 (d, 3JH,H = 7.8 Hz, 1 H, Hpy), 
7.31 (dd, 3JH,H = 7.6 Hz, 3JH,H = 5.4 Hz, 2 H, Hpy), 7.37 (d, 3JH,H = 7.6 Hz, 2 H, Hpy), 7.65 (t, 
3JH,H = 7.8 Hz, 1 H, Hpy), 7.74 (d, 3JH,H = 7.8 Hz, 1 H, Hpy), 7.81 (td, 3JH,H = 7.6 Hz, 
4JH,H = 1.6 Hz, 2 H, Hpy), 8.33 (d, 3JH,H = 5.4 Hz, 2 H, Hpy) ppm. 
13C-NMR (150.92 MHz, 22 °C, D2O): δ = 46.7, 52.5, 53.4, 53.9, 60.1, 68.9, 70.8, 122.5, 
124.6, 125.2, 126.3, 140.7, 141.1, 143.3, 147.7, 149.7, 151.6, 170.1, 170.9 ppm. 
HR-ESI MS (pos, MeOH): [ZnII(B1b)]+ calcd. 624.14312, obsd. 624.14347. 
Elemental analysis (report no. 3574): [[ZnII(B1b)](TFA)H2O0.5MeCN] calcd. C, 49.43; 
H, 4.34; N, 9.91 %; obsd. C, 49.63; H, 4.00; N, 9.84 %. 
Solid state X-ray structure: co_kr25 (CCDC 1481469). 
Gallium(III) bispa complexes 
[GaIII(B1a)](TFA)(NO3) (C31H30F3GaN6O12, 805.33 g/mol).[359] 
Solutions of B1aH(TFA) (100 mg, 148 µmol, 1.0 eq) in 10 mL of a MeOH-H2O mixture 
(1:2) and Ga(NO3) (37.9 mg, 148 µmol, 1.0 eq) in 5 mL of a MeOH-H2O mixture (1:2) were 
combined and the pH was adjusted to 5 by addition of 0.1 M NaOH. The reaction mixture 
was then stirred at 60 °C for 2 h and after evaporation of the solvent, the residue was 
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taken up in a mixture of MeOH and H2O (2:1). By slow evaporation of the solvent mixture, 
[GaIII(B1a)](TFA)(NO3)3H2O was obtained as colorless crystals (83.0 mg, 96.6 µmol, 
65 %). 
1H-NMR (200.13 MHz, 27 °C, D2O): δ = 2.67 (s, 3 H, N3CH3), 2.89 (d, 2JH,H = 13.7 Hz, 2 H, 
N7CH2ax,eq), 3.57 (d, 2JH,H = 13.7 Hz, 2 H, N7CH2ax,eq), 3.86 (s, 6 H, COOCH3), 4.60 (s, 2 H, 
N7CH2), 5.21 (s, 1 H, CHOH), 5.70 (s, 1 H, N3CH), 7.73-7.81 (m, 4 H, Hpy), 7.99 (d, 
3JH,H = 5.3 Hz, 2 H, Hpy), 8.10 (dd, 3JH,H = 7.3 Hz, 4JH,H = 1.3 Hz, 1 H, Hpy), 8.38 (td, 
3JH,H = 7.8 Hz, 4JH,H = 1.5 Hz, 2 H, Hpy), 8.66-8.78 (m, 2 H, Hpy) ppm. 
13C-NMR (150.92 MHz, 22 °C, D2O): δ = 44.4, 52.1, 52.1, 53.2, 54.1, 62.1, 67.3, 67.6, 
125.1, 125.1, 125.8, 128.3, 128.3, 128.4, 142.9, 145.8, 147.4, 147.6, 148.7, 151.5, 151.6, 
164.6, 168.7 ppm. 
HR-ESI MS (pos, MeOH): [GaIII(B1a)]2+ calcd. 314.56950, obsd 314.56964; [B1a+H]+ 
calcd. 562.22941, obsd. 562.22962; [GaIII(B1a)-H]+ calcd. 628.13173, obsd. 628.13167. 
Elemental analysis (report no. 36368): [[GaIII(B1a)](TFA)(NO3)3H2O] calcd. C, 43.33; H, 
4.22; N, 9.78 %; obsd. C, 43.33; H, 4.40; N, 9.71 %. 
Solid state X-ray structure: co_kr07 (CCDC 1481464). 
[GaIII((p-MeO)B1a)](X)2 
Solutions of (p-MeO)B1aH(TFA) (100 mg, 136 µmol, 1.0 eq) in 10 mL of a MeOH-H2O 
mixture (1:2) and Ga(NO3)6H2O (49.5 mg, 136 µmol, 1.0 eq) in 5 mL of a MeOH-H2O 
mixture (1:2) were combined and the pH was adjusted to 5 by addition of 0.1 M NaOH. 
The reaction mixture was stirred at 60 °C for 2 h and after evaporation of the solvent, the 
crude product was obtained as colorless solid. Attempts to purify the compound by 
recrystallization from different solvents were not successful. 
HR-ESI MS (pos, MeOH): [GaIII((p-MeO)B1a)]2+ calcd. 344.5801, obsd. 344.5804. 
[GaIII(B1b)](NO3)2 (C29H30GaN7O13, 754.32 g/mol). 
Solutions of B1bH(TFA) (100 mg, 148 µmol, 1.0 eq) in 5 mL of a MeOH-H2O mixture 
(1:2) and Ga(NO3)6H2O (37.9 mg, 148 µmol, 1.0 eq) in 5 mL of a MeOH-H2O mixture 
(1:2) were combined and the pH was adjusted to 5 by addition of 0.1 M NaOH. The 
reaction mixture was stirred at 60 °C for 3 h and after evaporation of the solvent, the 
residue was taken up in MeOH and subjected to Et2O diffusion at 5 °C yielding 
[GaIII(B1b)](NO3)22H2O as colorless crystals (62.6 mg, 83.0 µmol, 56 %). 
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1H-NMR (600.13 MHz, 22 °C, D2O): δ = 3.05 (s, 3 H, N7CH3), 3.08 (d, 2JH,H = 14.1 Hz, 2 H, 
N7CH2ax,eq), 3.27 (d, 2JH,H = 14.1 Hz, 2 H, N7CH2ax,eq), 3.77 (s, 6 H, COOCH3), 4.95 (s, 2 H, 
N3CH2), 5.23 (s, 1 H, CHOH), 5.97 (s, 2 H, N3CH), 7.42 (d, 3JH,H = 7.9 Hz, 1 H, Hpy), 7.67 -
 7.71 (m, 4 H, Hpy), 8.05 (t, 3JH,H = 7.9 Hz, 2 H, Hpy), 8.11 (d, 3JH,H = 7.9 Hz, 1 H, Hpy), 8.19 
(td, 3JH,H = 8.0 Hz, 4JH,H = 1.2 Hz, 2 H, Hpy), 8.60 (d, 3JH,H = 5.3 Hz, 2 H, Hpy) ppm. 
13C-NMR (150.92 MHz, 22 °C, D2O): δ = 46.7, 53.8, 53.8, 54.1, 62.1, 67.4, 70.1, 124.9, 
126.3, 126.9, 128.9, 139.3, 144.9, 145.0, 146.2, 146.4, 147.9, 165.6, 168.5 ppm. 
Elemental analysis (report no. 37566): [[GaIII(B1b)](NO3)22H2O] calcd. C, 44.07; H, 
4.34; N, 12.41 %; obsd. C, 43.75; H, 4.23; N, 12.26 %. 
Solid state X-ray structure: co_kr26 (CCDC 1481470). 
7.3.2 Metal complexes based on the octadentate bispa ligand 
[InIII(B2)](TFA) (C37H32F3InN6O11, 908.51 g/mol). 
Solutions of B2H(TFA) (52.9 mg, 66.4 µmol, 1.0 eq) in 5 mL MeOH and In(OAc)35H2O 
(27.9 mg, 73.0 µmol, 1.1 eq) in 30 mL H2O were combined and the colorless solution was 
stirred for 2 h at room temperature. After evaporation of the solvent, the crude product 
was purified by reverse phase (RP)-HPLC using eluents: A: 0.1 % H(TFA) in H2O and 
B: MeCN with a linear gradient of 5 to 100 % B over a period of 25 min and a flow rate set 
to 1 mL/min. The retention time of the metal complex was tR ([InIII(B2)]+) = 12.9 min. The 
HPLC fractions were combined and concentrated in vacuo yielding [InIII(B2)](TFA)5H2O 
as a colorless solid (58.5 mg, 58.6 µmol, 88 %). Crystals suitable for X-ray analysis were 
obtained by slow evaporation from a methanolic solution.  
1H-NMR (400.19 MHz, 25 °C, D2O): δ = 3.24 (d, 2JH,H = 12.0 Hz, 2 H, N7CH2ax,eq), 3.46 (d, 
2JH,H = 12.0 Hz, 2 H, N7CH2ax,eq), 3.66 (s, 6 H, COOCH3), 4.54 (bs, 2 H, N7CH2), 4.63 (s, 
2 H, N3CH2), 5.19 (s, 1 H, CHOH), 5.46 (bs, 2 H, N3CH), 7.31-7.34 (m, 2 H, Hpy), 7.38 (d, 
3JH,H = 7.7 Hz, 1 H, Hpy), 7.43 (bd, 3JH,H = 7.5 Hz, 1 H, Hpy), 7.84-7.90 (m, 3 H, Hpy), 7.92-
7.96 (m, 1 H, Hpy), 7.98 (dd, 3JH,H = 6.9 Hz, 4JH,H = 2.0 Hz, 1 H, Hpy), 8.35 (bs, 
3JH,H = 5.1 Hz, 2 H, Hpy), 8.48-8.54 (m, 2 H, Hpy) ppm. 
13C-NMR (100.64 MHz, 25 °C, D2O): δ = 51.3, 53.8, 54.4, 61.5, 62.8, 70.0, 71.1, 124.4, 
125.8, 126.0, 126.2, 126.7, 128.1, 141.7, 143.9, 145.1, 145.5, 146.9, 149.8, 150.1, 150.6, 
150.7, 167.2, 167.2, 170.1 ppm.  
HR-ESI MS (pos, MeOH): [InIII(B2)]+ calcd. 795.1264, obsd. 795.1268.  
Elemental analysis (report no. 39940): [[InIII(B2)](TFA)5H2O] calcd. C, 44.50; H, 4.24; N, 
8.42 %; obsd. C, 44.41; H, 4.08; N, 8.77 %. 
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Solid state X-ray structure: co500 (CCDC 1550810). 
[LuIII(B2)](TFA) (C37H32F3LuN6O11, 968.66 g/mol).  
Solutions of B2H(TFA) (20.0 mg, 25.1 µmol, 1.0 eq) and Lu(OAc)34H2O (10.7 mg, 
25.1 µmol, 1.0 eq) in 3 mL MeOH each were combined and the colorless solution was 
stirred for 4 h at room temperature. After evaporation of the solvent, the residue was 
redissolved in MeOH and subjected to Et2O diffusion yielding [LuIII(B2)](TFA)3.5H2O as a 
colorless solid (21.8 mg, 21.1 µmol, 84 %). 
1H-NMR (400.13 MHz, 25 °C, D2O): δ = 2.77-2.85 (m, 2 H, N7CH2ax,eq), 3.09 (d, 
2JH,H = 13.4 Hz, 1 H, N7CH2ax,eq), 3.36 (d, 2JH,H = 13.4 Hz, 1 H, N7CH2ax,eq), 3.72 (s, 3 H, 
COOCH3), 3.77 (s, 3 H, COOCH3), 3.84 (d, 2JH,H = 15.7 Hz, 1 H, N7CH2), 4.40-4.54 (m, 
2 H, N3CH2), 4.86 (d, 2JH,H = 15.7 Hz, 1 H, N7CH2), 5.17 (s, 2 H, N3CH), 5.19 (s, 1 H, 
CHOH), 6.98-7.00 (m, 1 H, Hpy), 7.20 (ddd, 3JH,H = 7.9 Hz, 3JH,H = 3.9 Hz, 4JH,H = 1.2 Hz, 
1 H, Hpy), 7.33-7.37 (m, 2 H, Hpy), 7.40 (bd, 3JH,H = 7.9 Hz, 1 H, Hpy), 7.70-7.74 (m, 3 H, 
Hpy), 7.81 (td, 3JH,H = 7.8 Hz, 4JH,H = 1.5 Hz, 1 H, Hpy), 7.85 (td, 3JH,H = 7.8 Hz, 
4JH,H = 1.7 Hz, 1 H, Hpy), 8.09 (bd, 3JH,H = 7.6 Hz, 1 H, Hpy), 8.16 (t, 3JH,H = 7.6 Hz, 1 H, 
Hpy), 8.24 (dd, 3JH,H = 5.4 Hz, 4JH,H = 0.7 Hz, 1 H, Hpy), 8.93 (dd, 3JH,H = 5.4 Hz, 
4JH,H = 0.7 Hz, 1 H, Hpy) ppm.  
13C-NMR (100.62 MHz, 25 °C, D2O): δ = 48.2, 49.9, 53.4, 53.5, 53.6, 54.3, 67.4, 68.4, 
70.4, 74.4, 74.6, 122.6, 122.9, 123.7, 124.8, 125.1, 125.6, 126.6, 140.5, 141.1, 141.5, 
142.2, 150.1, 150.2, 150.8, 154.0, 155.2, 155.7, 156.2, 171.0, 171.1, 171.7, 172.2.  
HR-ESI MS (pos, MeOH): [LuIII(B2)]+ calcd. 855.1633, obsd. 855.1641.  
Elemental analysis (report no. 39879): [[LuIII(B2)](TFA)3.5H2O] calcd. C, 43.07; H, 3.81; 
N, 8.15 %; obsd. C, 43.23; H, 4.11; N, 8.21 %. 
[LaIII(B2)](TFA) (C37H32F3LaN6O11, 932.60 g/mol).  
Solutions of B2H(TFA) (54.8 mg, 68.8 µmol, 1.0 eq) and LaCl37H2O (25.5 mg, 
68.8 µmol, 1.0 eq) in 10 mL MeOH each were combined and the pH was adjusted to 7 by 
addition of 10wt% NaOH. The colorless reaction mixture was stirred overnight at room 
temperature. After evaporation of the solvent, the crude product was purified by RP-HPLC 
using eluents: A: 0.1 % H(TFA) in H2O and B: MeCN with a linear gradient of 5 to 100 % B 
over a period of 25 min and a flow rate set to 1 mL/min. The retention time of the metal 
complex was tR ([LaIII(B2)]+) = 14.0 min. The HPLC fractions were combined and 
concentrated in vacuo yielding [LaIII(B2)](TFA)5H2O as a colorless solid (56.9 mg, 
55.6 µmol, 81 %). 
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1H-NMR (400.13 MHz, 25 °C, D2O): δ = 2.55 (d, 2JH,H = 12.9 Hz, 1 H, N7CH2ax,eq), 2.70 (d, 
2JH,H = 12.9 Hz, 1 H, N7CH2ax,eq), 2.76 (d, 2JH,H = 13.1 Hz, 1 H, N7CH2ax,eq), 3.33 (d, 
2JH,H = 13.1 Hz, 1 H, N7CH2ax,eq), 3.56 (d, 2JH,H = 14.3 Hz, 1 H, N7CH2), 3.63 (s, 3 H, 
COOCH3), 3.67 (s, 3 H, COOCH3), 4.32 (d, 2JH,H = 15.6 Hz, 1 H, N3CH2), 4.48 (d, 
2JH,H = 15.6 Hz, 1 H, N3CH2), 4.68 (d, 2JH,H = 14.3 Hz, 1 H, N7CH2), 4.92 (s, 1 H, N3CH), 
4.99 (s, 1 H, N3CH), 5.04 (s, 1 H, CHOH), 7.02 (d, 3JH,H = 7.8 Hz, 1 H, Hpy), 7.16 (dd, 
3JH,H = 6.9 Hz, 3JH,H = 5.6 Hz, 1 H, Hpy), 7.32-7.46 (m, 4 H, Hpy), 7.55 (td, 3JH,H = 7.8 Hz, 
3JH,H = 1.4 Hz, 1 H, Hpy), 7.67-7.72 (m, 2 H, Hpy), 7.90 (td, 3JH,H = 7.8 Hz, 3JH,H = 1.4 Hz, 
1 H, Hpy), 8.13 (t, 3JH,H = 7.8 Hz, 1 H, Hpy), 8.17 (dd, 3JH,H = 7.8 Hz, 4JH,H = 1.4 Hz, 1 H, 
Hpy), 8.28 (bd, 3JH,H = 4.9 Hz, 1 H, Hpy), 8.71 (bd, 3JH,H = 4.9 Hz, 1 H, Hpy) ppm. 
 13C-NMR (100.62 MHz, 25 °C, D2O): δ = 50.0, 50.4, 53.3, 53.4, 53.9, 54.6, 66.0, 67.1, 
70.5, 73.9, 75.1, 123.3, 124.3, 124.7, 125.0, 125.1, 125.3, 125.4, 127.2, 140.4, 140.5, 
140.7, 141.4, 148.4, 149.5, 150.2, 151.3, 153.5, 155.3, 155.5, 155.8, 171.6, 171.7, 172.3, 
173.1 ppm. 
HR-ESI MS (pos, MeOH): [LaIII(B2)]+ calcd. 819.1289, obsd. 819.1311. 
Elemental analysis (report no. 39880): [[LaIII(B2)](TFA)5H2O] calcd. C, 43.46; H, 4.14; 




7.4 Details of the radiochemical investigations of the hexadentate bispa 
ligands 
7.4.1 Materials and methods 
Radionuclide production 
The production of 64CuII was performed at a PET cyclotron (Cyclone® 18/9, Helmholtz-
Zentrum Dresden-Rossendorf) as described in detail elsewhere.[199] The yields of the 
nuclear reaction 64Ni(p,n)64Cu were between 3.6-5.2 GBq with molar activities of 
150-250 GBq/µmol CuII diluted in 0.01 M HCl. The 68GaIII generator was purchased from 
Eckert & Ziegler (Berlin, Germany) with a nominal activity of 1100 MBq. The radionuclide 
68GaIII was eluted as [68Ga]GaCl3 (68GaCl3) with 0.1 M HCl using the fractionated elution 
approach.[419] 
Radio-thin layer chromatography (radio-TLC) 
Neutral Al2O3 thin layer chromatography (TLC) plates (Merck, F254) were used to assay 
the degree of 64CuII radiolabeling, whereas instant TLC strips impregnated with silica gel 
(iTLC-SG, Agilent) were used to assay 68GaIII radiolabeling reaction progress and complex 
stability. After the development in an appropriate mobile phase (MP) the radio-TLC 
chromatograms were exposed to reusable imaging plates, which were then analyzed on 
the radioisotope thin layer analyzer BAS-1800II (Raytest). Radiochemical yields (RCY) 
were determined by integrating the peaks in the chromatograms. 
Radio-high performance liquid chromatography (radio-HPLC) and radio-size 
exclusion chromatography (radio-SEC) 
Radio-HPLC was performed on a Knauer WellChrom system equipped with the solvent 
organizer K-1500, the HPLC pump K-1001 (10 mL), a dynamic mixing chamber, the UV 
detector K-2501 and the gamma radioactivity detector Gabi Star (Raytest). A 
Phenomenex Aqua C18 column (250 mm x 4.6 mm, 125 Å, 5 µm) was used for 
separation and the injection volume was 10 µL. Radio-SEC was performed on the same 
Knauer WellChrom system with a self-packed Sephadex G25 size exclusion column 
(200 x 15 mm). Areas under the peaks observed in the HPLC and SEC radiotraces were 




Native polyacrylamide gel electrophoresis (PAGE) for the analysis of the SOD challenge 
experiments and sodium dodecyl sulfate (SDS)-PAGE for the analysis of the serum 
stability assays were performed according to the procedure described in reference [182]. 
7.4.2 Radiochemical studies with copper(II)-64 and gallium(III)-68 
Radiolabeling experiments with bispa ligands 
64CuII radiolabeling. Experiments were performed at final ligand concentrations of ~10–4, 
510–5, 10–5, 510–6 and 10–6 M corresponding to 10, 5, 1, 0.5 and 0.1 µg of B1aH(TFA) or 
B1bH(TFA) in a total volume of 100 µL. In all radiochemical studies the ligands were 
used as TFA salts. The starting activities were 10 and 100 MBq, respectively, which 
corresponds to different volumes of 64CuCl2 in 0.01 M HCl depending on the molar activity 
of different 64Cu production runs and the time of 64Cu use after end of bombardment 
(EOB). The aqueous sample solutions were diluted with 0.05 M 2-(N-morpholino)-
ethanesulfonic acid (MES) / NaOH buffer (pH 5.5) such that the final volume was 100 µL 
after the addition of 64CuCl2. Formation of the radiocopper(II) bispa complexes was 
quantified using radio-TLC after 5, 30 and 60 min. Small aliquots of the samples were 
spotted on neutral Al2O3 TLC plates and a 1:1 (v/v) mixture of 2 M NH4OAc and MeOH 
was used as mobile phase (MP). At these conditions, the Rf-values of the radiolabeled 
compounds were Rf (64CuCl2) = 0, Rf (64Cu-B1a) = 0.8, and Rf (64Cu-B1b) = 0.8.  
The molar activity of a compound can be calculated according to the following equation: 
 
molar activity = 
RCY [%] ∙ starting activity 
amount of substance
 Eq. 7 
In the case of 64CuII-B1a 0.1 µg (148 pmol) B1aH(TFA) was reacted with 
100 MBq 64CuCl2. With a radiochemical yield (RCY) of 15 % after 5 min this leads to a 
molar activity of ~100 GBq/µmol. The molar activity of B1b was calculated based on a 
radiolabeling experiment under the same conditions with a RCY of 30 %. 
68GaIII radiolabeling. Experiments were carried out at final ligand concentrations of ~10–4, 
510–5, 10–5, 510–6 and 10–6 M corresponding to 30, 15, 3, 1.5 and 0.3 µg of B1aH(TFA) 
in a total volume of 300 µL. Therefore, a 1 mg/mL stock solution of B1aH(TFA) in 
1 M NaOAc buffer (pH 4.6) with 10 % EtOH was prepared. For example to obtain a ligand 
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concentration of ~10–4 M, 30 µL stock solution, 231 µL 1 M NaOAc buffer (pH 4.6) and 
39 µL 68GaCl3 in 0.1 M HCl (~65 MBq) were combined. The volume aliquots of 68GaCl3 
were chosen depending on the activity of the 68GaIII-eluate. The samples were incubated 
at 37 °C and 750 rpm in the thermomixer. The degree of radiolabeling was monitored by 
radio-TLC after 5, 10, 15 and 30 min. Small aliquots of the samples were spotted on 
iTLC-SG plates and a 1:1 (v/v) mixture of 2 M NH4OAc and MeOH was used as mobile 
phase (MP). At these conditions, the Rf-values were Rf (68GaCl3) = 0 and Rf 
(68GaIII-B1a) = 0.87. The molar activity of B1a was calculated based on a radiolabeling 
experiment using 0.5 µg ligand (~510-6 M) and 47.6 MBq 68GaCl3 with a RCY of 55 % 
after 15 min. 
Competition assays of radiolabeled bispa ligands 
64CuII complex stability studies in cyclam and EDTA. For the challenge experiments 
100 µg (148 nmol, 1.0 eq) B1aH(TFA) or B1bH(TFA) in 0.05 M MES / NaOH buffer 
(pH 5.5) was radiolabeled with 10 MBq 64CuCl2. Quantitative formation of 64CuII-B1a and 
64CuII-B1b was confirmed by radio-TLC as described above. Subsequently 2.97 mg 
(14.8 µmol, 100 eq) cyclam or 4.33 mg (14.8 µmol, 100 eq) EDTA in MES / NaOH buffer 
was added, resulting in a total volume of 200 µL. After 2 and 24 h the samples were 
analyzed by radio-HPLC using eluents A: 0.1 % H(TFA) in H2O and B: 0.1 % H(TFA) in 
MeCN with a gradient of 0 to 70 % B over a period of 20 min, 70 to 100 % B over a period 
of 2 min, 100 % B for 5 min and a flow rate set to 1 mL/min. The retention times of the 
compounds were tR (64CuII-EDTA) = 4.8 min, tR (64CuII-cyclam) = 9.5 min, tR (64CuII-
B1a) = 13.8 min, and tR (64CuII-B1b) = 14.4 min. All experiments were performed in 
triplicate and samples with the pure 64CuII-(competing ligand) complex and with 64CuCl2, 
respectively, were always prepared as references and analyzed in parallel. 
64CuII complex stability studies in superoxide dismutase (SOD) and human serum. The 
challenge assays of 64CuII-B1a and 64CuII-B1b were carried out according to the 
procedures described in reference [182]. The experiments were performed in triplicate and 
the amount of transchelation is given as mean value ± standard deviation. The Coomassie 
stained polyacrylamide gels and autoradiographies are depicted in Appendix H. The 
serum stability of 64CuII-B1a and 64CuII-B1b was additionally analyzed by radio-SEC. The 
64CuII-bispa complexes were prepared by incubating 10.1 µL (15 nmol) B1aH(TFA) or 
B1bH(TFA), 130.9 µL 0.05 M MES / NaOH buffer (pH 5.5), and 9 µL 64CuCl2 in 0.01 M 
HCl (~35 MBq) for 20 min at 25 °C. Quantitative formation was confirmed by radio-TLC as 
described above after which 100 µL of the samples were added to 50 µL 0.05 M 4-(2-
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hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) / NaOH buffer (pH 7.4) and 
250 µL human serum. During incubation at 37 °C and 750 rpm in a thermomixer the 
samples were analyzed by radio-SEC at time points of 2 and 24 h. 150 mM PBS was 
used as eluent with a flow rate of 1 mL/min and these conditions allowed the clear 
separation of the relevant compounds with the following retention times: tR (64CuII-
serum) = 6.8 min, tR (64CuII-B1a) = 14.2 min, and tR (64CuII-B1b) = 21.2 min. 
68GaIII complex stability studies in EDTA and human serum. For the EDTA challenge 
experiment the following stock solutions were prepared: 1 mg/mL B1aH(TFA) in 
1 M NaOAc buffer (pH 4.6) with 10 % EtOH and 14.8 M EDTA in 0.1 M MES / NaOH 
buffer (pH 5.5). In the first step 100 µL (100 µg, 148 nmol, 1.0 eq) B1a solution were 
radiolabeled with ~20 MBq 68GaCl3. Prior to the addition of 100 µL (433 µg, 1.48 µmol, 
10 eq) EDTA solution, quantitative formation of 68GaIII-B1a was confirmed by radio-TLC as 
described above. The samples were subsequently incubated at 25 °C and 750 rpm in a 
thermomixer. At time points of 1, 2 and 4 h small aliquots were taken and analyzed by 
radio-TLC using iTLC-SG plates and 0.1 M citric acid as mobile phase (MP). With this MP 
68GaIII-B1a and 68GaIII-EDTA can be separated chromatographically with Rf values of 0 
and 0.93, respectively. The experiments were performed in duplicate. The human serum 
stability assay with 68GaIII-B1a was carried out according to the procedure published for 
64CuII complexes in reference [182]. Aliquots of the B1a stock solution were first 
radiolabeled with 68GaCl3 at 50 °C and 750 rpm for 30 min (10 µg ligand, 135 µL total 
volume, ~70 MBq). The samples were analyzed by radio-TLC as described above to 
confirm quantitative radiolabeling and then incubated with human serum for 1 h at 37 °C. 
The remaining analysis steps were performed as described in the literature.[182] The 
experiments were undertaken in triplicate and the resulting gel is depicted in Appendix H. 
Lipophilicity studies of 64CuII-bispa complexes 
Aqueous solutions containing 1 mM bispa ligand B1aH(TFA) or B1bH(TFA) and 
100 µM Cu(NO3)2 spiked with 4 MBq 64CuCl2 were prepared. Full complexation was 
checked by radio-TLC or radio-HPLC, which gave no evidence of free copper(II)-64 in the 
aqueous phase. Then, 50 µL of this solution was added to 450 µL of 0.05 M 4-(2-
hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) / NaOH (pH of 7.2, 7.4, 7.6). The 
distribution experiments in 1-octanol / buffer systems were carried out at 25 ± 1 °C in 
microcentrifuge tubes (2 mL) with mechanical shaking for 30 min. The phase ratio 
V (1-octanol) / V (aqueous solution) was 1:1 (0.5 mL each). All samples were centrifuged 
and the phases separated. The copper complex concentration in both phases was 
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determined radiometrically using γ radiation (64Cu, NaI(Tl) scintillation counter automatic 
γ counter 1480, Wizard 3’’, PerkinElmer). All experiments were performed four times to 
obtain an average value. 
Biodistribution of 64CuII- and 68GaIII-bispa1 complexes 
The animal experiments were carried out in male Wistar rats (Wistar-Kyoto strain; aged 
7-8 weeks, 140-195 g; Harlan Winkelmann GmbH, Borchen, Germany) according to the 
guidelines of the German Regulations for Animal Welfare. The protocol was approved by 
the local Ethical Committee for Animal Experiments. The biodistribution studies were 
performed by Prof. Dr. Jens PIETZSCH and coworkers as published in detail 
elsewhere.[172,393]  
The preparation of the radiolabeled ligands 64CuII-B1a and 64CuII-B1b was carried out by 
Karin LANDROCK in the group of Dr. Holger STEPHAN. Therefore, 1 mg/mL stock solutions 
of the bispa ligands B1aH(TFA) and B1bH(TFA) in 0.05 M MES / NaOH buffer (pH 5.5) 
were prepared, respectively. In the next step 1.5 µL ligand solution, 136.5 µL MES buffer 
(see above) and 12 µL 64CuCl2 in 0.01 M HCl (~50 MBq) were combined and incubated 
for 20 min at 25 °C. The samples were subsequently checked for quantitative 
radiolabeling by radio-TLC as described above and then used for the biodistribution 
studies. The 68GaIII-B1a sample was prepared by Madlen MATTERNA in the group of Dr. 
Holger STEPHAN. B1aH(TFA) was first dissolved in a 1 M NH4OAc buffer (pH 7) with 
10 % EtOH to obtain a ligand concentration of 1 mg/mL. A 100 µL ligand solution, 
750 µL NH4OAc buffer (see above), and 150 µL 68GaCl3 in 1 M HCl were combined and 
incubated for 30 min at 50 °C and 750 rpm. Quantitative radiolabeling was checked by 
radio-TLC as described above. 
The accumulated radioactivity in organs and tissues was calculated as either the 
percentage of the injected dose per gram (%ID/g) or, for stomach, intestine, feces, and 





7.5 Details of the radiochemical investigations of the octadentate bispa 
ligand 
7.5.1 Materials and methods 
Radionuclide production 
111InCl3 was cyclotron produced and provided by Nordion (Vancouver, BC, Canada) as a 
~0.05 M HCl solution. 177LuCl3 was purchased from Perkin-Elmer and received as 
~0.05 M HCl solution. 225Ac(NO3)3 in 0.05 M HNO3 was produced in-house (TRIUMF) by 
the spallation of a uranium carbide target and separated downstream from other 
radionuclides by a mass separator,[420,421] chemical purification of 225AcIII was 
accomplished by modifying previously published procedures on a N,N,N’,N’-tetrakis-2-
ethylhexylglycolamide (DGA) resin (branched, 50-100 µm, Eichrom Technologies 
LLC).[422,423] 
Radio-thin layer chromatography (radio-TLC) 
Instant thin layer chromatography paper strips impregnated with silica gel (iTLC-SG, 
Varian) were used to analyze 225AcIII radiolabeling reaction progress and complex stability 
and were counted on a BioScan System 200 imaging scanner equipped with a BioScan 
Autochanger 1000. 
Radio-high performance liquid chromatography (radio-HPLC) 
Analysis of 111InIII- and 177LuIII-radiolabeled complexes was carried out using a 
Phenomenex Synergi 4 µ Hydro-RP analytical column (250 mm x 4.60 mm, 80 Å, 4 µm) 
using an Agilent HPLC system equipped with a model 1200 quaternary pump, a model 




7.5.2 Radiochemical studies with indium(III)-111, lutetium(III)-177, and 
actinium(III)-225 
Radiolabeling experiments with bispa ligand B2 
111InIII and 177LuIII radiolabeling. The radiolabeling procedures followed closely those 
outlined previously.[58,424] Briefly, B2H(TFA) and standard DOTA was made up as a stock 
solution (1 mg/mL, ~10-3 M) in deionized water. Using serial dilution, stock ligand solutions 
of B2H(TFA) with concentrations of ~10-4-10-6 M were also prepared. A 100 µL aliquot of 
each ligand stock solution (or 100 µL of deionized water as a blank) was added to a 
screw-cap mass spectrometry vial and diluted with sodium acetate buffer (10 mM, pH 4) 
such that the final volume was 1.0 mL after the addition of 111InCl3 or 177LuCl3, resulting in 
final ligand concentrations of 10-4-10-7 M. An aliquot of 111InCl3 or 177LuCl3 (~3.7-18.5 MBq 
for labeling and ~111-333 MBq for serum competition) was added to the vials containing 
the ligand and buffer and allowed to react at ambient temperature for 10 min. The reaction 
mixture was analyzed by radio-HPLC to confirm radiolabeling and calculate yields. Areas 
under the peaks observed in the HPLC radiotrace were integrated to determine 
radiolabeling yields. For radio-HPLC the eluents A: 0.1 % H(TFA) in H2O and B: MeCN 
were used with a linear gradient of 0 to 100 % B over a period of 20 min and a flow rate 
set to 1 mL/min. The retention times of the compounds were tR (111InIII-B2) = 10.5 min, 
tR (177LuIII-B2) = 10.9 min, tR (111InCl3) = ~5-7 min, and tR (177LuCl3) = 3.3-3.5 min. The 
molar activity of B2 with indium(III)-111 was calculated based on a radiolabeling 
experiment using 0.1 µg ligand (10-7 M) and 8.9 MBq 111InCl3 at pH 4 resulting in a RCY of 
> 99 % after 10 min at room temperature. For the calculation of the molar activity of B2 
with lutetium(III)-177 an experiment with the following reaction conditions was used: 
100 µg ligand (10-4 M), 3.7 MBq 177LuCl3, pH 4, RCY = 49 % after 15 min at room 
temperature. 
225AcIII radiolabeling. A stock ligand solution of B2 was prepared (10 mg/mL) in deionized 
water. A 10 µL (100 µg) aliquot of ligand stock was added to a screw-cap mass 
spectrometry vial and diluted with 140-150 µL ammonium acetate buffer (0.15 M, pH 6). 
To the vial containing ligand and buffer, 225Ac(NO3)3 (10 µL, 40 kBq) was added, and the 
reaction was left to react at ambient temperature. Radiolabeling reactions were analyzed 
by modifying previously published procedures.[120,288,408,425] Reaction progress was 
analyzed at 5, 30 and 60 min by spotting a small aliquot on iTLC-SG paper (1-5 µL, 2 x 
10 cm strips), and developing the strips with mobile phase (MP) A: 10 mM NaOH / 
9 % NaCl solution, or spotting an aliquot on aluminum backed silica TLC plates developed 
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in MP B: 0.4 M sodium citrate, pH 4 with 10 % methanol. With MP A, uncomplexed 225AcIII 
precipitates and sticks to the baseline (Rf = 0) while 225AcIII-chelate species migrate up the 
plate (Rf > 0.5); with MP B, uncomplexed 225AcIII travels with the solvent front (Rf ~ 1) while 
225AcIII complexes stick to the baseline (Rf = 0). Developed plates were counted 
immediately and the following day to allow for 213BiIII decay (t1/2 = 45.6 min[27]), and 
corrected 225AcIII radiolabeling yields were calculated by integrating the peaks in the 
radiochromatogram. The molar activity of B2 with actinium(III)-225 was calculated based 
on a radiolabeling experiment using 1 µg ligand (10-6 M) and 40 kBq 225Ac(NO3)3 at pH 6 
resulting in 64 % RCY after 30 min at room temperature. 
Competition assays of radiolabeled bispa ligand B2 
111InIII and 177LuIII complex stability studies in human serum. 111InIII- or 177LuIII-ligand human 
serum stability experiments were analyzed using GE Healthcare Life Sciences PD-10 
desalting columns (size exclusion for MW < 5000 Da) and counted with a Capintec CRC 
55t dose calibrator. The procedures closely followed those outlined previously.[58,424] The 
compounds 111InIII-B2 and 177LuIII-B2 and corresponding blanks were prepared with the 
radiolabeling protocol described above. Solutions were prepared in vials with 1.0 mL of 
human serum, 325 µL of 111InIII or 177LuIII complex, and 675 µL of phosphate buffered 
saline (PBS, pH 7.4) and incubated at 37 °C in a sand bath. The experiments were 
performed in triplicate for each 111InIII and in duplicate for each 177LuIII complex. For 
111InIII competitions, at time points of 1 h, 1 and 5 d, 400 µL of the human serum 
competition mixture were removed from each vial (800 µL were removed for the last time 
point). For 177LuIII competitions, after 1 h, 1, 5 and 7 d, 330, 330, 660 and 660 µL of the 
human serum competition mixture were removed, respectively. The aliquot was diluted to 
a total of 2.5 mL with PBS, and then counted in a dose calibrator to obtain a value for the 
total activity to be loaded on the PD-10 column (F). The diluted human serum mixture 
(2.5 mL) was then loaded onto the PD-10 column (pre-conditioned with 20 mL of PBS) 
and the empty vial was counted in the dose calibrator to determine the residual activity left 
in the vial (R). The 2.5 mL of loading volume were eluted into a waste container, and then 
the PD-10 column was eluted with 3.5 mL of PBS and collected into a separate vial. The 
eluent that contained 111InIII or 177LuIII bound / associated with serum proteins (size 
exclusion for MW < 5000 Da) was counted in the dose calibrator (E) and then compared 
to the total amount of activity that was loaded on the PD-10 column to obtain the 
percentage of 111InIII or 177LuIII that was still ligand-bound and not transchelated to serum 
proteins using the equation: 1–[E(F–R)]. 
Experimental Section 
 150 
225AcIII complex stability studies in human serum. The compound 225AcIII-B2 was prepared 
with the radiolabeling procedure described above. To the reaction vial containing the 
radiometal-ligand complex (160-170 µL), an equal volume of human serum was added 
and the competition mixture was incubated at room temperature. The experiments were 
performed in triplicate for 225AcIII-B2 and in duplicate for 225AcIII-DOTA. At time points of 
1 h, 1, 3, 5 and 7 d, aliquots (5 µL) were spotted on iTLC-SG plates and developed with 
MP A, as described above, or on aluminum backed silica TLC plates developed with MP 
C: 50 mM EDTA, pH 5. Using MP C, chelate-bound 225AcIII sticks to the baseline (Rf = 0), 
and any 225AcIII that has de-complexed from the chelate will travel with the solvent front 
(Rf ~ 1). The TLC gradient was validated by incubating “free” 225AcIII with human serum 
under analogous conditions, to ensure that all the activity is eluted with the solvent front 
(Rf ~1). 
LaIII exchange 225AcIII Complex Stability Studies. The compound 225AcIII-B2 was prepared 
according to the radiolabeling procedure as described above. An aliquot of lanthanum(III) 
nitrate solution (0.1 M, 6.3 µL, 5 eq compared to B2) was added to the preformed 225AcIII 
complex, and the mixture was allowed to react at ambient temperature. After 0.08, 0.2, 1, 
3, 6, and 7 d, aliquots of the competition reactions (1-3 µL) were spotted on aluminum 
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Appendix A: 1H- and 13C-NMR spectra 
 
Figure A 1. 1H-NMR (600.13 MHz, 25 °C, CDCl3) spectrum of compound B12. 
 
                                                
viii Reproduced in part with permission from P. Comba, L. Grimm, C. Orvig, K. Rück, H. Wadepohl, 
Inorg. Chem. 2016, 55, 12531-12543, Copyright 2016 American Chemical Society.; Parts of this 
chapter will be published in P. Comba, U. Jermilova, C. Orvig, B. O. Patrick, C. F. Ramogida, 
K. Rück, C. Schneider, M. Starke, Chem. Eur. J., submitted manuscript. 
 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 2. 13C-NMR (150.92 MHz, 25 °C, CDCl3) spectrum of compound B12. 
  









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 3. 1H-NMR (600.13 MHz, 25 °C, MeOH-d4) spectrum (top) and 13C-NMR 
(150.92 MHz, 25 °C, MeOH-d4) spectrum (bottom) of compound B13. 
 
 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 4. 1H-NMR (600.13 MHz, 25 °C, MeOH-d4) spectrum (top) and 13C-NMR 
(150.92 MHz, 25 °C, MeOH-d4) spectrum (bottom) of compound B14. 
 
 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 5. 1H-NMR (600.13 MHz, 25 °C, MeCN-d3) spectrum (top) and 13C-NMR 
(150.92 MHz, 25 °C, MeCN-d3) spectrum (bottom) of compound (p-MeO)(tBu)B1a. The 
water visible in the 1H-NMR spectrum originates from the deuterated solvent. 
 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 6. 1H-NMR (600.13 MHz, 25 °C, D2O) spectrum (top) and 13C-NMR 
(150.92 MHz, 25 °C, D2O) spectrum (bottom) of compound (p-MeO)B1aH(TFA). 
 
 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 7. 1H-NMR (600.13 MHz, 22 °C, MeCN-d3) spectrum (top) and 13C-NMR 
(150.92 MHz, 22 °C, MeCN-d3) spectrum (bottom) of compound (tBu)B1b. The water 
visible in the 1H-NMR spectrum originates from the deuterated solvent. 
 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 8. 1H-NMR (600.13 MHz, 22 °C, D2O) spectrum (top) and 13C-NMR 
(150.92 MHz, 22 °C, D2O) spectrum (bottom) of compound B1bH(TFA). 
 
 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 9. 1H-NMR (600.13 MHz, 25 °C, MeOH-d4) spectrum (top) and 13C-NMR 
(150.92 MHz, 25 °C, MeOH-d4) spectrum (bottom) of compound B19H(TFA). 
 
 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 10. 1H-NMR (600.13 MHz, 25 °C, MeCN-d3) spectrum (top) and 13C-NMR 
(150.92 MHz, 25 °C, MeCN-d3) spectrum (bottom) of compound (tBu)2B2. The water 
visible in the 1H-NMR spectrum originates from the deuterated solvent. 
 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 11. 1H-NMR (400.19 MHz, 25 °C, D2O) spectrum (top) and 13C-NMR 
(100.64 MHz, 25 °C, D2O) spectrum (bottom) of compound B2H(TFA). 
 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 12. 1H-NMR (600.13 MHz, 22 °C, D2O) spectrum (top) and 13C-NMR 
(150.92 MHz, 22 °C, D2O) spectrum (bottom) of compound [ZnII(B1a)](TFA). 
 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 13. 1H-NMR (600.13 MHz, 22 °C, D2O) spectrum (top) and 13C-NMR 
(150.92 MHz, 22 °C, D2O) spectrum (bottom) of compound [ZnII((p-MeO)B1a)](TFA). 
 
 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 14. 1H-NMR (600.13 MHz, 22 °C, D2O) spectrum (top) and 13C-NMR 
(150.92 MHz, 22 °C, D2O) spectrum (bottom) of compound [ZnII(B1b)](TFA). 
 
 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 15. 1H-NMR (200.13 MHz, 27 °C, D2O) spectrum (top) and 13C-NMR 
(150.92 MHz, 22 °C, D2O) spectrum (bottom) of compound [GaIII(B1a)](TFA)(NO3). 
 
 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 16. 1H-NMR (600.13 MHz, 22 °C, D2O) spectrum (top) and 13C-NMR 
(150.92 MHz, 22 °C, D2O) spectrum (bottom) of compound [GaIII(B1b)](NO3)2. 
 
 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 17. 1H-NMR (400.19 MHz, 25 °C, D2O) spectrum (top) and 13C-NMR 
(100.64 MHz, 25 °C, D2O) spectrum (bottom) of [InIII(B2)](TFA). 
 
 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 18. 1H-NMR (400.13 MHz, 25 °C, D2O) spectrum (top) and 13C-NMR 
(100.62 MHz, 25 °C, D2O) spectrum (bottom) of [LuIII(B2)](TFA). 
 
 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A 19. 1H-NMR (400.13 MHz, 25 °C, D2O) spectrum (top) and 13C-NMR 
(100.62 MHz, 25 °C, D2O) spectrum (bottom) of [LaIII(B2)](TFA). 
 
  
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix B: Details of the solid state structure determinations 
The experimental structures reported herein are or will be deposited at the Cambridge 
Crystallographic Data Centre (CCDC) and can thus be obtained free of charge via 
https://www.ccdc.cam.ac.uk/structures/. The corresponding CCDC-reference codes of the 
compounds are given in the following tables. Note that the numbering scheme in the 
present thesis slightly differs from the crystallographic numbering scheme. 
 B1aH(TFA) B120.5H2O 
B130.5(1,4-
dioxane) 
identification code co_kr09 co_kr14 co_kr15 
CCDC number 1481459 1547413 1547414 
formula C31H32F3N5O9 C31H35N4O7.5 C33H40N4O8 
crystal system triclinic triclinic monoclinic 
space group P –1 P –1 P 21/c 
a  /Å 10.785(6) 13.795(7) 14.759(6) 
b  /Å 11.054(7) 14.223(7) 11.471(5) 
c  /Å 15.067(9) 17.438(9) 18.289(8) 
α  /° 75.338(8) 110.369(9) 90 
β  /° 71.848(15) 107.207(12) 95.841(12) 
γ  /° 71.608(9) 99.843(15) 90 
V  /Å3 1595.6(16) 2917(2) 3080(2) 
Z 2 4 4 
Mr 675.61 583.63 620.69 
F000 704 1236 1320 
dc  /Mg·m-3 1.406 1.329 1.338 
µ  /mm-1 0.116 0.096 0.096 
max., min. transmission factors 0.7464, 0.7004 (a) 0.7464, 0.6952 (a) 0.7464, 0.7143 (a) 
X-radiation, λ  /Å Mo-Kα, 0.71073 Mo-Kα, 0.71073 Mo-Kα, 0.71073 
data collect. temperat.  /K 100(1) 100(1) 100(1) 
θ range  /° 2.0 to 32.5 1.6 to 29.6 2.1 to 32.6 
index ranges  h,k,l –16 ... 16, –16 ... 16, –22 ... 22 
–19 ... 19, –19 ... 
19, –24 ... 24 
–21 ... 21, –17 ... 
17, –27 ... 27 
reflections measured 40054 68517 78152 
                 unique [Rint] 10692 [0.0334] 16340 [0.0649] 10620 [0.0471] 
                 observed [I≥2σ(I)] 7720 10732 8303 
Appendix 
 185 
 B1aH(TFA) B120.5H2O 
B130.5(1,4-
dioxane) 
data / restraints /parameters 10692 / 0 / 442 16340 / 0 / 779 10620 / 83 / 469 
GooF on F2 1.026 1.030 1.025 
R indices [F>4σ(F)]  R(F), wR(F2) 0.0526, 0.1278 0.0562, 0.1353 0.0448, 0.1069 
R indices (all data)  R(F), wR(F2) 0.0792, 0.1443 0.0971, 0.1564 0.0636, 0.1183 
largest residual peaks  /e⋅Å-3 0.977, –0.847 0.531, –0.782 0.515, –0.231 
instrument Smart 1000 Smart 1000 Smart 1000 
(a) empirical absorption correction.  
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 B14MeOH (p-MeO)(tBu)B1a B1bH(TFA) 
identification code co_kr17a co_kr20 co_kr23 
CCDC number 1547415 1547416 1481465 
formula C25H34N4O8 C35H34N5O9 C31H32F3N5O9 
crystal system monoclinic triclinic monoclinic 
space group P 21/c P –1 P 21/c 
a  /Å 12.493(7) 11.050(4) 15.6763(4) 
b  /Å 20.536(11) 12.145(5) 15.6292(3) 
c  /Å 11.051(6) 13.994(6) 13.6985(4) 
α  /° 90 85.073(11) 90 
β  /° 112.618(12) 76.819(8) 109.606(3) 
γ  /° 90 68.427(10) 90 
V  /Å3 2617(3) 1700.4(12) 3161.65(15) 
Z 4 2 4 
Mr 518.56 677.74 675.61 
F000 1104 720 1408 
dc  /Mg·m-3 1.316 1.324 1.419 
µ  /mm-1 0.099 0.096 0.117 
max., min. transmission factors 0.8620, 0.7681 (a) 0.8623, 0.8137 (a) 1.0000, 0.9186 (b) 
X-radiation, λ  /Å Mo-Kα, 0.71073 Mo-Kα, 0.71073 Mo-Kα, 0.71073 
data collect. temperat.  /K 100(1) 100(1) 120(1) 
θ range  /° 2.0 to 26.5 2.2 to 32.5 3.3 to 32.6 ° 
index ranges  h,k,l –15 ... 15, –24 ... 25, –13 ... 13 
–16 ... 16, –18 ... 
18, –21 ... 21 
–22 ... 23, –23 ... 
23, –20 ... 20 
reflections measured 44523 44381 89608 
                 unique [Rint] 5387 [0.0641] 11478 [0.0292] 11017 [0.0651] 
                 observed [I≥2σ(I)] 3850 9747 8190 
data / restraints /parameters 5387 / 1 / 361 11478 / 0 / 515 11017 / 91 / 545 
GooF on F2 1.042 1.028 1.068 
R indices [F>4σ(F)]  R(F), wR(F2) 0.0521, 0.1405 0.0399, 0.1062 0.0563, 0.1341 
R indices (all data)  R(F), wR(F2) 0.0798, 0.1575 0.0485, 0.1136 0.0809, 0.1472 
largest residual peaks  /e⋅Å-3 0.987, –0.274 0.514, –0.216 0.427, –0.302 
instrument Smart 1000 Smart 1000 Supernova 
(a) empirical absorption correction. (b) numerical absorption correction.  
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 B19H(TFA) [NaI((tBu)2B2)]Br B27H2O 
identification code co_kr32 co_kr33_sq co498 
CCDC number 1547417 1547418 1550809 
formula C23H25F3N4O7 C47H58BrN6NaO11 C35H48N6O16 
crystal system monoclinic orthorhombic orthorhombic 
space group P 21/c A e a 2 P n a 21 
a  /Å 10.617(5) 13.19166(6) 16.1688(5) 
b  /Å 16.091(8) 35.73270(15) 12.4691(4) 
c  /Å 14.083(6) 22.02932(13) 19.1512(6) 
α  /° 90 90 90 
β  /° 102.890(10) 90 90 
γ  /° 90 90 90 
V  /Å3 2345.4(19) 10384.04(9) 3861.1(2) 
Z 4 8 4 
Mr 526.47 985.89 808.79 
F000 1096 4128 1712 
dc  /Mg·m-3 1.491 1.261 1.391 
µ  /mm-1 0.126 1.663 0.941 
max., min. transmission factors 0.7464, 0.6908 (a) 0.929, 0.704 (b) 0.877, 0.800 (a) 
X-radiation, λ  /Å Mo-Kα, 0.71073 Cu-Kα, 1.54184 Cu-Kα, 1.54184 
data collect. temperat.  /K 100(1) 120(1) 90 
θ range  /° 2.0 to 32.5 2.0 to 32.5 133.4 (c) 
index ranges  h,k,l –15 ... 15, –24 ... 23, –21 ... 20 
–16 ... 16, –43 ... 
43, –26 ... 26 
–19 ... 19, –14 ... 
14, –22 ... 22 
reflections measured 59693 199437 26819 
                 unique [Rint] 8074 [0.0460] 9874 [0.0354] 6470 [0.036] 
                 observed [I≥2σ(I)] 6359 9730 6124 
data / restraints /parameters 8074 / 205 / 425 9874 / 273 / 611 6470 / - / 584 
GooF on F2 1.045 1.033 1.06 
R indices [F>4σ(F)]  R(F), wR(F2) 0.0473, 0.1133 0.0355, 0.0936 0.029, 0.069 
R indices (all data)  R(F), wR(F2) 0.0662, 0.1237 0.0359, 0.0941 - 
largest residual peaks  /e⋅Å-3 0.723, –0.531 0.856, –0.977 0.27, –0.17 
instrument Smart 1000 Supernova Bruker APEX DUO 










identification code co_kr30 co_kr31 co_kr12 
CCDC number 1481460 1481466 1481461 
formula C33H38CoF3N5O11 C32H34CoF3N5O10 C31H44F3N5NiO16 
crystal system triclinic triclinic triclinic 
space group P –1 P –1 P –1 
a  /Å 10.74834(19) 9.7429(7) 11.172(5) 
b  /Å 11.9384(2) 10.3992(7) 11.783(5) 
c  /Å 14.7516(2) 18.0310(11) 15.767(7) 
α  /° 80.4845(14) 83.892(5) 79.170(8) 
β  /° 74.3407(15) 84.613(5) 78.226(6) 
γ  /° 71.9137(16) 66.113(7) 66.386(13) 
V  /Å3 1725.70(6) 1658.3(2) 1848.7(14) 
Z 2 2 2 
Mr 796.61 764.57 858.42 
F000 826 790 896 
dc  /Mg·m-3 1.533 1.531 1.542 
µ  /mm-1 4.647 4.788 0.620 
max., min. transmission factors 0.723, 0.547 (b) 0.853, 0.601 (b) 0.7464, 0.7104 (a) 
X-radiation, λ  /Å Cu-Kα, 1.54184 Cu-Kα, 1.54184  Mo-Kα, 0.71073 
data collect. temperat.  /K 120(1) 120(1) 100(1) 
θ range  /° 3.9 to 70.2 4.7 to 70.8 1.9 to 32.4 
index ranges  h,k,l –13 ... 13, –14 ... 14, –17 ... 17 
–11 ... 11, –12 ... 
11, –20 ... 21 
–16 ... 16, –17 ... 
17, –23 ... 23 
reflections measured 98093 19546 47875 
                 unique [Rint] 6536 [0.0386] 6261 [0.0460] 12406 [0.0256] 
                 observed [I≥2σ(I)] 6412 5306 11261 
data / restraints /parameters 6536 / 0 / 486 6261 / 168 / 530 12406 / 66 / 574 
GooF on F2 1.046 1.032 1.042 
R indices [F>4σ(F)]  R(F), wR(F2) 0.0415, 0.1192 0.0393, 0.0884 0.0328, 0.0867 
R indices (all data)  R(F), wR(F2) 0.0422, 0.1198 0.0505, 0.0932 0.0370, 0.0898 
largest residual peaks  /e⋅Å-3 0.761, –0.622 0.344, –0.272 1.325, –0.914 
instrument Supernova Supernova Smart 1000 










identification code co_kr27 co_kr08 co_kr22 
CCDC number 1481467 1481462 - 
formula C32H34F3N5NiO10 C33.50H40CuF3N5O11.50 C35H49.4CuF3N6O17.2 
crystal system triclinic monoclinic triclinic 
space group P –1 P 21/n P –1 
a  /Å 9.75342(18) 14.0568(2) 9.183(4) 
b  /Å 10.3822(2) 17.4975(2) 15.117(7) 
c  /Å 17.9979(3) 15.9217(2) 15.651(6) 
α  /° 84.1480(16) 90 92.310(11) 
β  /° 84.4177(15) 113.9347(17) 101.567(6) 
γ  /° 66.7227(19) 90 96.516(13) 
V  /Å3 1662.20(6) 3579.33(9) 2110.4(15) 
Z 2 4 2 
Mr 764.35 817.24 949.94 
F000 792 1696 990 
dc  /Mg·m-3 1.527 1.517 1.495 
µ  /mm-1 0.666 0.695 0.611 
max., min. transmission factors 0.950, 0.899 (a) 1.0000, 0.8932 (a) 0.7464, 0.6979 (a) 
X-radiation, λ  /Å Mo-Kα, 0.71073 Mo-Kα, 0.71073 Mo-Kα, 0.71073 
data collect. temperat.  /K 120(1) 120(1) 100(1) 
θ range  /° 3.2 to 32.9 3.3 to 32.9 1.3 to 32.5 
index ranges  h,k,l –14 ... 14, –15 ... 15, –26 ... 27 
–20 ... 21, –25 ... 26, –
23 ... 23 
–13 ... 13, –22 ... 22, 
–23 ... 23 
reflections measured 94547 226734 55228 
                 unique [Rint] 11605 [0.0486] 12735 [0.0718] 14264 [0.0299] 
                 observed [I≥2σ(I)] 10112 11542 12529 
data / restraints /parameters 11605 / 73 / 507 12735 / 0 / 506 14264 / 11 / 616 
GooF on F2 1.073 1.176 1.034 
R indices [F>4σ(F)]  R(F), wR(F2) 0.0399, 0.0968 0.0491, 0.1016 0.0334, 0.0873 
R indices (all data)  R(F), wR(F2) 0.0480, 0.1008 0.0576, 0.1047 0.0404, 0.0923 
largest residual peaks  /e⋅Å-3 0.600, –0.620 0.538, –0.475 0.685, –0.593 
instrument Supernova Supernova Smart 1000 










identification code co_kr24 co_kr11 co_kr19 
CCDC number 1481468 1481463 - 
formula C32H34CuF3N5O10 C31H34F3N5O11Zn C34H38F3N5O12Zn 
crystal system triclinic triclinic monoclinic 
space group P –1 P –1 P 21/c 
a  /Å 9.759(4) 8.07052(9) 12.00403(14) 
b  /Å 10.509(4) 11.30254(11) 20.1822(3) 
c  /Å 18.061(7) 18.06615(14) 14.46784(15) 
α  /° 83.634(12) 84.1173(7) 90 
β  /° 85.035(12) 88.3010(8) 91.0765(11) 
γ  /° 65.796(12) 80.5013(8) 90 
V  /Å3 1677.3(12) 1616.66(3) 3504.47(7) 
Z 2 2 4 
Mr 769.18 775.00 831.06 
F000 794 800 1720 
dc  /Mg·m-3 1.523 1.592 1.575 
µ  /mm-1 0.733 0.847 0.790 
max., min. transmission factors 0.7464, 0.6954 (b) 0.903, 0.870 (b) 1.00000, 0.88470 (a) 
X-radiation, λ  /Å Mo-Kα, 0.71073 Mo-Kα, 0.71073 Mo-Kα, 0.71073 
data collect. temperat.  /K 100(1) 120(1) 120(1) 
θ range  /° 2.1 to 32.5 3.4 to 29.0 3.3 to 32.8 
index ranges  h,k,l –14 ... 14, –15 ... 15, –26 ... 27 
–10 ... 11, –15 ... 
15, –24 ... 24 
–18 ... 17, –30 ... 
30, –21 ... 21 
reflections measured 43907 91634 122913 
                 unique [Rint] 11360 [0.0282] 8194 [0.0284] 12338 [0.0498] 
                 observed [I≥2σ(I)] 10145 7968 11198 
data / restraints /parameters 11360 / 73 / 507 8194 / 6 / 476 12338 / 91 / 554 
GooF on F2 1.048 1.085 1.214 
R indices [F>4σ(F)]  R(F), wR(F2) 0.0337, 0.0847 0.0429, 0.1016 0.0570, 0.1172 
R indices (all data)  R(F), wR(F2) 0.0395, 0.0879 0.0443, 0.1023 0.0648, 0.1201 
largest residual peaks  /e⋅Å-3 0.980, –0.369 1.674, –1.358 0.927, –0.548 
instrument Smart 1000 Supernova Supernova 










identification code co_kr25 co_kr07 co_kr26 
CCDC number 1481469 1481464 1481470 
formula C31H30F3N5O9Zn C31H44F3GaN6O19 C31.50H40GaN7O15.50 
crystal system monoclinic triclinic triclinic 
space group P 21/c P –1 P –1 
a  /Å 13.297(5) 10.5773(3) 9.142(5) 
b  /Å 15.114(7) 14.1652(4) 12.371(6) 
c  /Å 16.383(7) 15.4132(4) 16.188(10) 
α  /°  62.650(3) 101.721(11) 
β  /° 92.816(6) 72.710(2) 100.771(9) 
γ  /°  77.138(2) 92.801(15) 
V  /Å3 3289(2) 1948.41(10) 1753.9(17) 
Z 4 2 2 
Mr 738.97 931.44 834.42 
F000 1520 964 866 
dc  /Mg·m-3 1.492 1.588 1.580 
µ  /mm-1 0.825 0.808 0.870 
max., min. transmission factors 0.7464, 0.6986 (b) 0.928, 0.880 (a) 0.7464, 0.6617 (a) 
X-radiation, λ  /Å Mo-Kα, 0.71073 Mo-Kα, 0.71073 Mo-Kα, 0.71073 
data collect. temperat.  /K 100(1) 110(1) 100(1) 
θ range  /° 1.83 to 32.5 3.3 to 28.8 ° 2.3 to 30.5 
index ranges  h,k,l –19 ... 19, –22 ... 22, –23 ... 24 
–14 ... 14, –19 ... 
19, –20 ... 20 
–13 ... 13, –17 ... 
17, –22 ... 23 
reflections measured 84609 87392 39960 
                 unique [Rint] 11409 [0.0363] 9592 [0.0561] 10642 [0.0518] 
                 observed [I≥2σ(I)] 9324 8735 8138 
data / restraints / parameters 11409 / 129 / 503 9592 / 44 / 600 10642 / 0 / 455 
GooF on F2 1.023 1.128 1.028 
R indices [F>4σ(F)]  R(F), wR(F2) 0.0415, 0.1091 0.0508, 0.1224 0.0436, 0.1010 
R indices (all data)  R(F), wR(F2) 0.0555, 0.1191 0.0575, 0.1255 0.0655, 0.1090 
largest residual peaks  /e⋅Å-3 1.210, –0.661 0.697, –0.824 0.753, –0.580 
instrument Smart 1000 Supernova Smart 1000 






identification code co500 
CCDC number 1550810 
formula C37H40InF3N6O15 
crystal system monoclinic 
space group C 2/c 
a  /Å 18.4408(9) 
b  /Å 13.2688(7) 
c  /Å 32.7981(19) 
α  /° 90 
β  /° 105.509(2) 
γ  /° 90 




dc  /Mg·m-3 1.684 
µ  /mm-1 0.708 
max., min. transmission factors 0.919, 0.864 (a) 
X-radiation, λ  /Å Mo-Kα, 0.71073 
data collect. temperat.  /K 100 
2θ max 61.4 
index ranges  h,k,l –26 ... 26, –18 ... 18, –46 ... 46 
reflections measured 105852 
                 unique [Rint] 11855 [0.036] 
                 observed [I≥2σ(I)] 10863 
data / restraints / parameters 10863 / - / 607 
GooF on F2 1.05 
R indices [F>4σ(F)]  R(F), wR(F2) 0.023, 0.055 
R indices (all data)  R(F), wR(F2) - 
largest residual peaks  /e⋅Å-3 0.66, –0.62 
instrument Bruker X8 APEX II 
(a) empirical absorption correction.  
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Appendix C: Potentiometric titrations – simulated titration curves, species 
distribution diagrams, and stability data of selected metal complexes 
Simulated titration curves 
 
Figure C 1. Titration curve of an aqueous solution of B1a with 0.1 M KOH. 
 
 
Figure C 2. Titration curve of an aqueous solution of B1b with 0.1 M KOH. 
Obs-calc pH for selected data. sigma=2.3851




































Obs-calc pH for selected data. sigma=1.6182





































Figure C 3. Titration curve of an aqueous solution of B2 with 0.1 M KOH. 
 
 
Figure C 4. Titration curve of an aqueous solution of B1a, EDTA, and CuII (1:1:1) with 
0.1 M KOH. 
Obs-calc pH for selected data. sigma=1.2351




































Obs-calc pH for selected data. sigma=3.6217





































Figure C 5. Titration curve of an aqueous solution of B1b, EDTA, and CuII (1:1:1) with 
0.1 M KOH. 
 
 
Figure C 6. Titration curve of an aqueous solution of B2, EDTA, and InIII (1:1:0.5) with 
0.1 M KOH. 
 
Obs-calc pH for selected data. sigma=3.6644

































Obs-calc pH for selected data. sigma=1.3308





































Figure C 7. Titration curve of an aqueous solution of B2 and LuIII (1:1) with 0.1 M KOH. 
 
 
Figure C 8. Titration curve of an aqueous solution of B2 and LaIII (1:1) with 0.1 M KOH.  
Obs-calc pH for selected data. sigma=1.0266











































































Species distribution diagrams 
  
Figure C 9. Species distribution diagram of CuII in presence of B1a (left) and B1b (right) 
in aqueous solution for c(CuII) = c(ligand) = 10-3 M. 
 
  
Figure C 10. Species distribution diagram of InIII (left) and LuIII (right) in presence of B2 in 
aqueous solution for c(MIII) = c(B2) = 10-3 M. 
 


































































































Figure C 11. Species distribution diagram of LaIII in presence of B2 in aqueous solution 
for c(LaIII) = c(B2) = 10-3 M. 
 
Stability data for selected metal complexes 
Table C 1. Stability constants (log βML) and pM7.4 values for selected LuIII complexes. 
ligand log βML pM7.4 (a) ref 
DOTA (L5) 23.9 18.7 [415] 
DTPA (L10) 22.46(2) 19.1 [58,415] 
H4octapa (L35) 20.08(9) 19.8 [58] 
H2bispa2 (B2) 8.51(3) 9.1  
(a) Calculated for 10 µM total ligand and 1 µM total metal ion concentration at pH 7.4 and 25 °C. 
Table C 2. Stability constants (log βML) and pM7.4 values for selected LaIII complexes. 
ligand log βML pM7.4 (a) ref 
DOTA (L5) 22.0(3) 16.8 [415] 
PEPA (L7) 13.57(5) 9.7 [117] 
HEHA (L8) 19.11(5) 20.8 [117] 
H2bispa2 (B2) 11.42(6) 12.0  
(a) Calculated for 10 µM total ligand and 1 µM total metal ion concentration at pH 7.4 and 25 °C. 



























Appendix D: UV-vis-NIR spectra 
 
Figure D 1. UV-vis-NIR spectrum of [CoII(B1a)](TFA) (DMSO, rt). 
 
 

























































Figure D 3. Part of the UV-vis-NIR spectrum of [CoII((p-MeO)B1a)](TFA) (black) and 
simulation (red) with two Gaussian envelopes (blue, dotted line). 
 
 












































Figure D 5. Part of the UV-vis-NIR spectrum of [CoII(B1b)](TFA) (black) and simulation 
(red) with four Gaussian envelopes (blue, dotted line). 
 
 
Figure D 6. UV-vis-NIR spectrum of [NiII(B1a)](TFA) (MeOH, rt). 































Figure D 7. Part of the UV-vis-NIR spectrum of [NiII(B1a)](TFA) (black) and simulation 
(red) with two Gaussian envelopes (blue, dotted line). 
 
 
Figure D 8. UV-vis-NIR spectrum of [NiII((p-MeO)B1a)](TFA) (MeOH, rt). 
 

































Figure D 9. UV-vis-NIR spectrum of [NiII(B1b)](TFA) (MeOH, rt). 
 
 
Figure D 10. Part of the UV-vis-NIR spectrum of [NiII(B1b)](TFA) (black) and simulation 
(red) with two Gaussian envelopes (blue, dotted line). 
 


































Figure D 11. UV-vis-NIR spectrum of [CuII(B1a)](TFA) (MeOH, rt). 
 
 
Figure D 12. UV-vis-NIR spectrum of [CuII((p-MeO)B1a)](TFA) (MeOH, rt). 
 
































Figure D 13. UV-vis-NIR spectrum of [CuII(B1b)](TFA) (MeOH, rt). 
 
  
















Appendix E: ESR spectra 
 
Figure E 1. ESR spectrum (frozen solution, X band) of [CuII(B1a)](TFA) (MeOH, 8 K). 
Solid line: experimental spectrum, dashed line: simulation with XSophe (gx,y = 2.059, 
gz = 2.243, Ax,y = 13 [10-4 cm], Az = 164 [10-4 cm], f = 9.63491 GHz). 
 
 
Figure E 2. ESR spectrum (frozen solution, X band) of [CuII((p-MeO)B1a)](TFA) (MeOH, 
8 K). Solid line: experimental spectrum, dashed line: simulation with XSophe (gx,y = 2.057, 
gz = 2.244, Ax,y = 10 [10-4 cm], Az = 170 [10-4 cm], f = 9.636852 GHz). 
 

















Figure E 3. ESR spectrum (frozen solution, X band) of [CuII(B1b)](TFA) (MeOH, 8 K). 
Solid line: experimental spectrum, dashed line: simulation with XSophe (gx = 2.016, 













Appendix F: Details of the AOM analysis 
AOM parameters 
donor group interaction 
published parameter 
[cm-1] (for M-L = 1 Å) 
adjusted parameter 
[cm-1] (for M-L = 1 Å) 
amine[385] eσ 492471 492471 
pyridine[390] eσ 432598 375000 
 eπ 64890 85000 
carboxylate[393] eσ 294458 250000 
 eπ 73314 62500 
In the calculations ds-mixing was considered by assigning each ligand an additional 








Setup-file based on structure CCDC 1481462: 
TITL 1A 
CELL 1 1 1 90.0 90.0 90.0 
CONF 2 9 
BASE 2D 
CU1  -3.050719 6.332817 10.939760 
N7   -3.679929 8.547090 10.592288 
N3   -1.191356 7.061325 11.165078 
NPY1 -2.400448 6.065630  9.042959 
NPY2 -3.040171 6.469892 12.969834 
NPA  -5.017398 6.098928 10.753094  
OPA  -3.361979 4.048186 11.119674 
CPY1 -2.904762 5.250649  8.100358 
CPY2 -3.875976 5.888135 13.844606 
CPA  -5.565974 4.877130 10.921177 
MULT 1 
XREF 2 1 6 
LGND 1 2 1 3 
LGND 2 3 1 2 
LGND 3 4 1 8 
LGND 4 5 1 9 
LGND 5 6 1 10 









LIST 1 1 1 0 0 0 1 1 0 1 
B    0 
K    0.7 
ZETA 406 
ESIG 1 3094 
ESIG 2 7475 
ESIG 3 6061 
EPIX 3 0 
EPIY 3 909 
ESIG 4 6276  
EPIX 4 0 
EPIY 4 941 
ESIG 5 6939 
EPIX 5 0 
EPIY 5 1041 
ESIG 6 1924 
EPIX 6 0 
EPIY 6 0 
LINK 34 33 0.25 
LINK 35 33 0.25 
LINK 12  8 0.25 
LINK 17 13 0.25 
LINK 22 18 0.25 
LINK 27 23 0.25 
LINK 32 28 0.25 








Setup-file based on structure CCDC 1481468: 
TITL 1B 
CELL 1 1 1 90.0 90.0 90.0 
CONF 2 9 
BASE 2D 
CU1  5.439298 5.748974 3.074448 
N7   5.556156 7.284103 1.785827 
N3   4.146473 6.852681 4.262388 
NPY1 6.892935 6.724293 4.744298 
NPY2 3.289752 5.008898 2.373942 
NPA  5.234356 4.428460 4.443221  
OPA  6.692553 4.363589 2.327716 
CPY1 8.064439 6.340780 5.272901 
CPY2 2.853520 3.859104 1.838293 
CPA  5.955613 3.310090 4.317310 
MULT 1 
XREF 5 1 3 
LGND 1 2 1 3 
LGND 2 3 1 2 
LGND 3 4 1 8 
LGND 4 5 1 9 
LGND 5 6 1 10 










LIST 1 1 1 0 0 0 1 1 0 1 
B    0 
K    0.7 
ZETA 406 
ESIG 1 7520 
ESIG 2 6191 
ESIG 3 2158 
EPIX 3 0 
EPIY 3 324 
ESIG 4 2387  
EPIX 4 0 
EPIY 4 358 
ESIG 5 8829 
EPIX 5 0 
EPIY 5 1324 
ESIG 6 4440 
EPIX 6 0 
EPIY 6 0 
LINK 34 33 0.25 
LINK 35 33 0.25 
LINK 12  8 0.25 
LINK 17 13 0.25 
LINK 22 18 0.25 
LINK 27 23 0.25 
LINK 32 28 0.25 






Appendix G: Cyclovoltammograms and details of the RORABACHER plot 
Cyclovoltammograms 
 
Figure G 1. Cyclovoltammogram of [CoII(B1a)](TFA) (DMF, 0.1 M (n-Bu4N)(ClO4)). 
 
 
Figure G 2. Cyclovoltammogram of [CoII((p-MeO)B1a)](TFA) (DMF, 0.1 M (n-
Bu4N)(ClO4)). 
 














E vs. fc/fc+ [V]
















Figure G 3. Cyclovoltammogram of [CoII(B1b)](TFA) (DMF, 0.1 M (n-Bu4N)(ClO4)). 
 
 
Figure G 4. Cyclovoltammogram of [NiII(B1a)](TFA) (DMF, 0.1 M (n-Bu4N)(ClO4)). 
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Figure G 6. Cyclovoltammogram of [NiII(B1b)](TFA) (DMF, 0.1 M (n-Bu4N)(ClO4)). 
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Figure G 7. Cyclovoltammogram of [CuII(B1a)](TFA) (DMF, 0.1 M (n-Bu4N)(ClO4)). 
 
 
Figure G 8. Cyclovoltammogram of [CuII((p-MeO)B1a)](TFA) (DMF, 0.1 M (n-
Bu4N)(ClO4)). 
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Figure G 9. Cyclovoltammogram of [CuII(B1b)](TFA) (DMF, 0.1 M (n-Bu4N)(ClO4)). 
 
  













E vs. fc/fc+ [V]
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Potentials of CuII/IL redox couples and CuIIL formation constants used for the plot in 
Figure 50 (Chapter 4.1.6) 










log KCuL (e) ref. 
[21]aneS6 0.89   0.49 1.09 [167,280] 
[15]aneS5 0.68   0.28 4.18 [167,280] 
[15]aneNS4 0.46   0.06 9.8 [167,280] 
[15]aneN2S3 0.1   –0.3 16.02 [167,280] 
[14]aneNS3 0.38   –0.02 9.25 [167,280] 
[14]aneN2S2 0.04   –0.36 15.26 [167,280] 
[14]aneNSSN –0.01   –0.41 15.72 [167,280] 
[14]aneN3S –0.24   –0.64 20 [167,280] 
[14]aneN4 –0.66   –1.06 27.2 [167,280] 
[9]aneS3 0.72   0.32 4.42 [167,280] 
[13]aneS4 0.52   0.12 3.44 [167,280] 
[14]aneS4 0.58   0.18 4.34 [167,280] 
[15]aneS4 0.64   0.24 3.17 [167,280] 
[16]aneS4 0.71   0.31 2.2 [167,280] 
oxathiane-
[12]aneS4 0.72   0.32 3.02 [167,280] 
[13]aneS4-ol 0,54   0.14 3.1 [167,280] 
[14]aneS4-ol 0.49   0.09 5.59 [167,280] 
[15]aneS4-ol 0.71   0.31 2.28 [167,280] 
[16]aneS4-ol 0.73   0.33 1.51 [167,280] 
Me2-2.3.2-S4 0.79   0.39 1.97 [167,280] 
Me2-3.2.3-S4 0.83   0.43 1.18 [167,280] 
cis-cyhx-Me2-
3.2.3-S4 0.75   0.35 2.45 [167,280] 
trans-cyhx-
Me2-3.2.3-S4 0.77   0.37 2.94 [167,280] 
TMMEA 0.68   0.28 6.29 [167,280] 
TEMEA 0.67   0.27 6.35 [167,280] 
PMMEA 0.38   –0.02 11.06 [167,280] 
PMAS 0.4   0 10.48 [167,280] 
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PEMEA 0.6   0.2 7.89 [167,280] 
PEAS 0.61   0.21 7.87 [167,280] 
BPMMEA 0.06   –0.34 16.1 [167,280] 
BPMEEA 0.08   –0.32 15.82 [167,280] 
BPEMEA 0.46   0.06 9.1 [167,280] 
BPEEEA 0.47   0.07 9.2 [167,280] 
TPMA –0.15   –0.55 17.6 [167,280] 
TPEA 0.51   0.11 9.35 [167,280] 
N2py2  –0.42 –0.43 
–0.51 /  
–0.6 16.56 [303] 
(Me)N2py2  –0.1 –0.05 
–0.19 /  
–0.22 9.6 [303] 
N2py3o  –0.6 –0.52 
–0.69 /  
–0.69 18.31 [303] 
N2py3u  –0.49 –0.41 
–0.58 /  
–0.58 15.66 [303] 
N2py4  –0.57 –0.5 
–0.66 /  
–0.67 16.28 [303] 
Hbispa1a   –0.47  (–0.63) 
–1.02  
(–1.06) 18.88 ([359]) 
Hbispa1b   –0.62 –1.17 19.44  
(a) H2O, 0.1 M NaClO4. (b) MeCN, 0.1 M (n-Bu4N)(PF6). (c) H2O, 0.1 M KNO3 for the bispidines or 
DMF (MeCN), 0.1 M (n-Bu4N)(ClO4) (0.1 M (n-Bu4N)(PF6)) for the bispa ligands. (d) Potentials of 
fc/fc+ used for the conversion of the measured redox values: –0.4 V (vs. SHE, H2O), –0.09 V (vs. 
Ag/AgNO3, MeCN),[303] –0.17 V (vs. Ag/AgCl, H2O),[303] –0.43 (vs. Ag/AgCl, MeCN),[359] and –0.55 





Appendix H: Details of the radiochemical investigations of the hexadentate bispa 
ligands 
SOD challenge experiment 
Figure H 1. Analysis of 64CuII transchelation to human erythrocyte superoxide dismutase 
(SOD) for 64CuII-B1b. Colloidal Coomassie stained native polyacrylamide gel (left) and 
autoradiography showing 64CuII-labeled bands of SOD (right). 
Serum stability assay analyzed by gel electrophoresis 
 
Figure H 2. Analysis of 64CuII transchelation to human serum proteins for 64CuII-B1b. 
Colloidal Coomassie stained native polyacrylamide gel (left) and autoradiography showing 





Table H 1. Amount of 64CuII-B1a in selected organs, tissues and excretion in rats at 5 min, 
60 min, and 24 h p.i. (four Wistar Kyoto rats per time point, mean value ± standard 
deviation SD). 
%ID/g 5 min ± SD 60 min ± SD 24 h ± SD 
Blood 0.825 0.156 0.040 0.013 0.014 0.013 
Heart 0.373 0.089 0.028 0.011 0.015 0.009 
Lung 0.625 0.123 0.063 0.020 0.021 0.012 
Muscle 0.232 0.047 0.222 0.314 0.006 0.003 
WAT 0.614 0.469 0.120 0.112 0.009 0.009 
BAT 0.315 0.070 0.043 0.013 0.015 0.011 
Bone 0.382 0.098 0.044 0.016 0.014 0.009 
Spleen 0.391 0.260 0.241 0.222 0.018 0.010 
Adrenals 0.596 0.327 0.129 0.087 0.022 0.008 
Kidneys 4.266 1.681 0.760 0.202 0.414 0.210 
Liver 0.413 0.162 0.156 0.034 0.059 0.035 
Brain 0.033 0.005 0.005 0.001 0.002 0.001 
Pancreas 0.556 0.405 0.250 0.155 0.014 0.007 
Thymus 0.276 0.049 0.029 0.011 0.017 0.013 
Thyroid 0.576 0.080 0.054 0.011 0.030 0.017 
Harderian 0.363 0.119 0.062 0.020 0.015 0.007 
Testes 0.258 0.063 0.032 0.014 0.016 0.012 
Skin 0.624 0.121 0.058 0.008 0.029 0.011 
%ID 5 min ± SD 60 min ± SD 24 h ± SD 
Stomach 0.789 0.296 0.254 0.234 0.127 0.175 
Intestine 3.194 0.487 3.116 2.521 11.388 14.977 
Feces 0.000 0.000 0.000 0.000 5.219 4.992 





Table H 2. Amount of 64CuII-B1b in selected organs, tissues and excretion in rats at 5 min, 
60 min, and 24 h p.i. (four Wistar Kyoto rats per time point, mean value ± standard 
deviation SD). 
%ID/g 5 min ± SD 60 min ± SD 24 h ± SD 
Blood 1.116 0.062 0.149 0.029 0.013 0.001 
Heart 0.493 0.016 0.085 0.013 0.021 0.004 
Lung 0.824 0.036 0.194 0.021 0.026 0.002 
Muscle 0.309 0.016 0.101 0.087 0.012 0.008 
WAT 0.490 0.103 0.230 0.246 0.010 0.009 
BAT 0.545 0.051 0.142 0.034 0.025 0.005 
Bone 0.549 0.024 0.114 0.015 0.019 0.003 
Spleen 0.346 0.037 0.200 0.178 0.033 0.005 
Adrenals 0.579 0.058 0.196 0.117 0.036 0.014 
Kidneys 3.913 0.482 1.245 0.174 0.219 0.004 
Liver 0.517 0.024 0.287 0.049 0.086 0.005 
Brain 0.051 0.007 0.013 0.002 0.003 0.000 
Pancreas 0.703 0.096 0.758 0.264 0.061 0.009 
Thymus 0.427 0.033 0.126 0.018 0.033 0.006 
Thyroid 0.960 0.053 0.498 0.235 0.030 0.007 
Harderian 0.429 0.042 0.138 0.049 0.017 0.003 
Testes 0.264 0.021 0.073 0.018 0.023 0.001 
Skin 0.962 0.072 0.390 0.155 0.035 0.003 
%ID 5 min ± SD 60 min ± SD 24 h ± SD 
Stomach 1.187 0.563 5.244 3.836 0.640 0.840 
Intestine 4.470 0.536 15.980 10.693 1.368 0.482 





Table H 3. Amount of 68GaIII-B1a in selected organs, tissues and excretion in rats at 5 min 
and 60 min p.i. (four Wistar Kyoto rats per time point, mean value ± standard deviation 
SD). 
%ID/g 5 min ± SD 60 min ± SD 
Blood 1.870 0.241 1.616 0.051 
Heart 0.698 0.076 0.494 0.057 
Lung 0.952 0.072 0.953 0.158 
Muscle 0.256 0.043 0.186 0.018 
WAT 1.244 0.640 1.327 0.948 
BAT 0.508 0.152 0.482 0.198 
Bone 0.618 0.046 0.980 0.108 
Spleen 0.373 0.175 0.849 0.675 
Adrenals 0.463 1.350 0.818 0.363 
Kidneys 1.576 0.255 0.931 0.120 
Liver 0.700 0.140 0.683 0.079 
Brain 0.062 0.012 0.065 0.013 
Pancreas 0.472 0.126 0.942 0.979 
Thymus 0.413 0.041 0.376 0.096 
Thyroid 0.874 0.216 0.768 0.236 
Harderian 0.638 0.124 0.786 0.234 
Testes 0.337 0.115 0.359 0.019 
Skin 0.692 0.072 0.458 0.040 
%ID 5 min ± SD 60 min ± SD 
Stomach 0.741 0.113 0.571 0.256 
Intestine 3.722 1.242 3.472 0.374 
Feces 0.000 0.000 0.000 0.000 
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